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ABSTRACT 
 
 One of the most successful treatments for obesity is bariatric surgery. The Roux-
en-Y gastric bypass (RYGB), in particular has been the most commonly performed 
bariatric surgery over the past decade. It is not well known how time will influence the 
broader inflammatory-related health outcomes of bariatric surgery, which may depend on 
complex inter-relationships between nutritional status and body fat mass (FM). This 
dissertation focuses on the long-term changes in nutritional status and body composition 
after RYGB with a particular focus on vitamins and minerals that have potential 
inflammatory action and the development of improved methods to assess changes in body 
composition in obese individuals. In Chapter 3 we report the results of a pilot study to 
assess long-term changes in body composition and nutritional and inflammatory status 
after RYGB. From the assessment of 5 women who were monitored over an 8.5-year 
period after RYGB we found that improvements in vitamin D status and potential 
improvements in inflammatory status can occur over time. However, continued loss of 
lean soft tissue (LST) occur on the background of weight regain between 1-year and 8.5-
years post-RYGB. Losses of LST were correlated with decreased handgrip strength. In 
Chapter 4 we report the results of a validation study to compare the results of a new 
application of bioimpedance spectroscopy (BIS) based on multicomponent physiologic 
models with existing body composition data from dual energy X-ray absorptiometry 
(DXA) in a large NHANES dataset with 5470 observations and in a longitudinal dataset 
of 25 women for the first-year after RYGB. We found that the BIS method was in 
  v 
relatively good agreement with DXA for the assessment of FM and lean tissue, and that 
the BIS method was equally as good as DXA for assessing changes in FM in particular 
after RYGB, over the period from 6-months to 1-year. In the coming years, bariatric 
surgery is sure to remain a popular treatment for obesity and it is clear that we need better 
methods to assess changes in body composition in a more comprehensive way, in order to 
better understand the ramifications of these changes in light of long-term nutritionally 
relevant health outcomes, including inflammation. This dissertation could serve to inform 
future studies that should aim to tease apart the factors contributing to long-term FM 
gain, but more importantly loss of LST and muscle strength, to establish evidence based 
guidelines.  
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CHAPTER 1 :  INTRODUCTION 
 
Bariatric surgery is one of the most successful treatments for obesity. The long-
term ramifications of bariatric surgery for broader nutrition-related health outcomes are 
not well studied, in part due to logistical difficulties in following individuals for years 
after surgery.  The impact on body composition and nutrition, and the potential 
implications of the complex interactions between nutrition and inflammation may be 
important.  Although other procedures have recently gained in popularity, the Roux-en-Y 
gastric bypass (RYGB) surgery continues to be utilized at a high frequency, given its 
documented long-term success for inducing both weight loss and diabetes remission. The 
bypass of the small intestine during this procedure can and does result in variable rates of 
nutrient deficiencies. For example, deficiency of vitamin D is documented in the 
literature and may have implications for inflammatory status in the long-term after 
surgery.  
 
This project is unique in that it reports on body composition and nutritional status 
changes 8.5-years post-RYGB. From other studies we know that by 1-year the primary 
change in body composition is a substantial loss of fat mass (FM), accompanied by 
smaller losses in lean tissue. Weight regain in the long term after RYGB is documented 
in the literature; however, we do not know which tissue compartments are responsible for 
that weight gain and it is not known if the lean tissue losses that occur in the first year 
after bariatric surgery continue in the long-term or stabilize. It is not clear how lean tissue 
changes in the long-term affect functional status and strength. Muscle loss is one of the 
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major criteria in the diagnosis of malnutrition, thus it is of paramount importance to 
monitor these changes as people age. Accurate bedside methods for the assessment of 
lean tissue loss are lacking.  The ability to measure lean tissue would be advantageous for 
evaluating the response to nutritional interventions in clinical settings, and to weight 
management interventions (including physical activity, nutrition, and surgical) in 
individuals with obesity.  Knowledge of the timing and magnitude of lean tissue changes 
after bariatric surgery would be also be quite valuable for monitoring health outcomes.  
 
 This dissertation focuses on the long-term changes in nutritional status with a 
particular emphasis on vitamins and minerals with potential inflammatory action, body 
composition and muscle strength changes that occur after bariatric surgery, and the 
development of improved methods to potentially assess changes in body composition in 
individuals with obesity. Chapter 2 is a literature review that will present background 
information to frame the two research chapters. This chapter focuses on the types of 
bariatric surgeries; how body composition is measured; how body composition changes 
after bariatric surgery in the short- and long-term; and how nutritional status also changes 
in the long-term after surgery with possible inflammatory complications. Included in this 
chapter is an in-depth published review of vitamin D status changes after bariatric 
surgery and the potential implications of these changes. Chapter 3 presents a long-term 
assessment of body composition changes and select nutrient status after RYGB with a 
focus on vitamin D changes and inflammation. Chapter 4 is a validation study comparing 
new models for the generation of body composition components from bioimpedance 
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spectroscopy (BIS) data to dual energy X-ray absorptiometry (DXA) data in a large 
NHANES dataset and in a longitudinal dataset of weight loss after RYGB. Chapter 5 is a 
discussion of the overall conclusions that can be drawn from these studies and the 
potential future directions for research.  
  4 
CHAPTER 2:   LITERATURE REVIEW* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Publication Citation (portions of this Literature Review have been published):  
Cole AJ, Beckman LM, Earthman CP. Vitamin D Status Following Bariatric Surgery. 
Nutrition in Clinical Practice. 2014;29:751-758.   
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2.1:  Bariatric Surgical Procedures 
 
Historically, bariatric surgeries have been described as either malabsorptive or 
restrictive. As more is learned about the mechanisms driving the success of bariatric 
surgeries, these classifications may not hold. For many years, the most common bariatric 
surgeries have been the Roux-en-Y gastric bypass (RYGB) and the biliopancreatic 
diversion (BPD) with and without douodenal switch (DS). The RYGB and BPD/DS are 
often termed restrictive and malabsorptive. However these classifications are limiting 
and do not accurately address all the numerous mechanisms thought to be involved in the 
metabolic improvements seen after bariatric surgery. The most common types of so 
called restrictive surgeries are vertical sleeve gastrectomy (VSG) and laparoscopic 
adjustable gastric banding (LAGB).
1
 Again, the historic classification system may be too 
simplistic, particularly when discussing the VSG because newer research suggests that 
mechanistically there is more involved in the success of this surgery than simply caloric 
restriction and that rapid gut transit and gastric emptying have been shown after VSG.
2,3
 
Throughout the years there have been numerous other iterations of bariatric surgeries. For 
the sake of simplicity, here the discussion will focus on the four most commonly 
performed procedures. 
2.1.1:  Roux-en-Y Gastric Bypass 
 During the RYGB a small gastric pouch, approximately 15 ml, is created and 
connected to the jejunum via what is commonly termed the Roux-limb. Gastric and 
pancreatic secretions as well as bile are secreted into the pancreatobiliary limb, which is 
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anastomosed with the jejunum. The major mechanism for weight loss following RYGB is 
thought to be the reduction in stomach size, which leads to smaller meal size and fewer 
calories consumed. Additionally, the length of the Roux limb is thought to be 
proportional to the degree of malabsorption following surgery. Finally, the physiologic 
changes following surgery appear to alter gut hormones,
4
 increasing those that promote 
satiety and reducing those that suppress hunger.
5
 In addition, RYGB has shown 
remarkable success for inducing remission of type 2 diabetes mellitus (T2DM).
6
  
2.1.2:  Vertical Sleeve Gastrectomy 
 During the VSG procedure the stomach is resected longitudinally, removing 80% 
to form a tubular pouch. The procedure preserves the antrum and the pylorus. The newly 
created gastric pouch has an approximate volume of <100ml. The sleeve has been shown 
to be as effective as the RYGB in terms of weight loss and T2DM remission rates.
7,8
 As 
with RYGB, the VSG has an impact on gut hormones, which impact metabolic signaling 
pathways.
7
  
2.1.3:  Biliopancreatic Diversion With and Without Douodenal Switch 
With the BPD and the DS procedures, 70% of the stomach is resected much like 
the VSG to create a tubular pouch. Much of the small intestine is bypassed. BPD can be 
performed with and without DS where the proximal duodenum is anastomosed to the 
distal small intestine to create a short common channel. This procedure allows for 
preservation of the pylorus and reduces risk of dumping syndrome. The bypassing of the 
small intestine limits absorptive area where the food can mix with bile secretions and 
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pancreatic enzymes, which results in increased malabsorption. Similar to the VSG and 
RYGB, the BPD/DS is successful in resolving T2DM and is often considered the most 
effective surgery for treating T2DM.
6
 The BPD/DS also affects gut hormones in a way 
that appears to influence hunger and satiety.
6
 
2.1.4:  Laparoscopic Adjustable Gastric Banding 
LAGB is a reversible procedure and is often the first choice for patients and 
surgeons.
9
 During the LAGB procedure, an inflatable band is secured around the top of 
the stomach allowing for variable restriction of the movement of food from the small 
gastric pouch into the remainder of the stomach and the duodenum. Weight loss is slower 
after LAGB than other surgeries as the band is slowly inflated to restrict the stomach in 
the weeks after surgery. The mechanism for LAGB success is unclear but is thought to be 
related to increased satiety.
10,11
  
2.1.5:  Prevalence of Bariatric Procedures 
 Until very recently, the most common procedure performed in the United States 
and worldwide was the RYGB, although the VSG is quickly surpassing the RYGB in 
popularity due to its nearly equal or better efficacy for weight management
12
 and diabetes 
resolution. VSG is further favored due to its lower complication rate.
7
 In 2013, the most 
recent year for which estimated numbers are available from the American Society for 
Metabolic and Bariatric Surgery (ASMBS), there were approximately 179,000 bariatric 
surgeries performed in the United States. Of these, 34.2% were RYGB, and 42.1% were 
VSG. 14% were LAGB and only 1% were BPD/DS. Approximately 6% of bariatric 
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surgeries are revisions and a small amount (2.7%) are classified as other.
1
 The prevalence 
of revision has also been reported and has been recently reviewed by O’Brien.9 After 10-
years, the reported revision rates range from 8-38% for RYGB, 8-60% for LAGB, and 
10-40% for gastroplasty.
9
 As with other metrics, long-term data for revision rates is not 
available for VSG.  
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2.2:  Commonly Used Body Composition Assessment Methods 
 
One of the challenges facing clinicians with the increasing prevalence of obesity 
in the US and worldwide is the need to evaluate changes in body composition in 
individuals with extreme obesity. A large majority of the reference methods for the 
evaluation of body composition have been developed using normal weight, healthy 
individuals. Thus, there is a need to validate, refine, and improve these methods so they 
can be utilized in the obese population.  
 
2.2.1:  Reference Methods for Assessing Body Composition: DXA, Body Density, Dilution 
and 4-Component Models 
 
As has been well described by Heymsfield and Wang, the human body can be 
thought about in terms of the five-level model including the atomic or elemental level 
(oxygen, hydrogen, carbon, nitrogen and other elements), the molecular level (lipid, 
water, proteins, glycogen, and minerals), the cellular level (cells, extracellular fluid, 
extracellular solids), and the tissue-system level (adipose, skeletal muscle, visceral 
organs, skeleton) and finally, the whole body level.
13
 Many methods have been developed 
for the assessment of body composition. Detailed reviews of these methods, their history, 
and use are widely available.
13,14
 Traditional body composition models are based on 2-
compartments where body weight is divided into two fractions, FM and FFM. These are 
often referred to as 2-component models and they assume that the density of FM and 
FFM are stable for all adults.
15
 These models may be too simplistic and may fail to adjust 
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adequately for ethnicity, aging, gender, and excess adiposity, leading to the development 
of multi component models based on multiple reference techniques.
16,17
  
 
Body composition methods range in complexity from field anthropometric 
techniques like skin fold thickness and waist-to-hip ratio, to technologically advanced 
imaging techniques like computed tomography (CT) and magnetic resonance imaging 
(MRI).
18
 The most commonly used reference methods to assess body composition fall in 
between these methods in terms of cost, reliability, and accessibility to researchers: these 
include the total body water (TBW) and extracellular water (ECW) assessment by 
deuterium and bromide dilution, respectively (i.e. multiple dilution), body density by 
underwater weighing or air displacement plethysmography (ADP), DXA, and multi-
component models based on these techniques.
14,18
 Here we will focus on the following 
reference methods of body composition assessment:  multiple dilution, body density 
measured by ADP, DXA and a 4-component model based on these methods.  
 
DXA provides information about body composition divided into 3-compartments 
where body weight = FM + bone mineral content (BMC) + lean soft tissue (LST).
17
 LST 
is composed of water, proteins, glycogen and minerals, and FFM is LST with the addition 
of BMC.
17
 DXA typically produces photons at 40 and 70 keV, which pass through tissues 
at rates depending on their elemental composition.
14
 DXA output allows for visualization 
and analysis of the separate tissue types.
14,19
 While DXA has its own limitations and sets 
of assumptions, it is well regarded as a method to accurately assess BMC, FM, FFM, and 
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LST. Height, weight and width limitations have historically restricted the use of DXA to 
those individuals who are mobile and who meet the body physical size specifications 
required to use the machine. However, newer machines (e.g. iDXA, GE Healthcare) are 
capable of measuring larger individuals.  
 
 Dilution methods measure the ratio of a dose of a tracer to the concentration in the 
body compartment after a defined follow-up time. A known concentration of tracer is 
compared with the difference between levels of the tracer (in urine, saliva or blood) 
before (background) and after dosing. Dilution methods rely on the assumptions that that 
the tracer is distributed only in the body compartment of interest, that it is equally 
distributed in this compartment, that it is not metabolized during the monitoring period, 
and that the time to equilibrium is achieved quickly and reached by the time of 
measurement.
14
  
 
 Dilution is one of the more common methods to assess TBW. TBW is an 
important measurement for body composition as FFM has been shown to be hydrated at 
73% in healthy adults.
20,21
 TBW can be measured with a variety of tracers including 
tritium, deuterium or oxygen-18. Deuterium is ideally given as an oral diluted dose of 
99.9 atom% deuterium oxide in tap water. Typical equilibration times are 3-hours after 
oral deuterium dosing for TBW; equilibration time may be shorter with IV dosing and are 
extended by 1-hour in individuals with obesity.
22
 ECW is typically measured in the same 
fashion using non-radioactive bromide (Br) delivered as a 3% sodium bromide oral dose 
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solution in tap water. Typically Br dilution is assessed in plasma or serum 3-4 hours after 
dosing, with 1-hour extension in individuals with obesity of known fluid overload. It has 
been documented that Br equilibrium may not be reached until 8.5-12 hours after dosing, 
although longer equilibration periods are rarely used.
23,24
 Inadequate equilibration time 
could lead to over-estimation of the ECW compartment. Intracellular water (ICW) can be 
determined using radioactive potassium (
42
K), although this method is not frequently 
used. Alternatively ICW can be calculated from deuterium and Br dosing as the 
difference between TBW and ECW.  
 
Hydrodensitometry (under-water weighing) has long been considered the gold-
standard for assessment of body density. Hydrodensitometry is technically challenging 
and difficult for study subjects to accept because it involves complete submersion in 
water with maximal expiration, ideally followed by measurement of residual lung 
volume. In recent years, the availability of ADP has provided an alternative to 
hydrodensitometry that is more acceptable to study participants. ADP has been shown to 
have good agreement with hydrodensitometry, thus it has been accepted as a reference 
method for density.
25–27
 ADP devices use the relationship between pressure and volume, 
at a fixed temperature, to solve for the volume of air displaced when an individual sits in 
a chamber. ADP has been reviewed by numerous groups.
13,14
 In brief, FM and FFM are 
calculated from the volume and density estimates using established prediction equations 
(e.g. Siri
15
). These devices are also capable of measuring thoracic gas volume, which is 
important for the correction of body volume.  
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Multi-component models are often considered superior to single reference 
methods because by measuring several compartments there is less need for reliance on 
assumptions, e.g., the FFM hydration constant. For example, a 4-component model, aim 
to account for aqueous, protein, mineral, and fat fractions by using different reference 
methods to measure each.
17
 One 4-component model commonly utilized is based on 
TBW by deuterium dilution, body density by ADP, BMC by DXA, and body weight.
28
  
As with any method, there are of course issues with the multi-component models. With 
more independent measurements there exists a greater risk of measurement error; 
however, overall error of the model is thought to decline with the incorporation of more 
measurements.
16
 
2.2.2:  Field Technique: Bioimpedance Spectroscopy 
Limitations of existing body composition reference methods is that they are 
costly, difficult to transport, and require specialized maintenance and training for optimal 
performance.
13
 Bioimpedance analysis techniques such as bioimpedance spectroscopy 
(BIS) are commonly referred to as field techniques because they require validation 
against reference methods and are typically portable, non-invasive, lower in cost, and 
applicable for bedside use. We have recently reviewed these techniques and their 
potential for application at the bedside.
29
 Most of literature focuses on single- and multi-
frequency bioelectrical impedance analysis (SF-BIA and MF-BIA) approaches that rely 
on population specific regression derived prediction equations to estimate body 
compartments from impedance data. Although these techniques may produce reasonably 
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accurate and precise estimates in healthy individuals, the underlying assumptions (e.g. 
one or a few concise frequencies are sufficient to adequately capture body water, and 
relationships between water compartments, bone and protein are static).  
 
Unlike SF-BIA and MF-BIA, BIS involves the application of biophysical 
modeling algorithms to bioimpedance data measured across a spectrum of frequencies 
(e.g. from ~5 to 1200 kHz, using data from 50 or more frequencies) in order to generate 
body composition data. Simply put, at low frequencies (e.g. approaching theoretical 0 
frequency), the current produced by a BIS device is conducted only by ECW, due to the 
capacitance effect of cell membranes and tissue interfaces. At relatively high frequencies 
(e.g. approaching theoretical infinity frequency), BIS devices measure ICW as the 
capacitive property of cells is lost at higher frequencies, allowing the current to pass 
through cell membranes and tissues and thus quantifying both ICW and ECW (i.e. TBW).  
 
The bioimpedance data are typically fit to the Cole model
30
 using nonlinear least 
squares curve fitting; the semicircle formed by plotting resistance (R) and reactance (X) 
values is extrapolated to reach the x-axis in order to determine R at zero (R0, also called 
RE) and infinity (R). From these, RI can be calculated, representing the resistance related 
to the ICW. Cell membrane capacitance (CM) is also calculated in the model. Cole model 
terms can be applied to the Xitron-Hanai-based
31,32
 mixture equations to determine ECW 
and ICW; these equations are based on the conductivity of suspensions
33
 and 
consequently can be used in conjunction with the presumed conductivity and resistivity 
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of the different body compartments (i.e. ECW and ICW). These equations incorporate 
several constants including intra- and extra-cellular apparent resistivity, shape factor, and 
body density. The apparent resistivity constants for the ICW and ECW compartments that 
are typically applied to the mixture equations require the assumption that the resistivity of 
all tissue types is constant, however, it has been shown that these constants may vary 
with adiposity, and the errors in ICW and related lean tissue compartments increase with 
increasing adiposity.
34–36
   
 
2.2.3:  Limitations for Assessing Body Composition in Obese Individuals 
Until recently DXA was limited to use in individuals who were below weight and 
size thresholds required to meet device specifications – typically below 300 lbs and less 
than 60 cm wide.
19
 The newer DXA devices such as the iDXA (GE, Lunar Medical 
Systems, Madison, WI) can accommodate larger individuals up to 450 lbs and 66 cm 
wide, maximal torso thickness is constrained only by the height of the scanning arm 
which is set at 46 inches.
19
 FM thickness and distribution may also impact the validity of 
DXA in assessing body composition, including bone mass.
37
 Other methods such as 
multiple dilution using deuterium depend on a set of standard assumptions for the 
hydration of FFM (0.738
20
) and body density (1.1 g/ml
15
) that may be violated in 
extremely obese individuals who tend to have elevated levels of ECW,
38
 which persists 
even after weight loss as previously discussed.
39,40
 Increased adiposity also introduces 
error due to violation of underlying assumptions in bioimpedance techniques. For 
example, in individuals with obesity, hydration of FFM is higher than 73%, body 
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proportions are skewed compared to normal weight, and resistivity constants for intra and 
extracellular compartments applied to BIS equations are likely affected by increasing 
adiposity and could be more variable across tissues. 
 
  
  17 
2.3:  Changes in Body Composition Following Bariatric Surgery 
The most recent data available from the Centers for Disease Control and 
Prevention (CDC) for 2011-2012 showed that 35% of adults 20 years and older in the US 
were classified as obese (body mass index [BMI] ≥ 30 kg/m2) and 6.4% were extremely 
obese (Class III obesity, BMI ≥ 40 kg/m2).41 One of the most effective treatments for 
obesity is bariatric surgery. Bariatric surgery is typically only recommended for 
individuals with BMI ≥ 40 kg/m2 or for those individuals with a BMI ≥ 35 kg/m2 with 
one or more serious comorbidities (e.g. T2DM, hypertension, hyperlipidemia, etc.).
42
 
Although, it should be noted that there are some professionals who currently support 
lowering this cut-point to a BMI of 30 kg/m
2
,based on growing evidence of lower risk of 
morbidity and mortality with currently applied procedures.
9
 This lower risk is thought to 
be due to the advances in laparoscopic techniques used in modern version of the bariatric 
surgieries.
9
  
 
In addition to weight loss, one important benefit of bariatric surgery is the 
improvement of insulin sensitivity, and in many cases, the resolution of T2DM. In a 
meta-analysis of 621 bariatric surgery studies published between 1990 and 2006, it was 
shown that the BPD/DS was most effective for both weight loss and diabetes resolution.
6
 
For all bariatric surgeries assessed in the meta-analysis, 78% resulted in the resolution of 
diabetes.
6
 Furthermore, total weight loss for all bariatric surgeries, for which data were 
available, was 38.5 kg or 55.9% of excess body weight lost, defined as weight loss 
divided by ideal body weight or weight at BMI of 25 kg/m
2
, expressed as a percent.
6
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2.3.1:  Loss of Fat and Lean Tissue After RYGB 
 Numerous studies have attempted to quantify the changes in fat mass (FM) after 
bariatric surgery. Excess FM is associated with low-grade inflammation, T2DM, 
hypertension, non-alcoholic fatty liver disease, and increased risk for cardiovascular 
disease. The loss of FM following bariatric surgery is beneficial for the potential 
resolution of many of these complications and is well documented. However, the FM loss 
following bariatric surgery is also accompanied by the loss of fat free mass (FFM) 
(comprised of LST and BMC as measured by dual-energy X-ray absorptiometry [DXA]), 
which may contribute to potentially significant complications after surgery such as 
increased all-cause mortality,
43
 although this finding is not confirmed in bariatric 
populations. Loss of FFM also occurs with T2DM and aging,
44
 thus the population 
undergoing bariatric surgery may be at particular risk for lean tissue losses. 
 
There have been a number of reports in the literature using various reference 
methods to assess changes in body composition in adults after RYGB. FM loss as a 
percent of weight loss has been reported to be between 73-80% at 6-months to 1-year 
after RYGB.
39,45–51
 FFM loss has been reported to be between 18-25% of weight loss 1-
year after RYGB;
39,46–48,51
 and LST loss has been reported to be between 12-23% of 
weight loss 1-year after RYGB.
49,50
 Olbers et al reported body composition changes in 29 
individuals (22 female, 7 male; mean BMI 42.3 ± 4.5 kg/m
2
) 1-year after RYGB as 
measured by DXA and found that total FM decreased by a mean of 26.9 ± 9.4 kg (~73% 
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of weight loss) and LST decreased by a mean of 4.4 ± 2.6 kg (~12% of weight loss).
50
 
Carrasco et al also reported body composition changes over 1-year after RYGB measured 
by DXA in 42 women (BMI 45.0 ± 4.3 kg/m
2
) and found that FM decreased by 28.6 kg 
(73% of weight loss) and FFM decreased by 10.7 kg (27% of weight loss).
48
 Zalesin et al 
followed 32 individuals (mean age, 46.7 ± 10.4 years; initial BMI 50.1 ± 8.9) between 3- 
and 14-months after RYGB and used DXA to assess body composition. They did not 
report mean changes in LST or FM for the overall dataset, but did report that mean FFM 
loss was 3.1 kg (13% of weight loss) over the time period.
52
 They also reported that only 
3/32 patients maintained or gained lean mass as measured by DXA after RYGB.
52
 The 
correlation between rates of FFM and FM lost was 0.37 (P=0.049) and patients losing 
weight at the fasted rates appeared to have accelerated losses of both lean and FM. 
 
Carey et al followed 17 individuals (12 female, 5 male; BMI 48.5 kg/m
2
) over 1-
year post-RYGB and measured body composition using underwater weighing. They 
reported that FM loss and reported that between over 1-year FM loss was 38.3 kg (~75% 
of weight loss) and FFM loss was 12.7 kg (~25% of weight loss). Due to the limitations 
of underwater weighing, no data on LST is available for this dataset. Das et al reported 
changes in body composition in a cohort of 20 women (BMI 47.8 ± 8.8 kg/m
2
) using a 3-
component model based on ADP and deuterium dilution after weight stabilization post-
RYGB (~14 months). FM decreased by 35.7 kg (80% of weight loss) and FFM decreased 
by 9.1 kg (20%) at weight stabilization (BMI 30.5 ± 7.0 kg/m
2
).
39
 Carrasco et al assessed 
changes in body weight using TBW measured by deuterium dilution and the hydration 
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constants of 0.756 and 0.747 reported by Das et al
39
 to calculate FFM and to indirectly 
calculate FM as the difference between FFM and body weight.
47
 In 30 individuals (BMI 
44.4 ± 4.8 kg/m
2
) over a 6-month period after RYGB, FM loss was 26.0 kg (77% of 
weight loss) and FFM loss was 7.8 kg (23% of weight loss).
47
  
 
In another study similar changes have been reported in a small cohort of 5 
adolescents/young adults (all female; BMI 49.8 ± 5.4 kg/m
2
) between 13-21 years of 
age.
49
 Inge et al measured changes in body composition measured by DXA and found 
that that by 1-year after RYGB, overall mean FM loss was 36 kg (74% of weight loss) 
and LST loss was 11.1 kg (23% of weight loss).
49
 
 
A potential long term consequence of bariatric surgery that has not been 
addressed in the literature is sarcopenic obesity, defined as low muscle mass or function 
in the presence of obesity. This condition is associated with diminished quality of life and 
functional status and is compounded by inactivity, low protein intake,
53
 and aging.
54
 
While exact recommendations vary, it has been proposed that a minimum protein intake 
of 80-90 g/d may be beneficial for preservation of lean mass.
42,55
 Unfortunately due to 
changes in stomach size and satiety, protein intake substantially decreases after surgery,
56
 
and most individuals do not meet the minimum recommendations even at 1-year post-
RYGB.
57
 While some studies suggest that protein supplementation could be beneficial for 
the maintenance of lean mass, consensus has not been reached due to a lack of causative 
evidence to support this relationship.
42
 More research is needed in this area. 
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Exercise is also likely to be important for the preservation of lean mass after 
bariatric surgery. Many individuals who undergo bariatric surgery do not get adequate 
exercise before or after surgery.
58
 Exercise is recommended before and after bariatric 
surgery
42
 as it has been associated in this population with increased excess weight 
loss,
59,60
 prevention of strength loss,
61
 improved cardiac and pulmonary function, 
increased resting energy expenditure (REE), and improved glucose tolerance.
62,63
 
However, while exercise has been regarded as beneficial for post-bariatric individuals, 
there is not yet solid evidence to suggest that it is linked to prevention of lean tissue 
losses that typically accompany losses in FM.  
 
2.3.2:  Altered Fluid Status in Extreme Obesity Persists After Massive Weight Loss 
Altered fluid status in the obese state before and after bariatric surgery has been 
reported by a number of groups. Das et al measured changes in body composition in 20 
women before (BMI 48.7 ± 8.8 kg/m
2
) and after weight loss (BMI 30.5 ± 7.0 kg/m
2
) from 
RYGB and reported that FFM hydration was significantly higher than the standard 
reference of 0.738 before weight loss (0.756, P<0.001) but not after weight loss.
39
 
Mazariegos et al studied the changes TBW, ECW, and ICW in 25 extremely obese 
women (BMI 48 ± 7 kg/m
2
) before and after bariatric surgery (either restrictive or 
malabsorptive). Compared with normal weight controls, the extremely obese group had 
elevated ratios of ECW/ICW (0.82 ± 0.17 v. 0.63 ± 0.06, P<0.05).
40
 Furthermore, this 
group reported that the elevated ECW/ICW ratio was related to the type of surgery 
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performed, and was higher (1.09 ± 0.25 v. 0.83 ± 0.14, P<0.01) after weight stabilization 
at a mean of 22 months after malabsorptive procedures compared to restrictive 
procedures.
40
 Levitt et al also assessed the ECW/ICW ratio in 20 women (BMI 46.7 
kg/m
2
) after RYGB and found that the ratio was higher in the obese individuals at 
baseline than might be expected for lean individuals (0.82 ± 0.19) and increased 1-year 
after surgery (1.08 ± 0.3, P=0.002).
45
  
 
2.3.3:  Weight Regain After Bariatric Surgery 
Long-term data for bariatric surgical success as measured by weight loss 
maintenance over time indicates that most patients regain at least a portion of their body 
weight in the long-term after surgery.
64–66
 Few well designed, and well-controlled studies 
have assessed weight loss and health outcomes between 3-15 years post-surgery.
67,68
 The 
older surgeries, such as the RYGB are typically discussed, as are gastric banding 
procedures such as LAGB, although newer surgeries like the VSG are rarely mentioned, 
likely due to the lack of long-term data for these individuals. Most studies report weight 
change and changes in metabolic status (i.e. diabetes remission), but do not look at more 
complex metrics or body composition as the primary datasets are often from existing 
medical records or self-report. There is some evidence that weight regain may mitigate 
the positive health outcome effects of bariatric surgery (particularly of RYGB and 
LAGB).
67
 The underlying causes of weight regain are not well understood and are 
thought to be multifactorial and related to patient- (e.g. psychiatric, physical inactivity, 
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metabolic, dietary, etc.) and procedure- (e.g. surgery type, Roux limb length, etc.) 
specific factors.
68
 
 
The Swedish Obese Subjects study (SOS) is the largest non-randomized study of 
weight loss outcomes after bariatric surgery (n=4000).
69
 They reported 10-year data 
showing that individuals who underwent RYGB regained ~12% total body weight and 
those who underwent variable or fixed banding regained ~8% total body weight. For 
patients following RYGB, this means that by 10-years, individuals had regained ~34% of 
their maximal weight loss at 1-year.
64
 Cooper et al reported weight regain data for a 
cohort of 300 individuals who underwent RYGB and found that mean weight regain over 
a mean of ~7 years post-RYGB was 23.4% of maximum weight loss.
66
 Roslin et al 
reported that in 36 individuals post-RYGB mean weight change from lowest body weight 
after surgery was 8.2 ± 8.6 kg over a mean follow-up period of 3.4 ± 2 years.
69
 The 
Longitudinal Assessment of Bariatric Surgery study (LABS) assessed 3-year outcomes in 
individuals after either RYGB (n=1738) or LAGB (n=610).
65
 Median percent weight loss 
was 3.15% and 15.9 % of baseline weight for RYGB and LAGB, respectively. Maximal 
weight loss was observed 1-year post surgery for both RYGB and LAGB, although from 
2 to 3 years post-surgery while LAGB weight remained stable, RYGB showed some 
evidence of weight regain.
65
 Others have also reported long-term weight maintenance 
after LAGB, with one study reporting 47.1% of excess weight loss at 15-years after 
surgery.
70
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2.4:  Long-Term Development of Nutritional Deficiencies with Implications for 
Inflammatory Status Following Bariatric Surgery 
 
Manipulation of the gastrointestinal tract during bariatric surgery can alter the 
absorption of nutrients that can lead to the development of nutritional deficiency after 
surgery. Nutritional deficiencies following bariatric surgery have been extensively 
reviewed in the literature.71,72 Ideally, supplementation begins early after surgery and 
continues as part of ongoing post-surgical care.
42
 Many individuals require life-long 
additional supplementation above the levels found in over-the-counter vitamin and 
mineral supplements.71 Despite this supplementation nutritional deficiencies can persist 
after bariatric surgery.73  
 
Of particular concern are: vitamin B12, thiamin, vitamin C, folate, vitamin A, 
vitamin D, vitamin K, and trace minerals including iron, selenium, zinc, and copper.71 
After RYGB and VSG, individuals are instructed to consume two chewable adult 
multivitamins with minerals, 1200-1500 mg of elemental calcium, at least 3000 IU of 
vitamin D, and vitamin B12 as sublingual, subcutaneous or intramuscular preparations (or 
orally if shown to be adequately absorbed).
42
 For LAGB, supplementation is the same, 
but only one multivitamin is required per day and additional vitamin B12 supplementation 
is not recommended.
42
 If nutritional deficiencies are identified during follow-up, 
individuals are instructed to consume additional supplementation tailored to their specific 
needs.  
 
  25 
Of these vitamins and minerals, some in particular such as vitamin D, copper and 
zinc may have the potential to influence inflammatory status. This could be important in 
the context of bariatric surgery, as we know that typically the low-grade inflammation 
that occurs with obesity tends to resolve or improve with weight loss. It is possible 
however, that concomitant development of nutritional deficiencies could negatively 
impact the inflammatory improvement seen with bariatric surgery. However, this 
hypothesis is preliminary and has not been proven and the potential interrelationships are 
complicated. The interplay between trace element nutritional deficiency, inflammation 
and, to some extent, weight loss after bariatric surgery has been recently reviewed in the 
context of hematological disorders.
74
 This review suggests that the interplay between 
micronutrient status and circulating adipose-derived cytokines could contribute to 
hematologic abnormalities and anemia after bariatric surgery through a series of complex 
interactions and needs to be investigated further.
74
 
2.4.1:  Copper 
The relationship between dietary and serum copper with inflammation is complex 
and not fully understood. Copper may contribute to both pro- and anti-inflammatory 
effects. The major copper containing protein in the blood, ceruloplasmin, is an acute 
phase plasma protein that may contribute to protection from inflammation and injury in 
various inflammatory states, e.g., inflammatory bowel disease.
75
 However, in a large 
population based cohort study, serum copper concentrations were shown to be inversely 
related to unfavorable metabolic markers (e.g. circulating glucose, uric acid, total 
cholesterol, and LDL cholesterol) and positively associated with increased high-
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sensitivity CRP (C-reactive protein), a marker of inflammation.
76
 The impact of 
decreasing circulating copper and ceruloplasmin concentrations on inflammation in the 
long-term after RYGB has not yet been established.  
 
However, it is well established that copper deficiency occurs following RYGB. 
An analysis of copper levels in 52 patients five years following RYGB showed that 3.8% 
had copper deficiency.
73
 A retrospective chart review of 136 patients who were on 
average 33-months post-RYGB, found that 9.6% were copper deficient and a longitudinal 
study completed as part of the same analysis which followed 16 patients for 24-months 
post-RYGB found that plasma copper decreased by 10.1% at 24-months, and 
ceruloplasmin activity decreased by 18.6% compared with baseline.
77
 Compared with 
baseline values, a statistically significant decrease in white blood cells was also observed 
at 6- and 24-months post-RYGB in this population.
77
 The incidence of the development 
of copper deficiency in this same longitudinal population was 18.8%.
77
  
 
Copper deficiency, if left to progress can have serious complications. A published 
case study documented severe acquired copper deficiency development in two 
individuals >10 years following RYGB.
78
 Typical presentation of copper deficiency 
includes abnormalities in gait, anemia, and with severe copper depletion, neutropenia.
78
 
As is highlighted by these case studies, because copper is not typically measured as part 
of routine care following bariatric surgery, copper deficiency may progress unnoticed and 
numerous incorrect diagnoses may be tested before the true issue is identified. While 
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overt copper deficiency is relatively uncommon following RYGB, subclinical decreases 
in circulating copper and ceruloplasmin may be more common and could have the 
potential to impact the inflammatory, hematologic, and neurologic systems.  
2.4.2:  Zinc 
Although it is more common following BPD/DS, zinc deficiency can and does 
occur following RYGB. The prevalence of zinc deficiency in a group of 52 subjects 
following RYGB was reported to be 15.4% and 21.2% at 48- and 60-months post RYGB 
respectively.
73
 In the same study, the circulating zinc level was associated with the 
alimentary limb length resulting from the surgery.
73
 One long-term study looking at 
deficiency at least 5 years after RYGB (average 6.9 years) showed that 40.5% were 
deficient in zinc at their last follow-up.
79
 
 
Zinc plays an important role in many of the functions of the immune system and 
is essential for the development of neutrophils and natural killer (NK) cells.
80
 Mild zinc 
deficiency, induced by restricting dietary zinc intake to 3-5 mg daily in healthy subjects, 
has been shown to impair cell-mediated immunity, IL-2 production, and decrease NK cell 
lytic activity.
81
 Additionally, in mild zinc deficiency, IFN-γ was decreased, but IL-4, IL-6 
and IL-10 expression was not altered.
80
 Overt zinc deficiency has also been shown to 
increase susceptibility to disease and infection.
82
  
 
 Only one study has attempted to evaluate the changes in trace element (iron, zinc, 
and copper) status and relate those changes and their potential associations with 
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inflammatory markers after RYGB. In a cohort of 63 women (mean age 36.9 ± 9.2 years, 
BMI 43.8 ± 4.3 kg/m
2
 who were evaluated at baseline and 6-months after RYGB, Rojas 
et al reported that hemoglobin, serum ferritin, the size of the rapidly exchangeable zinc 
pool (potentially a better measure of zinc status than plasma or serum zinc), and plasma 
copper decreased and leukocytes polymorphonuclear neutrophils (PMN) and high 
sensitivity CRP decreased post-RYGB.
83
 However, plasma and hair zinc as well as zinc 
protoporphyrin increased 6-months after RYGB. The increased zinc protoporphyrin was 
slightly positively associated with PMN, r = 0.32.
83
 These authors did not observe any 
significant associations between other measured markers of inflammation (including 
adiponectin, high sensitivity CRP and leukocytes) and any of the iron, zinc, and copper 
parameters that were measured.
83
 
 
2.4.3:  Vitamin D 
We have previously reported that in the first year following RYGB, serum 
vitamin D levels increased concomitantly with weight loss in many (but not all) 
individuals.
84
 In the extended post-operative period, however, others have shown that 
vitamin D deficiency develops and becomes prevalent in as many as 60.5%
79
 or 63%
85
 of 
patients after an average of 6.9
79
 and 4 years,
85
 respectively. In recent years, large 
volumes of research have been published linking vitamin D levels to inflammation. 
Vitamin D’s distribution includes adipose deposition.84 Vitamin D appears to modulate 
macrophage inflammation and treatment of low vitamin D status may reduce adipose 
inflammation. In a recent study utilizing peripheral blood mononuclear cells and cultured 
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bone marrow derived macrophages from mice, within physiologic ranges, higher 25- and 
1,25-dihydroxy vitamin D concentrations were shown to decrease TNF-alpha mRNA 
levels and decrease IL-6 in culture supernatants.
86
 TNF-alpha is known to be a potential 
inhibitor of mitochondrial biogenesis and functions through a number of mechanisms 
including inhibition of endothelial nitric oxide synthase (eNOS).
87
 Vitamin D may shift T 
cell profiles from Th1 toward Th2.
88,89
 Vitamin D status has also been linked with the 
levels of a number of interleukins (including IL-2, IL-6, IL-8, IL-12), IFN and MCP-
1.
90,91
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2.5:  Vitamin D Status Following Bariatric Surgery:  Implications and 
Recommendations* 
 
2.5.1:  Introduction 
The relationship between obesity and low levels of circulating 25-hydroxyvitamin 
D (25(OH)D) is consistently observed.
92
 While this relationship is not yet well 
understood, what is clear is that obesity and vitamin D deficiency are inversely related 
and there is a high prevalence of vitamin D deficiency in obese individuals.
93,94
 
Individuals with extreme obesity who qualify for bariatric surgery
42
 are frequently 
vitamin D deficient before
95–102
 and after
103–105
 surgery. Consequences of vitamin D 
deficiency include an increased risk of osteopenia and osteoporosis, muscle weakness and 
falls, and general overall pain and discomfort.
106
 
 
Vitamin D deficiency traditionally has been diagnosed based on the classic 
symptoms of osteomalacia and rickets due to its role in bone health. While vitamin D as 
it relates to bone health after bariatric surgery has been reviewed previously,
101,107
 there is 
growing interest in the non-bone functions of vitamin D that may have implications for 
obesity-related comorbidities. Emerging evidence suggests that higher than sufficient 
levels of serum vitamin D may be necessary to realize the non-bone-health-related 
benefits of vitamin D, but there is no current consensus on the definition of optimal 
vitamin D status.
108
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There is ongoing debate over the definition of vitamin D deficiency. In their 
recent update, the Institute of Medicine concluded that serum 25(OH)D ≥ 20 ng/ml is 
sufficient to cover the needs of 97.5% of the population, and overt deficiency occurs 
when serum 25(OH)D is < 12 ng/ml.
109
 In contrast, the US Endocrine Society maintained 
the previous definitions of deficiency as serum 25(OH)D < 20 ng/ml, insufficiency as 
serum 25(OH)D between 21-29 ng/ml, and sufficiency as ≥ 30 ng/ml.110 These 
discrepancies are the combined result of differing goals for each group and the large gaps 
that exist in the vitamin D literature. The controversy over what constitutes vitamin D 
deficiency has been addressed by both sides,
108,111
 but a consensus definition has not been 
reached. For the purpose of this review we define deficiency as < 20 ng/ml and 
insufficiency as < 30 ng/ml, unless reporting research where a different definition was 
used, in that case, the authors’ definition will be noted when it is available. 
 
Currently, there are no evidence-based guidelines for optimal vitamin D dosing 
strategies after bariatric surgery. It is also not known if attaining and maintaining 
sufficient or even optimal vitamin D levels before and after surgery improves outcomes. 
In this review we focus on summarizing the results of studies reporting vitamin D 
deficiency before and after surgery as well as studies assessing treatment and dosing 
regimens for vitamin D deficiency in the bariatric patient population. The current 
guidelines for treatment and potential implications of vitamin D deficiency in individuals 
following bariatric surgery are also discussed. 
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2.5.2:  The Potential Impact of Bariatric Surgery on Vitamin D Absorption 
Understanding how vitamin D levels are affected by bariatric surgery requires 
knowledge of the various procedures commonly performed. Bariatric surgical procedures 
can be narrowly classified as restrictive, malabsorptive, or as a combination of both 
depending on the traditional understanding of how the procedure promotes weight loss. 
Briefly, procedures that reduce the volume of the gastric reservoir and limit the transit of 
food are generally termed restrictive and procedures that prevent the absorption of 
nutrients are widely termed malabsorptive.
112,113
 
 
The LAGB procedure and the VSG are typically considered restrictive while the 
RYGB and the BPD with and without DS are considered restrictive and malabsorptive. 
For the LAGB procedure, an inflatable band is secured around the top of the stomach 
allowing for variable restriction of the movement of food from the small gastric pouch 
into the remainder of the stomach and the duodenum. During the VSG procedure the 
stomach is resected longitudinally, preserving the antrum and the pylorus. The newly 
created gastric pouch has an approximate volume of < 100ml. During the RYGB a small 
gastric pouch, approximately 15ml, is created and connected to the jejunum via what is 
commonly termed the Roux limb. Gastric and pancreatic secretions as well as bile are 
secreted into the pancreatobiliary limb, which is anastomosed with the jejunum. Longer 
Roux limbs result in a greater degree of malabsorption following surgery. For the BPD 
and the DS procedures, 70% of the stomach is resected and much of the small intestine is 
bypassed. BPD can be performed with and without DS where the proximal duodenum is 
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anastomosed to the distal small intestine to create a short common channel. The 
malabsorptive component of the DS is reversible because no intestine is removed during 
the procedure. Considering the gastrointestinal rearrangement and/or restriction that 
occurs following these surgeries, nutritional deficiencies, including vitamin D deficiency 
are common in this patient population. 
 
Vitamin D is endogenously produced after skin exposure to UVB light and can 
also be absorbed from dietary sources of either ergocalciferol (vitamin D2) or 
cholecalciferol (vitamin  D3). The two forms of vitamin D do not have equal biological 
activity and may not be equally effective at maintaining vitamin D status.
114
 At doses 
lower than 1000 IU, vitamin D2 and D3 appear equally effective; however, at doses higher 
than 1000 IU per day, vitamin D3 appears to be significantly more effective at raising 
serum 25(OH)D concentrations than vitamin D2.
114,115
 Ingested vitamin D is incorporated 
into chylomicrons, which are absorbed into the lymphatic system and then enter the 
venous circulation. Decreasing the absorptive area of the small intestine and altering the 
delivery of pancreatic secretions and bile with bariatric surgery may therefore lead to 
decreased absorption of vitamin D.
116
 The understanding of vitamin D absorption 
following bariatric surgery is complicated by the fact that a number of other factors 
beyond simple malnutrition likely contribute to the vitamin D deficiency in individuals 
with obesity.
92
 These include, but are not limited to, the potential sequestration of vitamin 
D by adipose tissue,
117
 the dilution of vitamin D in the presence of increased adiposity,
118
 
a lack of sun exposure, and a potential interaction between low-grade inflammation and 
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vitamin D levels.
119
 Because of the aforementioned factors and due to the substantial 
weight loss and lifestyle changes that occur afterward surgery, it is difficult to tease apart 
the impact of bariatric surgery on vitamin D absorption. 
 
There are limited data concerning vitamin D absorption before and after bariatric 
surgery. Aarts et al
116
 measured the response of 14 women to an oral dose of 50,000 IU 
vitamin D3 at 1-, 2-, 3-, and 14-days after dosing before and after RYGB.
116
 The 
investigators noted an approximate 25% decline in post-operative absorption,
116
 
indicating that dose adjustments may be necessary in order to replete vitamin D after 
surgery. The anatomical changes resulting from each of the four most common bariatric 
surgeries suggest that the greatest impact on vitamin D absorption is most likely to occur 
following the malabsorptive surgeries. Unfortunately, there are no studies directly 
assessing the absorption of vitamin D after LAGB, VSG, or BPD/DS. 
 
2.5.3:  Prevalence of Vitamin D Deficiency Before and After Bariatric Surgery 
Pre-Operative Vitamin D Status 
Low vitamin D status is prevalent in the pre-bariatric patient population.
95–102
 The 
pre-operative vitamin D status of bariatric patients has been thoroughly reviewed by 
Compher et al
101
 In their analysis of 14 studies (1566 patients), only one study
120
 reported 
a mean pre-operative serum 25(OH)D concentration > 32 ng/ml.
101
 More recently, in a 
sample of 115 women assessed for eligibility to undergo bariatric surgery, de Luis et al
102
 
found that 71.3% had serum 25(OH)D levels < 30 ng/ml and 26.1% had levels < 15 
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ng/ml.
102
 Numerous other studies in Europe
96,97,99
 and the United States,
84,98
 including 
northern and more southerly latitudes over the range of seasons, have also shown 
deficiency in a majority of study participants before VSG
96,97
 and RYGB.
96,98,99
 It is clear 
from these data that individuals undergoing bariatric surgery are frequently vitamin D 
deficient or insufficient. 
 
Post-Operative Vitamin D Status 
Vitamin D levels have also been evaluated after various bariatric surgeries with 
conflicting results noted. The prevalence of deficiency after bariatric surgery is likely 
impacted by the type of surgery performed, among other factors. 
 
Very few studies have assessed vitamin D status following LAGB. DiGiorgi et 
al
121
 reported a nonsignificant trend towards increased serum 25(OH)D from baseline at 
3-, 6-, 12-, and 24-months after LAGB.
121
 Before surgery, 58% of individuals who 
received LAGB were vitamin D deficient, after 24 months, 33% remained vitamin D 
deficient.
121
 Mean serum 25(OH)D for this patient population before and after surgery 
was not reported.
121
 All patients were advised to consume 800-1200 IU vitamin D daily 
before and after surgery.
121
 Similarly, Sinha et al
122
 reported that serum 25(OH)D levels 
significantly increased from pre-LAGB to 9-12 months post-LAGB (20 ng/ml to 33 
ng/ml, P=0.03). 
122
 These individuals were instructed to consume 400 IU vitamin D3 per 
day after surgery, and some individuals were instructed to consume either 1200 IU 
vitamin D3 or 50,000 IU vitamin D2 depending on their pre-surgery vitamin D status.
122
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From the limited evidence available, it appears that vitamin D status may moderately 
improve following LAGB when supplementation is included as part of pre- and post-
operative care. 
Despite the increasing popularity of the VSG procedure, there is a paucity of 
studies specifically addressing nutritional deficiencies afterwards. Most of the studies that 
do report vitamin D status after VSG are more appropriately classified as treatment 
studies and will be discussed later.
99,123
 Moizé et al
96
 reported the vitamin D levels of 61 
individuals following VSG.
96
 They found that at baseline, approximately 93% of these 
individuals had serum 25(OH)D levels < 30ng/ml. Post-operatively, all individuals were 
prescribed approximately 1040 IU oral vitamin D per day from daily multivitamins and 
calcium supplements containing vitamin D. Compliance with supplementation was not 
recorded. Four years after surgery, the percentage of individuals with serum 25(OH)D 
levels < 30 ng/ml ranged between 66% and 85%,
96
 indicating that for many individuals, 
vitamin D deficiency persists long after VSG. 
 
Numerous studies have assessed vitamin D status after RYGB and inconsistent 
results between studies are evident. Beckman et al
84
 studied a cohort of 20 women for 1-
year after RYGB and found that serum 25(OH)D increased by 10 ng/ml from baseline.
84
 
At baseline, all serum 25(OH)D levels were below 30 ng/ml.
84
 Individuals in this study 
were advised to consume 400-800 IU per day.
84
 Conversely, Ybarra et al
105
 reported no 
significant change in vitamin D levels approximately 36-months post-RYGB compared to 
individuals with obesity who had not undergone RYGB.
105
 In addition, the mean post-
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surgery serum 25(OH)D concentration was 13.5 ng/ml, which was not different from 
non-RYGB subjects, suggesting that vitamin D deficiency is prominent both before and 
after surgery. Individuals in this study were not taking supplemental vitamin D and 
vitamin D levels before RYGB were not reported. Studies with longer follow-up times 
also suggest that vitamin D deficiency persists after RYGB for some individuals.
103
 
Johnson et al
103
 prospectively evaluated 266 RYGB patients. At baseline, mean serum 
25(OH)D was 25 ng/ml and 41/266 individuals were reported to have levels below 30 
ng/ml. The mean post-operative serum 25(OH)D levels were 34 ng/ml and 35 ng/ml at 1-
year and 2-years post-surgery, respectively.
103
 Study subjects were reported to consume a 
standard multivitamin three times per day (approximately 800 IU vitamin D per day) 
however compliance was not ascertained.
103
 Carlin et al
124
 also reported increased, but 
still suboptimal, vitamin D levels post-operatively.
124
 These authors followed 60 women 
for 1-year after RYGB.
124
 Each woman was randomly instructed to consume either 800 
IU alone or 800 IU plus an additional 50,000 IU vitamin D2 per day, compliance was 
assessed during patient interviews but not reported for each group overall.
124
 At baseline, 
mean serum 25(OH)D was not different between groups (19.7 and 18.5 ng/ml for the 
50,000 and 800 IU groups, respectively).
124
 After 1-year, 19.2% of the women in the 
group receiving 50,000 IU per day were still vitamin D deficient despite having 
significantly increased vitamin D levels when compared to the 800 IU per day group 
(37.8 ng/ml vs 15.2 ng/ml, P<0.001).
124
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Vitamin D deficiency following BPD has been evaluated in a limited number of 
studies.
85,104,125
 In a retrospective analysis of post-BPD patients, 73% of individuals had 
vitamin D levels < 30 ng/ml and 47% had levels < 20 ng/ml.
104
 Indicating that over 
approximately 3-years vitamin D levels continued to decrease despite supplementation of 
50,000 IU per day after surgery, though compliance was not measured.
104
 Additional 
studies have reported that vitamin D deficiency is present in 63% of individuals 
undergoing BPD after four years,
85
 and in 50% after a median of 32 months.
125
 
 
 Comparative studies of the impact of different bariatric procedures on post-
operative vitamin D status are limited in number. Reports indicate that the incidence of 
nutritional deficiencies after VSG is generally comparable with, or less than, the 
incidence after RYGB.
113,123
 Coupaye et al
99
 recently reported on a cohort of 202 patients 
who underwent RYGB, 30 of whom were matched for age, gender, weight, skin color, 
and season with patients who underwent VSG.
99
 Preoperatively, 91% of the entire cohort 
were vitamin D insufficient and 80% were deficient. Six months after surgery 
insufficiency and deficiency rates were 76% and 44% respectively.
99
 Between the two 
groups of matched controls (RYGB v. VSG), serum 25(OH)D levels six months after 
surgery were not significantly different. The participants were only prescribed a 
multivitamin providing 200 IU to 500 IU vitamin D3 daily, indicating that weight loss 
likely had a greater impact on serum 25(OH)D levels following surgery than 
supplementation.
99
 In contrast, Gehrer et al
123
 reported a lower incidence of vitamin D 
deficiency after VSG than RYGB. Before surgery 23% of patients were vitamin D 
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deficient, and following VSG and RYGB, 32% and 52%, respectively, were deficient 
(P=0.02).
123
 The mean follow-up time was 24-months after surgery.
123
 Individuals in both 
groups received no vitamin D supplementation unless deficiency was identified and both 
groups lost a similar amount of weight 1-year after surgery.
123
 LAGB was compared with 
RYGB by DiGiorgi et al
121
 and they reported that vitamin D deficiency decreased from 
58% and 67% pre-surgery to 33% and 40% two years post-surgery in individuals 
undergoing LAGB and RYGB, respectively.
121
 Given the range of results reported here, 
it is difficult to clearly ascertain the mechanisms driving vitamin D deficiency in this 
population. 
 
2.5.4:  Vitamin D Treatment and Dosage Studies 
There are a number of other factors that might contribute to the variability in 
vitamin D deficiency status reported in the literature. These factors include the level of 
and compliance to supplemental vitamin D after surgery and the method used to assess 
vitamin D status. 
 
Treatment studies of vitamin D repletion using standard dosing levels ranging 
from 200-400 IU
126,127
 and 800 IU
124,128
 have been reviewed previously; these intake 
levels are generally ineffective at positively impacting vitamin D status.
92
 One of the 
more comprehensive studies worth revisiting here was conducted by Aasheim et al
129
 
These investigators studied 31 RYGB and 29 DS patients who were instructed to 
consume 400 IU vitamin D3 per day and reported increased serum 25(OH)D levels at 1-
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year after RYGB (P<0.001, baseline mean = 13 ng/ml) and decreased at 1-year following 
DS (P=0.059, baseline mean = 12 ng/ml).
129
 These findings occurred despite self-
reported higher vitamin D supplement use (approximately 400 IU per day) by the DS 
group: 89% reported taking vitamin D3 1-year after surgery compared with 74% of 
RYGB patients.
129
 Results from this study and others that investigated standard treatment 
of 200-800 IU per day
124,126–128
 for vitamin D deficiency indicate that this level of 
supplementation is likely to be inadequate to restore vitamin D levels after surgery. 
 
Higher doses of supplemental vitamin D have also been evaluated after bariatric 
surgery.
100,130–133
 Moore and Sherman
134
 evaluated vitamin D3 supplementation following 
RYGB (n=11) and VSG (n=12) and found that daily supplementation of 2000 IU vitamin 
D3 three months following surgery reduced the prevalence of deficiency from 60.6% to 
26.1% (P=0.005). They report that the response to supplementation was not different 
between RYGB and VSG.
134
 Goldner et al
130
 evaluated three levels of vitamin D 
supplementation in a prospective randomized pilot trial following RYGB.
130
 They studied 
the efficacy of 800, 1200, and 5000 IU levels of supplementation (n=45) and found that 
47%, 70%, and 70% of each respective group achieved 25(OH)D levels > 30ng/ml after 
12 months.
130
 However, even after 5000 IU per day for two years, only 78% of 
participants achieved serum 25(OH)D levels > 30 ng/ml, indicating that many patients 
may require even higher daily doses of vitamin D to achieve sufficiency in the years 
following surgery.
130
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Intramuscular injected ‘megadoses’ of vitamin D show some promise as 
adjunctive therapies for vitamin D deficiency following BPD. Einarsdóttir et al
133
 
demonstrated that 600,000 IU vitamin D3 delivered intramuscularly to 29 individuals post 
BPD significantly raised serum vitamin D levels from baseline at 1.5- (P<0.001), 3- 
(P<0.001) and 6-months (P=0.014) post-injection, but not at 9- (P=0.248) and 12-months 
(P=0.278).
133
 Mean serum 25(OH)D concentration was 25 ng/ml and 28.6% of subjects 
had vitamin D levels below 25 ng/ml at baseline.
133
 No side effects or adverse events 
were reported during follow-up. Individuals in this study were also prescribed 1280 IU 
oral vitamin D3 throughout the study, however compliance was not assessed.
133
 The 
highest serum 25(OH)D level recorded was 64 ng/ml, indicating that this delivery method 
and level of supplementation did not raise serum 25(OH)D to levels outside of the normal 
range.
133
 These authors concluded that because non-compliance with dietary 
supplementation of vitamin D is relatively high post-BPD, a once or twice yearly 
intramuscular depot of vitamin D could provide an effective treatment for deficiency.
133
 
 
Another factor that may contribute to the variability of vitamin D status reported 
in the literature is the method used to evaluate serum 25(OH)D. There are many 
commonly used methods for measuring serum 25(OH)D. These include the competitive 
vitamin D protein binding assays (CPBA), immunoassays, high performance liquid 
chromatography (HPLC), and liquid chromatography-tandem mass spectroscopy (LC-
MS/MS).
135
 Most studies reviewed did not report the method of assay. Of those 
specifying the method, the vast majority used immunoassays.
105,122,124,129
 Between 
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method variance has been widely observed and underscores the need for standardization 
of 25(OH)D assays.
135,136
Assays using antibodies or vitamin D binding proteins may be 
unable to distinguish between 25(OH)D and 25(OH)D2, or various metabolites of 
25(OH)D3, leading to under and overestimation, respectively, when compared with LC-
MS/MS.
137
 LC-MS/MS has been chosen as a reference method by the National Institutes 
of Standards and Technology and also by the Centers for Disease Control and 
Prevention,
135
 yet many studies still report serum 25(OH)D levels determined by 
immunoassays and other methods. For many researchers, LC-MS/MS analysis may be 
cost and time prohibitive. Expensive equipment, technical expertise, and relatively low 
throughput are just some of the disadvantages of LC-MS/MS that need to be overcome so 
that the method is more available to researchers. Consideration of the method used for 
analysis of vitamin D status may help to explain some of the contradictory evidence for 
vitamin D deficiency after RYGB. There needs to be a coordinated push for all 
researchers to adopt the same method for analysis of serum 25(OH)D, ideally LC-
MS/MS, in order to allow for a true comparison between studies. 
 
2.5.5:  Current Recommendations for Treatment of Vitamin D Deficiency Before and 
After Bariatric Surgery 
Current recommendations from the US Endocrine Society advise individuals with 
obesity and those with malabsorptive syndromes to consume at least 6000-10,000 IU per 
day of vitamin D to treat deficiency (two to three times the level for healthy, normal 
weight adults) and to maintain serum 25(OH)D above 30 ng/ml.
108,110
 They recommend 
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maintenance therapy of 3000-6000 IU per day once sufficiency is achieved.
108,110
 The US 
Endocrine Society classifies these recommendations as weak, although based on high 
quality evidence.
110
 While these guidelines were developed with a bariatric population in 
mind, as has been clearly demonstrated, daily supplementation even at two to three times 
the level recommended for healthy adults may be inadequate to maintain vitamin D 
sufficiency after bariatric surgery. 
 
The AACE/TOS/ASMBS Bariatric Surgery Clinical Practice Guidelines 
recommend supplementation post-operatively with at least 3000 IU of vitamin D per day, 
with increasing dosage until a serum 25(OH)D level of > 30 ng/ml is reached (Grade A, 
based on randomized controlled trial data).
42
 In cases of severe malabsorption they 
recommend vitamin D2 or D3 doses as high as 50,000 IU delivered one to three times per 
week up to daily, and more recalcitrant cases may require concurrent oral administration 
of calcitriol (Grade D, indicating that a 2/3 consensus of the task force could not be met 
for the recommendation). 
 
The evidence for both of the aforementioned guidelines is quite limited because 
there have been very few randomized controlled trials of vitamin D dosing strategies. The 
US Endocrine Society cites two papers
138,139
 as evidence in support of their 
recommendation for obese patients and patients with malabsorption.
110
 However, neither 
of these papers are treatment studies of vitamin D repletion before and/or after bariatric 
surgery. The AACE/TOS/ASMBS guidelines are very comprehensive. However, the D 
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grade given for recommendation of up to 50,000 IU per day in cases of severe 
malabsorption indicates a low consensus among the task force members. These 
guidelines underscore the need for more research to develop evidence-based guidelines 
for repletion of vitamin D before and after bariatric surgery. 
 
2.5.6:  Implications and Clinical Outcomes of Vitamin D Deficiency after Bariatric 
Surgery 
While we know that vitamin D deficiency is prevalent before and after surgery, it 
is not clear what the potential impact of vitamin D deficiency or pre-surgery repletion 
would have on post-operative outcomes. Furthermore, this question becomes particularly 
important to consider in those individuals that develop significant post-operative 
complications (e.g. anastomotic leak, wound infection) and require intensive care. 
Vitamin D is thought to have wide-reaching effects that could potentially improve 
outcomes post-surgery. Active 1,25-dihydroxyvitamin D acts on various tissues 
throughout the body that express the vitamin D receptor, including adipose tissue, and 
may be responsible for up-regulating hundreds of genes that could impact multiple 
systems.
108
 Vitamin D has been reported to positively influence cellular and immune 
functions including inflammatory pathways,
140
 the renin angiotensin system and blood 
pressure regulation,
141
 insulin sensitivity,
142
 and other obesity related comorbidities.
108
 
Although observational studies support associations between vitamin D status and 
obesity-related comorbidities, there have not been enough long-term, randomized 
controlled trials to draw definitive conclusions.
143
 If vitamin D does indeed have wide-
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reaching effects throughout the body, the ramifications of vitamin D repletion have the 
potential for a profound impact on outcomes following bariatric surgery and may be 
particularly important in the setting of critical care. 
 
In light of the expanding literature linking vitamin D with inflammation,
144
 one 
recent study examined the impact of vitamin D deficiency on rates of post-RYGB 
infection. Quraishi et al
145
 investigated the association between 25(OH)D levels and the 
risk of hospital acquired infections (HAI) after RYGB through a retrospective analysis of 
770 patients. They found that the risk for HAIs was three-fold greater (adjusted odds ratio 
3.1; 95% CI 1.3-6.9) for patients with serum 25(OH)D levels < 30 ng/ml when compared 
to patients with levels > 30 ng/ml.
145
 What we do not know is whether repletion of 
vitamin D prior to surgery can have an impact on inflammation and decrease the risk of 
HAIs and complications following surgery. 
 
With the continued trend towards increasing rates of obesity and bariatric surgery 
it follows that individuals with a prior history of bariatric surgery will constitute an 
increasing percentage of those requiring care for critical illness.
146,147
 Furthermore, 
complications associated with aging including sarcopenic obesity are likely to be 
particularly problematic in individuals who have undergone bariatric surgery. These 
potential complications could be compounded by vitamin D deficiency in these 
individuals, given its potential to diminish muscle function and strength.
148
 Vitamin D 
deficiency has indeed been correlated with decreased muscle strength and incidence of 
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falls in older adults.
148–151
 Although it has not been the focus of current research on 
vitamin D and bariatric surgery, there is a pressing need for additional research to 
elucidate the role of vitamin D repletion in the management of muscle weakness and 
sarcopenic obesity in general, as well as in the critical care setting, in aging individuals 
with a history of bariatric surgery. 
 
2.5.7:  Research Needs and Future Directions 
The question of how to best treat vitamin D deficiency in a bariatric population 
remains unanswered. First, it is not known if repletion of vitamin D before bariatric 
surgery will have any impact on clinical outcomes. There are no randomized controlled 
trials to assess the effect of improving vitamin D status before surgery on post-operative 
clinical outcomes. Given vitamin D’s roles in regulating the immune system, it seems 
plausible that improving vitamin D status before surgery could result in decreased rates 
of surgical site infections and complications. More research is needed to determine if 
supplementation with an aim of achieving sufficiency prior to surgery should be 
recommended. 
 
Second, the question of how to determine optimal dosing regimens for repletion 
after each type of bariatric surgery, and how to adjust these regimens for long-term 
maintenance once sufficiency is achieved remains unanswered. Absorption and dosing 
studies are needed to establish specific guidelines for each type of bariatric surgery. 
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Third, a number of other potential routes of vitamin D administration exist that 
have yet to be tested in a bariatric population. A cursory search of the online retailer 
Amazon.com revealed numerous supplement companies who market vitamin D2 and D3 
dietary supplements in patch, cream, and sublingual spray form. Very little research 
exists to corroborate the use of alternative routes of delivery of vitamin D. One recent 
small pilot study from Saudi Arabia demonstrated that daily topical application of 5000 
IU vitamin D3 to the skin of 48 healthy individuals for three months was successful in 
significantly raising serum 25(OH)D concentrations from 12 ng/ml to 38 ng/ml 
(P=0.001).
152
 Routes of delivery that bypass the gastrointestinal tract should be 
investigated further particularly in individuals undergoing malabsorptive procedures. 
 
Last, not only is the aging bariatric population of significant concern, the younger 
bariatric population consisting of adolescents has been understudied. Other nutritional 
complications, including vitamin D deficiency, in these young individuals are particularly 
concerning given the potential impact on growth and development. Furthermore, these 
individuals will present important challenges for the medical community as they mature, 
reproduce, and age. It is likely that vitamin D deficiency both in the immediate and long-
term following bariatric surgery could have important implications for health outcomes. 
 
A number of logistical considerations should be made when designing future 
research to address these important issues. These include but are not limited to: recording 
vitamin D intake from diet and supplements and estimating UVB exposure; assessing 
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compliance with supplementation regimens potentially with electronic methods; 
including controls and randomization when appropriate; and using a standardized and 
validated 25(OH)D assay method (LC-MS/MS). 
 
2.5.8:  Conclusion 
Although vitamin D deficiency is widely observed in individuals undergoing 
bariatric surgery, very little is known about post-operative changes in vitamin D 
absorption and other factors that may be driving vitamin D deficiency in these 
individuals. From the limited dosing studies available it appears that the DRI for vitamin 
D is inadequate for this patient population. It has been reported that doses of 5000 IU per 
day can be effective, but even 50,000 IU per day is not always effective at achieving 
vitamin D sufficiency in some individuals. Clearly, more research is needed to develop 
evidence-based guidelines for dosing specific to each type of bariatric surgery. Current 
guidelines recommend anywhere from 3000 IU-50,000 IU per day depending on the 
estimated severity of malabsorption. The clinical implications of vitamin D deficiency in 
these individuals are relatively unexplored; vitamin D insufficiency post-RYGB was 
reported to increase the risk for HAIs. Vitamin D’s role in maintaining immunity and 
muscle function could have important clinical ramifications for the aging bariatric 
population, particularly in the critical care setting. Additional, well controlled studies are 
needed: 1) to evaluate the impact of vitamin D repletion before surgery on post-operative 
clinical outcomes; 2) to develop effective vitamin D repletion and maintenance dosing 
regimens and identify optimal routes of administration specific for each type of surgery; 
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and 3) to better understand the implications of vitamin D deficiency and optimal repletion 
in both young and aging bariatric populations. 
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2.6:  The Current Study 
In the short-term following RYGB significant changes in body composition 
occur. These changes include decreased FM and LST. The current literature indicates that 
in the long-term after RYGB weight regain tends to occur. It is not clear which body 
compartments are affected by weight regain after bariatric surgery. Changes in FM could 
have ramifications for inflammation and could be influenced by nutrient status. It is not 
known if field techniques for the assessment of body composition can be applied to the 
setting of long-term weight management after bariatric surgery to monitor these changes. 
An important question is whether we can monitor these changes with existing BIS 
technology.   
 
In this dissertation the relationships between long-term body composition, 
nutritional status and inflammation are explored. In Chapter 3 the long-term changes of 
body composition and nutritional status are investigated in a small cohort of 5 women 
8.5-years after RYGB. While the focus of this pilot study is primarily on body 
composition, nutritional status is also assessed, but only as it relates to the potential 
interplay between specific vitamins and minerals (namely: vitamin D, copper and zinc) 
and inflammation. In Chapter 4 an analysis of an advanced model for BIS assessment of 
body composition is presented with the goal of validating this model in comparison with 
DXA data from an NHANES dataset and a longitudinal dataset of women 1-year after 
RYGB. In Chapter 5, these studies are summarized and conclusions regarding their 
implications for future research are discussed.  
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CHAPTER 3:   LONG TERM FOLLOW-UP OF BODY COMPOSITION AND 
NUTRITIONAL STATUS FOLLOWING ROUX-EN-Y GASTRIC BYPASS SURGERY 
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3.1:  Overview 
 
Background:  The Roux-en-Y gastric bypass (RYGB) has been the most commonly 
performed bariatric surgery over the past decade; it is traditionally classified as a 
restrictive and malabsorptive procedure, but hormonal changes also likely contribute to 
its success in inducing weight loss. Few data exist regarding the long-term impact of 
RYGB on nutritional status, body composition, and tissue level inflammation. 
Methods:  Five women from an original larger cohort were monitored pre-RYGB and 
1.5-months, 6-months, 1-year and 8.5-years post-RYGB. Body composition was assessed 
using dual energy x-ray absorptiometry (DXA) and multiple dilution. Plasma, serum, and 
adipose tissue biopsies from surgery and 8.5-years post-RYGB were assessed for makers 
of nutritional status and inflammation. 
Results:  Compared to baseline, 8.5-year mean lean soft tissue (LST) was 11.9 ±5.6 kg 
lower (overall P=0.004) and 8.5-year LST was 4.4 ± 3.0 kg lower than 1-year post-
RYGB (paired P=0.04). Fat free mass (FFM) decreased over the 8.5-year period by 12.6 
± 5.8 kg (overall P=0.004). Total bone mineral content (BMC) also decreased over the 
8.5-year period from 3.0 kg to 2.3 kg (overall P=0.025). Unlike other tissue types, mean 
fat mass (FM) decreased after surgery from 75.4 ± 22.6 kg to 35.5 ± 21.5 kg 1-year post-
RYGB (paired P=0.0004), but then increased by 8.6 ± 7.0 kg after 1-year (paired 
P=0.05). Loss of LST was moderately well correlated with loss of handgrip strength (r = 
0.64, P=0.0005). Vitamin D status increased over time (P=0.01). Tissue level 
inflammation measured by cytokines (MCP-1, IL-6, and IL-8), trended towards a 
decrease over time, but was not significantly different from time of surgery. 
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Conclusion:  Improvements in vitamin D status and inflammatory status occur in good 
responders to RYGB. Continued decreases in LST, FFM, and BMC occur on the 
background of weight regain as FM. Losses of LST are correlated with decreased 
functional status measured by handgrip strength.   
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3.2:  Background 
The Roux-en-Y gastric bypass (RYGB) is a restrictive and malabsorptive 
procedure that reduces stomach capacity to approximately one ounce, bypasses part of 
the small intestine, and decreases nutrient absorption. Although overt macronutrient 
malabsorption is rarely reported, possible adverse outcomes of RYGB include protein 
deficiency, specific vitamin and mineral deficiencies, anemia, bone loss, abnormal fluid 
distribution, and excessive lean tissue loss.
153–156
 While body composition has been 
measured by many groups in the first year after surgery,
39,46–49,157–159
 few data exist 
regarding the long-term impact of RYGB on body composition. As might be expected, 
fat mass (FM)
39,46,49,158,159
 and percent body fat
46,47,49,158
 have been observed to 
substantially decrease after RYGB; however, fat free mass (FFM) also decreases after 
surgery, albeit to a lesser extent. The degree to which FFM is lost varies among 
individuals undergoing RYGB and is influenced by factors including dietary protein 
intake, exercise and mobility, and inflammation.
53,57,160,161
 It is not well-studied what 
impact the long-term changes in body composition, particularly FFM, may have on 
muscle strength, function, and quality of life over the long-term in post-RYGB patients. 
 
Within the FFM compartment is the intracellular water (ICW) and extracellular 
water (ECW), comprising the total body water (TBW). Abnormal fluid distribution 
between the ECW and ICW has been widely observed in the obese state.  Individuals 
with obesity have been found to have a relative expansion of the ECW compartment, 
which is typically expressed as an elevated ECW/ ICW or ECW/TBW ratio.
38,40
 For 
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example, the average ECW/ICW ratio of women with obesity (body mass index [BMI]: 
48.8 ± 6.8 kg/m
2
) has been reported to be 0.82 ± 0.17, while in lean individuals (BMI: 
21.0 ± 2.0 kg/m
2
) was reported to be 0.63 ± 0.06.
38,40
 Other researchers have evaluated 
the expansion of ECW and overall fluid distribution in bariatric populations prior to 
surgery and found elevated ECW/ICW ratios, e.g. 0.80 ± 0.08,
162
 0.89 ±0.18
163
 and 1.48 
± 0.57.
39
 The obesity associated expansion of ECW does not appear to normalize after 
significant weight loss, with investigators reporting no change in the ECW compartment 
following weight stabilization over the first 1-2 years after bariatric surgeries including 
duodenoileal bypass,
40
 gastroplasty,
162
 and lap band.
163
 
 
The relative expansion of ECW in individuals with obesity before and after 
RYGB has ramifications for body composition assessment because it causes violation of 
underlying assumptions inherent within the two-compartment measurement methods such 
as densitometry (e.g. air displacement plethysmography [ADP]) and deuterium dilution. 
Most notably, the assumptions that FFM is hydrated at 73%,
20
 and that the body has a 
density of 1.1 g/ml
15
 may not hold true in the obese and post-obese state, as observed by 
others.
38–40,162
 Therefore, a combination approach to body composition assessment in 
populations undergoing massive weight loss may minimize these errors, and allow for a 
more complete assessment of long-term lean tissue changes following RYGB. 
 
In addition to the changes in body composition, the restrictive and malabsorptive 
components of RYGB may contribute, in the long-term, to the development of rare 
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micronutrient deficiencies such as zinc and copper deficiency. These minerals are 
absorbed primarily in the duodenum and stomach and their absorption is decreased 
following RYGB.
71
 Deficiency of micronutrients (including vitamin D) can persist 
following RYGB despite supplementation; poor vitamin D, copper, and zinc status could 
have ramifications in terms of inflammation.
73,75,76,82
 The potential inflammatory 
implications of nutritional deficiencies after RYGB have not been explored.  
 
Here we report the descriptive results of an uncontrolled longitudinal long-term 
follow-up pilot study to assess body composition using multiple methods, nutritional 
status (with particular focus on vitamin D, zinc and copper), and inflammatory changes in 
the plasma and adipose tissue as measured by cytokine content and mRNA gene 
expression before and after RYGB.  
 
3.3:  Subjects 
As has been previously described,
4
 women with Class III obesity (BMI ≥ 40 
kg/m
2
) who were planning to undergo RYGB surgery at the Weight Loss Management 
and Surgery Center at the University of Minnesota Health, were recruited for the original 
1-year longitudinal study between 2005 and 2007.
4
 The follow-up study of these original 
study subjects was completed during 2014 and 2015 and was approved by the University 
of Minnesota Institutional Review Board (IRB) and the Clinical and Translational 
Science Institute (CTSI). Returning subjects were compensated for their time. The 20 
original subjects who attended at least three study visits as part of the original study were 
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re-contacted through an IRB approved mailed letter and asked to return to the Masonic 
Cancer Research Unit (MCRU) for one study visit. Individuals were excluded from the 
study if they (1) were on medications known to influence body composition (e.g. 
corticosteroids, anabolic steroids), (2) had a pacemaker or other internally-placed 
biomedical device, (3) had conditions associated with significant hydration changes, 
and/or metabolic disturbances, such as pulmonary hypertension, congestive heart failure, 
abnormal thyroid function indices, neoplastic disease, liver failure, renal failure, type 1 
diabetes, and poorly controlled type 2 diabetes, or (4) were pregnant. The original cohort 
was limited to women to maximize the homogeneity of the sample given the significant 
differences in body composition between men and women; and because at the time of 
recruitment, only ~15% of the patients undergoing RYGB at our site were male.  
 
3.4:  Methods 
3.4.1:  Study Protocol 
 Participants who were previously enrolled in the original study were re-contacted 
by mail and attended one additional study visit. The study visit began in the morning after 
a 12-hour fast. Participants remained fasted throughout all visit procedures. 
3.4.2:  Anthropometric Measurements 
Each participant’s height was measured to the nearest 0.1 cm using a wall-
mounted stadiometer (model S100; AYRTON, Prior Lake, MN) and weight was 
measured to the nearest 0.1 kg using a stand-on digital scale (model 5002, SCALE-
TRONIX, White Plains, NY). Waist and hip circumference were measured following 
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standardized procedures as outlined in the Anthropometric Standardization Reference 
Manual.
164
  
3.4.3:  Total Body Water and Extracellular Water 
The day before the long-term follow-up study visit, participants were asked to 
avoid alcohol and vigorous exercise, and to maintain their usual fluid intake, limiting 
water consumption to no more than 250 ml water during the 2-hours just prior to testing. 
To measure TBW, after an 12-hour fast consisting of nothing by mouth except water, 
participants consumed 25 g of a 16% (wt/wt) solution of deuterium oxide, prepared 
following the method described in Trabulsi et al
165
 (supplying 4 g of 99.9% 
2
H2O per pre-
weighted dose, Sigma-Aldrich) in tap water, followed by 25 ml tap water rinse. To 
measure ECW, participants consumed 1g/kg of a 3% (wt/vol) sodium bromide solution 
(Fisher) in tap water followed by a 25 ml tap water rinse. Serum samples were collected 
for analysis of bromide enrichment at baseline, and 4- and 5-hours post dose. The 5-hour 
time point was used for data analysis. Urine samples were collected for analysis of 
deuterium enrichment at baseline, and 3-, 4-, and 5- hours post-dose. The 5-hour time 
point was used for data analysis. Participants were asked to void their bladders hourly 
during the study visit and they did not break their fast or consume any additional fluids 
throughout the 5-hour post-dose equilibration period. Urine samples were analyzed for 
deuterium enrichment by the laboratory of Dr. Dale Schoeller (University of Wisconsin, 
Madison, WI).
22,165,166
 TBW was determined from the deuterium space after reducing it 
by 4% to correct for exchange with the non-aqueous compartment.
22
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Serum samples were analyzed by high-performance liquid chromatography for 
bromide by the laboratory of Dr. Jennifer Rood (Pennington Biomedical Research 
Center, Baton Rouge, LA).
167,168
 The bromide dilution space was used to calculate ECW 
using the equation: 
Equation 3-1:  ECW calculation 
ECW=[𝒅𝒐𝒔𝒆/([𝑩𝒓]𝟓−𝒉𝒐𝒖𝒓 − [𝑩𝒓]𝑩𝒂𝒔𝒂𝒍)]×0.95×0.9  
where 0.95 is the Donnan equilibrium correction and 0.9 corrects for the intracellular 
distribution (including red blood cells).
22 
The original TBW and ECW data collected during the first year of weight loss 
following RYGB were used for comparison with the long-term follow-up data. For the 
first year of the study, we completed multiple dilution using a peripheral intravenous (IV) 
dosing protocol for deuterium and sodium bromide as has been previously reported.
45
 For 
baseline, 1.5-months, 6-months, and 1-year post-RYGB, TBW was calculated from the 
average deuterium enrichment of the 3-hour and 4-hour urine samples. For the same four 
time points, ECW was calculated from the 4-hour post-sodium bromide infusion serum 
sample. For all time points, ECW and TBW were converted to kg by multiplying by 
0.993 (the density of water at 37C).  Oral dosing should result in slower time to 
equilibrium than IV dosing for both deuterium and bromide, thus we extended the 
equilibration time by 1-hour.  
3.4.4:  Body Composition by ADP 
Body composition was assessed by ADP using the BOD POD

  (COSMED USA, 
Inc.; Concord, CA) located at the Center for Neurobehavioral Development (CNBD), 
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University of Minnesota and following the standard BOD POD

 protocol included with 
the device’s software. The BOD POD was calibrated each day before use. Body weight 
was measured using the device’s electronic scale that was calibrated bi-weekly. 
Participants wore tight fitting Lycra

 or spandex

 swimwear or lightweight sports bra 
and close fitting underwear and covered their hair with a tight fitting swim cap. 
Participants were instructed to remove all metal and jewelry before entering the machine. 
The device reports the average of two raw body volume measurements. The Siri model 
was used to estimate body composition.
15
 When the participant was capable of doing so, 
thoracic gas volume (TGV) was measured using the device. TGV measurement was 
repeated until a merit value (<1.0) was obtained to signify compliance with the TGV 
protocol. For the one participant who was unable to complete the TGV measurement, the 
device-predicted TGV result was used. Calculations were performed by the BOD POD’s 
software (version 5.4.0). Repeat measurements of body volume using BOD POD have 
been shown to result in an error equivalent to 0.8% body fat.
169
 
3.4.5:  Body Composition by Dual Energy X-ray Absorptiometry 
As described by Levitt et al,
45
 half-body and whole body DXA scans from the 
original study were performed on the GE Lunar Prodigy (GE Healthcare, USA). By the 
time of the long-term follow-up the CTSI had discontinued the use of the GE Lunar 
Prodigy, so long-term follow-up visits were measured as both half- and whole-body 
(when possible) scans on the GE Lunar iDXA (GE Healthcare, USA). Half-body scans 
from baseline, 1.5-months, 6-months, and 1-year post-RYGB were re-analyzed using the 
Lunar iDXA software. The right-side half-body scans were mirrored around the mid-line 
  61 
to create a “whole” individual for analysis. For each original (baseline, 1.5-months, 6-
months, 1-year) scan, study participants were scanned using an acrylic board to separate 
arm tissue from breast tissue as previously described.
45
 Re-analysis of the isolated board 
using the new software indicated that it was interpreted by the iDXA as contributing the 
whole-body equivalent of 1.165 kg to FM and 0.365 kg to FFM. Thus, these values were 
subtracted from the results for mirrored body FM, LST, and FFM from the original scans. 
No corrections were made to the mirrored half-body scan for the one long-term follow-up 
visit where an acrylic board was not used. Precision of the iDXA instrument has 
previously been reported to be <1% for whole body bone mineral content
170
 and 1.5% for 
whole body FM and LST measures
171
 in individuals with extreme obesity. 
3.4.6:  Resting Energy Expenditure (REE) 
At the time of metabolic rate measurement study participants had been fasted for 
approximately 15-hours. After resting quietly in a recumbent position for at least 30-
minutes, measurement of REE was completed using a portable metabolic cart (TrueOne
®
 
2400, Parvo Medics, East Sandy, UT). A trained technician completed the REE 
measurement following the standard CTSI clinical protocol. Briefly, after a 30-minute 
device calibration period during which time the subject rested quietly in a quiet, 
thermoneutral environment, a ventilated canopy was placed over the participant and gas 
exchange was measured for at least 20 minutes. The room was kept at a comfortable 
temperature throughout the measurement and the participant was instructed to not talk or 
sleep during the measurement period. The first 5 minutes of data were discarded. For 
analysis purposes results for each minute of testing for VCO2, VO2, RQ, and REE were 
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averaged for the time period from 6-20 minutes, which for all individuals had coefficients 
of variation ≤10%, interpreted as steady-state. REE measurements were available for all 
participants using the same protocol and device for the visit at 1-year post-RYGB.  
3.4.7:  Handgrip Strength 
 Handgrip muscle strength was measured using a digital isokinetic hand 
dynamometer (Model T.K.K.5401, Grip D, Takei Scientific Instruments, Ltd., Japan). 
Handgrip strength was assessed with participants in a standing position. Participants were 
asked to keep their arm straight (elbow at full extension) and hanging by the side of their 
body. Participants were asked to squeeze the dynamometer with as much force as 
possible without changing their body position or leaning to one side. Two measurements 
were taken from the right and the left hand consecutively (R, L, R, L) and the four 
measurements were averaged. Handgrip assessment was completed at all visits of the 
original study following the same protocol. 
3.4.8:  4-Component Model 
 At the 8.5-year post-RYGB time point for which ADP was available to measure 
body volume, we calculated FM using the four-component model:
28,172
  
Equation 3-2:  FM by 4-Component Model 
FM, 𝒌𝒈 = 𝟐. 𝟕𝟒𝟕𝟒 × (body volume, 𝒍) − 𝟎. 𝟕𝟏𝟒𝟓 × (TBW, 𝒍) + 𝟏. 𝟒𝟓𝟗𝟗(BMC, 𝒌𝒈)
− 𝟐. 𝟎𝟓𝟎𝟑 × (body weight,𝒌𝒈) 
with body volume from ADP, TBW from deuterium dilution and bone mineral content 
(BMC) from DXA. FFM was calculated by subtracting FM from body weight.  
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3.4.9:  Adipose Biopsy 
At the follow-up visit, a subcutaneous adipose tissue biopsy was collected from 
each study subject. Briefly, under standard sterile technique and local anesthesia (1% 
lidocaine), an incision was created in the inferior periumbilical abdominal area and 
approximately 1 g of subcutaneous adipose tissue was obtained from each subject. The 
specimens were immediately frozen with liquid nitrogen in aliquots of 100-200 mg, and 
stored at -70°C until further study. At the time of the original surgery, for 4/5 subjects, a 
subcutaneous adipose tissue sample was collected as was previously described.
84
 These 
adipose samples were stored at -70°C since collection.  
3.4.10:  Serum Vitamin D and Plasma Micronutrients 
Fasting serum was collected in red-top gel vacutainer blood tubes.  Fasting 
plasma was collected in sodium-heparin trace element free vacutainer blood collection 
tubes (Greiner Bio-One North America, Monroe, NC). Whole samples were allowed to 
clot for 30 minutes after collection and spun at 10,000 x g for 10 minutes to separate 
serum. Plasma samples were spun at the same time and speed. Serum and plasma were 
sent directly to the University of Minnesota Health-Fairview Labs for analysis of serum 
25-OH vitamin D2 and D3 [25(OH)D] by liquid chromatography-tandem mass 
spectroscopy (LC-MS/MS), serum comprehensive metabolic panel, and plasma copper 
and zinc. Remaining aliquots of serum and plasma were frozen at -70 C. At each of the 
original study visits, serum 25(OH)D was assessed using the DiaSorin LIAISON total 25-
OH-vitamin D assay method (DiaSorin, Stillwater, MN) as previously described.
84
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3.4.11:  Tissue and Plasma Cytokines 
Approximately 100 mg of subcutaneous adipose tissue from each subject (time of 
surgery, and 8.5-years post-surgery) was homogenized in 250 μl of ice-cold 
homogenization buffer (0.1% Triton X-100, 15 mM NaCl, 10 mM Tris-HCL with added 
protease inhibitors). After centrifugation for 15 minutes at 4°C at 3000 x g, the fat layer 
was discarded and the homogenate was centrifuged again for 20 minutes at 4°C at 14000 
x g. The supernatant was immediately frozen on dry ice and stored at -70°C until 
processing. Tissue samples were normalized for protein content using the Bradford 
Assay. Plasma samples collected at time of surgery, 1-year post-surgery, and 8.5-years 
post-surgery were stored at -70°C until undiluted batch processing. Analysis of 
circulating plasma and subcutaneous tissue cytokines was completed by the Cytokine 
Reference Laboratory at the University of Minnesota using multiplex enzyme-linked 
imunosorbent assay (ELISA). All samples were run in duplicate. Cytokines assessed 
were: interleukin (IL)-1α, IL-1β, IL-1receptor agonist (ra), IL-2, IL-6, IL-8, IL-10, IL-12 
(p40 and p70), interferon (IFN)-γ, monocyte chemoattractant protein (MCP)-1, and tumor 
necrosis factor (TNF)-α.  
3.4.12:  Quantitative RT-PCR 
 Expression of mRNA was measured by quantitative RT-PCR. Between 150-250 
mg of subcutaneous human adipose tissue (from time of surgery and from long-term 
follow-up biopsy, four pairs total) was mechanically homogenized in Trizol reagent 
(Invitrogen Corp.). After treatment with deoxyribonuclease, cDNA was synthesized using 
an iScript cDNA synthesis kit (Bio-Rad Laboratories) using 1.5 g of RNA. 
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Amplification was monitored with iQ SYBR Green Supermix and the MyiQ detection 
system (BioRad Laboratories). Data for overall changes in gene expression (pre-RYGB 
v. post-RYGB) for four sample pairs were analyzed using the -Ct method173 and 
compared using student’s t-test as -Ct values. All genes of interest were normalized to 
TATA box binding protein (TBP). Primer pairs for genes of interest were as follows: 
prostaglandin endoperoxide synthase-2 (COX-2) (sense primer 5’-CCC TTG GGT GTC 
AAA GGT AA-3’; antisense primer 5’GCC CTC GCT TAT GAT CTG TC-3’), cluster 
of differentiation (CD)40 (sense primer 5’-GCA GTG GGT GGT TCT GGA T-3’; 
antisense primer 5’-CTG GTC TCA CCT CGC TAT GG-3’), endothelial nitric oxide 
synthase (e-NOS) (sense primer 5’-GAC ATC TCC ATC AGG GCA G -3’; antisense 
primer 5’-TGA GTA TGA CGT GGT GTC CC -3’), integrin alpha M (ITGAM) (sense 
primer 5’ GTG TCC TCA AGA GGA TAG TGA CAT T-3’; antisense primer 5’-CAG 
AGT ACT GCA TCA AAG AGA ACA A-3’) and TBP (sense primer 5’-AGC GGT 
TTG CTG CGG TAA TC-3’; antisense primer 5’-ACT GTT CTT CAC TCT TGG CTC 
CTG-3’). 
 
3.5:  Statistics 
Statistical analyses were performed using SAS software, version 9.4 of the SAS 
system (SAS Institute Inc. Cary, NC, USA) and GraphPad Prism version 6.0 for Mac OS-
X, (GraphPad Software, La Jolla California USA). Values are expressed as means ± 
standard deviations (SD), unless otherwise indicated. One-way analysis of variance 
(ANOVA) for repeated measures, with Geisser-Greenhouse correction for assumed 
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sphericity was used to determine significant differences in body composition 
measurements over time. Paired t-tests were used to compare between individual time 
points. A general linear model for repeated measures was used to determine the 
relationships between handgrip strength, LST, and age. For all tests, P<0.05 was 
considered significant. Pearson’s correlation (r) and the limits of agreement from Bland-
Altman (B-A) analysis are reported for comparisons between methods as is the 
coefficient of determination (r
2
) when appropriate.   
 
3.6:  Results 
3.6.1:  Subject Characteristics  
Of the 20 Caucasian, female subjects who completed the original study, 10 
expressed interest in returning to the study, 2/10 declined to participate in the follow-up 
study, 3/10 were lost to follow-up, and 5/10 individuals completed the follow-up study 
visit. Mean time to final long-term follow-up visit was 8.7 ± 0.3 years after surgery (see 
Table 3-1). All women were seen for the final follow-up between 8 and 9 years after 
surgery. Overall, 25% of the participants who completed the original study returned for 
the long-term follow-up visit. Mean age for these five women at time of surgery was 47.2 
± 10.9 years; at last follow-up visit, mean age was 56.2 ± 10.9 years. Most (4/5) women 
were post-menopausal at the time of final follow-up. One individual had diabetes (most 
recent Hemoglobin A1C of 7.6 mg/dl) and was taking insulin; all other individuals were 
non-diabetic. Fasting blood glucose was within normal limits (defined as >70 mg/dl and 
<99 mg/dl) at the follow-up visit for all participants. For the first three reported time 
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points (baseline, 1.5-months, and 6-months) post-RYGB, the individual with diabetes 
exhibited elevated fasting blood glucose levels.  
3.6.2:  Changes in Body Composition and Strength 
Table 3-1 shows the body composition of the 5 subjects at baseline (1-month 
before surgery), 1.5-months, 6-months, 1-year and 8.5-years after surgery. At each time 
point data were available for all five returning study subjects. Weight loss over the first 
year after RYGB was substantial. Mean weight loss to 1-year was 46.2 ± 10.2 kg which 
was significant compared with baseline (P=0.0005). Subjects gained 5.5 ± 6.7 kg of body 
weight back in the post-operative interval between 1-year and 8.5-years, although this 
weight gain was not significant (P=0.15). The relative greater weight loss success at 1-
year post-RYGB is reflected in BMI changes over the 8.5-year period. BMI decreased at 
each time point until 1-year (from 48.8 ± 9.7 to 32.6 ± 9.2 kg/m
2
, P=0.0003), and 
increased between 1-year and 8.5-years to 34.9 ± 8.8 kg/m
2
 (P=0.0008).  
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Table 3-1:  Body composition and muscle strength over 8.5 years after RYGB surgery 
 Baseline 1.5-months 6-months 1-year 8.5-years P-value 
Time relative to surgery, years -0.09 ± 0.07 0.12 ± 0.02 0.51 ± 0.01 1.0 ± 0.005 8.7 ± 0.3 - 
Age, years 47.2 ± 10.9  47.6 ± 10.9 48.0 ± 10.9 48.6 ± 11.0 56.2 ± 10.9 <0.0001 
Weight, kg 139.3 ± 35.9
a 
125.4 ± 33.2
b 
101.1 ± 32.2
c 
93.2 ± 33.0
d 
98.7 ± 30.2
cd 
<0.0001 
BMI, kg/m
2 
48.8 ± 9.7
a 
43.9 ± 9.0
b 
35.3 ± 9.2
c 
32.6 ± 9.7
d 
34.9 ± 8.8
c 
0.0001 
 
DXA 
      
Bone Mineral Content, kg 3.0 ± 0.7
a 
2.9 ± 0.6
a 
2.7 ± 0.5
ab 
2.7 ± 0.6
b 
2.3 ± 0.6
c 
0.025 
Lean Soft Tissue, kg 63.5 ± 13.2
a 
57.7 ± 12.3
b 
54.1 ± 10.6
c 
56.0 ± 10.6
b 
51.6 ± 8.7
c 
0.004 
Fat Free Mass, kg 66.4 ± 13.9
a 
60.6 ± 12.9
b 
56.8 ± 11.0
c 
58.6 ± 11.0
b 
53.9 ± 8.0
c 
0.004 
Fat Mass, kg 75.4 ± 22.6
a 
66.7 ± 23.0
b 
44.1 ± 20.6
c 
35.5 ± 21.5
b 
44.1 ± 19.5
c 
<0.0001 
       
Handgrip strength, kg 31.9 ± 6.1
a 
29.3 ± 5.8
b 
29.1 ± 5.2
b 
29.2 ± 5.5
b 
26.2 ± 4.5
c 
0.006 
 
Multiple dilution 
      
TBW, kg* 47.8 ± 10.9
a 
44.2 ± 8.8
b 
42.5 ± 8.3
cd 
44.3 ± 7.9
bd 
39.5 ± 7.4
c 
0.0021 
ECW, kg* 21.6 ± 6.5
a 
21.7 ± 5.6
a 
20.9 ± 4.6
ab 
22.3 ± 6.5
a 
18.0 ± 4.4
b 
0.06 
ICW, kg* 26.2 ± 4.4
a 
22.5 ± 4.3
b 
21.6 ± 5.0
b 
22.0 ± 3.4
b 
21.5 ± 3.6
b 
0.022 
ECW/ICW* 0.82 ± 0.16
a 
0.97 ± 0.20
ab 
1.00 ± 0.26
ab 
1.02 ± 0.28
b 
0.83 ± 0.13
ab 
0.21 
ECW/TBW* 0.45 ± 0.05
a 
0.49 ± 0.05
ab 
0.49 ± 0.07
ab 
0.50 ± 0.07
b 
0.45 ± 0.04
ab 
0.19 
 
FFM hydration coefficient 
      
TBW/DXAFFM* 0.719 ± 0.03
a 
0.731 ± 0.03
ab 
0.748 ± 0.01
ab 
0.757 ± 0.04
b 
0.732 ± 0.03
ab 
0.22 
Abbreviations: Roux-en-Y gastric bypass, RYGB; BMI, body mass index; DXA, dual energy X-ray absorptiometry; TBW, total body 
water from 
2
H2O dilution; ECW, extracellular body water from bromide dilution; ICW, intracellular body water (ICW=TBW-ECW); 
FFM, fat free mass. Data are reported for n=5. All values are reported as mean ± SD. Overall P-value from repeated measures, one-
way ANOVA, with Geisser-Greenhouse correction for assumed sphericity. Time points are baseline (pre-surgery) and 1.5-months, 6-
months, 1-year, and 8.5-years after RYGB surgery. 
a,b,c,d 
Means that do not share a letter within a row are significantly different 
(P<0.05) by paired t-test. *TBW and ECW at long-term follow-up (8.5-years) using an oral dosing protocol not IV dosing protocol as 
with all other time points. 
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DXA data are reported in Table 3-1 as the result of mirrored analysis of half-body 
scans at each time point. At baseline, study participants were too heavy and/or large to 
obtain a whole body scan using the available standard sized DXA instrument; thus half-
scans were performed initially as per others,
19,174
 and for consistency, for all study visits 
up to 1-year post-RYGB. At the 8.5-year follow-up visit, both whole and half-body scans 
were obtained for the 4/5 individuals for whom it was possible, using the iDXA 
instrument. It has been previously reported that mirrored half-body scans are comparable 
to whole body scans using the iDXA.
19
 To confirm validity of mirrored half-body scans 
in our small population, we compared mirrored half-body to whole-body scans from the 
long-term follow-up visit (n=4, for individuals with available whole-body and half-body 
scans). There were no differences between the whole-body and mirrored half-body scans 
for total BMC (P=0.98), total FM (P=0.94), total LST (P=0.91), and total FFM (P=0.91) 
and whole- and mirrored half-body scan were well correlated for BMC (r = 0.99, 
P=0.0018), total FM (r = 0.98, P=0.017), total LST (r = 0.98, P=0.01), and total FFM (r = 
0.99, P=0.009). 
 
The DXA data indicate that in this small sample, there was decreased LST, FFM, 
and BMC, which occurred on the background of weight regain, primarily as FM (Table 
3-1, Figure 3-1). Compared to baseline, mean LST was 11.9 ± 5.6 kg lower by 8.5-years 
post-RYGB (overall ANOVA across time P=0.004; paired v. baseline P=0.009). In 
addition, 8.5-year LST was 4.4 ± 3.0 kg lower than 1-year post-RYGB (paired P=0.04). 
FFM followed a similar trend and decreased by 12.6 ± 5.8 kg over the 8.5-year period 
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(overall P=0.004; paired v. baseline P=0.008). BMC also decreased over the 8.5-year 
period from 3.0 ± 0.7 kg to 2.3 ± 0.6 kg (overall P=0.025, paired v. baseline P=0.03). 
Unlike the other tissue compartments, mean FM decreased after surgery from 75.4 ± 22.6 
kg to 35.5 ± 21.5 kg 1-year post-RYGB (mean difference = 39.9 ± 8.32 kg, paired 
P=0.0004), but then increased by 8.6 ± 7.0 kg after 1-year (paired 1-year v. 8.5-years, 
P=0.05).  
 
Results from TBW for the long-term follow-up were compared for 3-, 4-, and 5-
hour urine collection time points by one-way ANOVA for repeated-measures. There was 
a difference between the three time points (P=0.009). Paired t-tests indicated that the 5-
hour time point was higher than the 3- and 4-hour time points. The overall difference 
between 3- and 5-hours was only 0.53 l, thus, while significant the difference was not 
physiologically relevant and is below the precision estimates for the technique. In light of 
this, the 5-hour time point was selected for analysis purposes. For ECW calculated from 
serum bromide collected at 4- and 5-hours, the 4-hour was significantly lower than the 5-
hour measurement by paired t-test (mean difference = 0.2 l, P-value =0.013). It has been 
previously demonstrated that bromide equilibrium may take up to 10-hours;
24
 although 
due to logistical constraints this length of time is never utilized and instead, it is standard 
to use a 3-5 hour equilibration period in most studies. Thus, the 5-hour time point was 
selected for analysis purposes, in an effort to maximize the equilibration time.  
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Figure 3-1:  Changes in DXA measured tissue compartments after RYGB by 
individual including (A) lean soft tissue, (B) fat free mass, (C) total bone mass, and 
(D) DXA fat mass.  
 
 
 
 
Abbreviations: RYGB, Roux-en-Y gastric bypass; DXA, dual energy X-ray 
absorptiometry; mo, month.  Time points are baseline (pre-surgery) and 1.5-months, 6-
months, 1-year, and 8.5-years after RYGB surgery.  All data are reported as kg. See 
Table 3-1 for mean values and significance. 
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From Table 3-1, there was a significant decrease in TBW over the study period 
(overall P=0.0021) and a trend towards a decrease in ECW over the study period (overall 
P=0.06). The ECW/ICW and ECW/TBW ratios did not differ over the study period 
(overall P=0.21 and 0.19, respectively). The range of mean ECW/ICW values over the 
8.5 time period was from 0.82 ± 0.6 to 1.02 ± 0.28, indicating that at all time points the 
mean ECW/ICW ratio remained elevated compared to what has been reported in the 
literature for lean individuals. The hydration of FFM (defined as TBW/DXA FFM) was 
not significantly different over time with weight loss (overall P=0.22). However, it is 
interesting to note that by 8.5-years post-surgery, the mean hydration of FFM was 0.732 
± 0.03, which was very similar to the reference hydration coefficient of 0.738.
20,21
 
 
Interestingly, mean handgrip strength decreased over the 8.5-year period from 
31.9 ± 6.1 kg of force to 26.2 ± 4.5 kg of force (overall P=0.006; paired baseline v. 8.5-
years P=0.008) (Figure 3-2A). When including all points in the data set, and not 
accounting for the effect of each visit, this handgrip force was moderately well correlated 
with DXA LST (r = 0.64, P=0.0005, r
2
=0.41, n=25 pairs) (Figure 3-2B). To control for 
the effect of visits and aging over the course of the study, handgrip strength was assessed 
as a function of DXA LST, age, and visit. Fitting a general linear model for handgrip, 
LST, age, visit, and time since surgery, we found that only LST (P<0.0001) and age 
(P<0.0001) were significant contributors to the model. Visit and the time since surgery 
were not significant predictors of handgrip strength. The model containing LST, age, and 
visit accounted for 84.4% of the variation in handgrip strength in this small cohort. LST  
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Figure 3-2:  Changes in handgrip strength after roux-en-Y gastric bypass (RYGB) 
are correlated with changes in lean soft tissue measured by DXA. 
 
(A) Changes in handgrip force over time by individual, (B) correlation between lean soft 
tissue and handgrip force, (C) Handgrip force by age compared to manufacturer normal 
ranges by age. Abbreviations: DXA, dual energy X-ray absorptiometry; mo, month. Time 
points are baseline (pre-surgery) and 1.5-months, 6-months, 1-year, and 8.5-years after 
RYGB surgery.  Normal handgrip strength values derived from handgrip device 
manufacturer (Model T.K.K., Grip D, Takei Scientific Instruments, Ltd. Japan). 
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is highly correlated with body weight in this sample (r = 0.94, P<0.0001). To account for 
the contribution of body weight to LST in this sample we also assessed a model 
containing the percent of body weight from LST (where percent of body weight form 
LST is expressed as %LST=LST/weight), age, and visit. In this model both %LST and 
age were significant (P=0.003 and 0.0002, respectively), and the model accounted for 
62% of the variation in handgrip strength.   
 
Figure 3-2C shows the handgrip measurements by age for each visit plotted in 
comparison to the manufacturer’s normal values for each age between 33 and 68 years 
(T.K.K.5401, Grip D, manual). At the final follow-up visit, 3/5 individuals were 
demonstrating below normal functional status for their age, and 2 of these 3 individuals 
had previously been classified as having normal handgrip force for their age. 
3.6.3:  Comparison of FM by Multiple Methods at 8.5-Years Post-RYGB 
 We calculated FM and FFM by the 4-component model, which utilizes body 
weight, BMC, TBW, and body volume and compared it to FM and FFM from the BOD 
POD
®
 (calculated using the Siri model
15
), and FM and FFM from DXA (Figure 3-3A and 
B). There appeared to be no difference between FM by the 4-component model and DXA 
(mean difference = 0.54 ± 1.3; P=0.41), and the two methods were highly correlated (r = 
0.99, P<0.0001). Limits of agreement by B-A analysis were -2.09 to 3.17 kg, and the 
proportional bias was not significant (r
2 
= 0.48, P=0.19) indicating relatively good 
agreement between methods (Figure 3-3C). There was also no apparent difference 
between FM by the 4-compartment model and BOD POD
®
 (-1.5 ± 1.4; P=0.08), and the  
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two methods were highly correlated (r = 0.99, P<0.0001). Limits of agreement by B-A 
analysis were -4.18 to 1.29 kg, and the proportional bias was not significant (r
2
= 0.22, 
P=0.41) indicating relatively good agreement between methods (Figure 3-3E).  
 
Similarly, there was no difference between FFM by the 4-component model and 
DXA (mean difference = -0.19 ± 1.7; P=0.82), and the two methods were highly 
correlated (r = 0.99, P=0.001). Limits of agreement by B-A analysis were -3.19 to 3.56 
kg, and the proportional bias was not significant (r
2 
= 0.16, P=0.56) indicating relatively 
good agreement between methods (Figure 3-3D). There was also no detectable difference 
between FFM by the 4-compartment model and BOD POD
®
 (-1.46 ± 1.4; P=0.08), and 
the two methods were highly correlated (r = 0.99, P=0.0006). Limits of agreement by B-
A analysis were -1.31 to 4.22 kg, and the proportional bias was not significant (r
2 
= 0.14, 
P=0.54) indicating relatively good agreement between methods (Figure 3-3F). 
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Figure 3-3:  Comparison between methods for assessment of (A) fat mass, and (B) 
fat free mass 8.5 years post-roux-en-Y gastric bypass (RYGB) surgery. 
 
 
 
Abbreviations: 4-comp, 4-component model calculated from density by air displacement 
plethysmography (ADP) using the BOD POD instrument, total body water (TBW) by 
deuterium dilution, and total bone mineral content (BMC) by dual-energy X-ray 
absorptiometry (DXA) using the following equation: Fat Mass, 𝑘𝑔 = 2.7474 ×
(body volume, 𝑙) − 0.7145 × (TBW, 𝑙) + 1.4599(BMC, 𝑘𝑔) − 2.0503 ×
(body weight,𝑘𝑔)28  
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3.6.4:  Changes in Vitamin D Status 
 We have previously reported on the vitamin D status of these women as part of 
the original 1-year study.
84
 We assessed the changes in vitamin D status in our small 5 
individual cohort and found that vitamin D status increased over time post-RYGB 
(P=0.01) (Figure 3-4). At the time of surgery all 5 individuals in the study had serum 
25(OH)D levels below 30 ng/ml, with mean 20.1 ± 5.5 ng/ml. At the 8.5 year follow-up 
all 5 individuals had serum 25(OH)D levels above 30ng/ml with mean 49 ± 10.27 ng/ml, 
indicating vitamin D sufficiency.
42,108
 All individuals in this cohort were consuming 
vitamin D3 supplements, with mean reported vitamin D3 intake from supplements of 2500 
± 660 international units (IU)/day. Most of the women (4/5) reported that they were 
prescribed a multivitamin by their regular care provider and all of the women reported 
that they consumed at least one multivitamin per day. Most of the women (3/5) reported 
that they were consuming an additional prescribed vitamin D3 supplement between 1200-
3000 IU/day.  
3.6.5:  Micronutrient Status at 8.5-Years Post-RYGB 
At the long-term follow-up visit we measured copper and zinc using plasma 
collected in trace-element free tubes. These two micronutrients are not frequently 
measured post-operatively, but deficiencies have been reported to occur in the long-term 
after malabsorptive bariatric surgeries. We found that all individuals had normal zinc 
(mean 87 ± 30.5; range 67-137 ng/ml) and copper (mean 108.8 ± 8.8; range 98-121 
ng/ml) status.  
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Figure 3-4:  Improved serum 25(OH)D status over time following roux-en-Y gastric 
bypass (RYGB). Dotted line indicates 30 ng/ml. 
 
 
 
 
Abbreviations: 25(OH)D, 25-hydroxy-vitamin D; mo, month. Time points are baseline 
(pre-surgery) and 1.5-months, 6-months, 1-year, and 8.5-years after RYGB surgery.   
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3.6.6:  Long-Term Post-RYGB Inflammatory Status 
There were no significant differences in subcutaneous white adipose tissue 
expression of COX-2 (P=0.36, n=2), CD40 (P=0.85, n=4), eNOS (P=0.33, n=4), and 
ITGAM (P=0.55, n=4) based on comparison between surgery and 8.5-year samples. 
There were also no significant pre-/post-RYGB differences in adipose tissue cytokine 
levels. MCP-1, IL-6 and IL-8 tended to decrease in the long-term post-surgical 
subcutaneous adipose samples compared with those taken at the time of surgery, although 
these decreases did not reach statistical significance (P=0.08, 0.015 and 0.08, 
respectively) (Figure 3-5). TNF-α and IL-1ra were not changed in the long-term after 
surgery. IFN-γ, IL-10, IL-1β, IL-12p70 and IL-2 were not detectable in most tissue 
samples. IL-12p40 was detectable in 3/4 pairs and was not significantly different. IL-1α 
was detectable in 2/4 pairs and was not significantly different. 
 
We were unable to detect changes between baseline, 1-year, and 8.5-years post-
RYGB in plasma pro-inflammatory cytokines IFN-γ, TNF-α, IL-1α, IL-1β, IL-6, IL-8, 
IL-12p40, IL-12p70, IL-2, or anti-inflammatory cytokines IL-10 and IL-1ra. Plasma 
MCP-1 appeared to increase over the three time points assessed by one-way ANOVA for 
repeated measures (P=0.0002). Paired t-tests show that at 8.5-years after surgery MCP-1 
was higher than baseline or 1-year. However this apparent increase, as well as the 
inability to detect changes in other cytokines, is most likely explained by the instability of 
plasma cytokines in long-term storage.
175,176
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Figure 3-5:  Cytokine expression in adipose tissue samples collected at time of Roux-en-Y gastric bypass (RYGB) surgery and 
8.5-years post-RYGB. 
 
 
 
Abbreviations: MCP-1, monocyte chemoattractant protein-1; IL-6, interleukin-6; IL-8, interleukin-8. 
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3.7:  Discussion 
3.7.1:  Body Composition and Handgrip Strength 
The results of our long-term assessment of body composition after RYGB agree 
with the findings of other researchers who have previously reported that significant 
changes in body composition accompany the weight loss following RYGB.
39,46–50,52,157,158
 
In our subjects, FM comprised ~84% of DXA total mass loss at 1-year post-RYGB.  FM 
loss as a percent of weight loss has been reported to be between 73-80% at 6-months to 
1-year after RYGB.
39,45–51
 In our subjects, LST loss was ~16% of DXA total mass loss at 
1-year post-RYGB. FFM loss has been reported to be between 18-25% of weight loss 1-
year after RYGB;
39,46–48,51
 and LST loss has been reported to be between 12-23% of 
weight loss 1-year after RYGB.
49,50
 The majority of these assessments have been 
completed within the first two years following surgery. To the best of our knowledge, no 
other groups have assessed very long-term changes in body composition after RYGB. 
The most important finding from this study is the concerning trend of continued loss of 
LST in the background of weight regain, primarily as FM. At 1-year post-RYGB on 
average our subjects had 38% body fat and at 8.5-years that number had increased to 
45%. Controlling for age, the loss of LST remains significant over time and is associated 
with a loss of functional strength as measured by handgrip force. 
 
According to the device manufacturer, normal handgrip strength for 56-year old 
women is 26.6 kg, thus on average, at the long-term follow-up, the individuals in our 
study demonstrated slightly reduced functional status, with 40% of individuals classified 
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as below normal for their age at long-term follow-up when before surgery they were 
considered normal for their age. It is possible that weight regain and continued loss of 
lean tissue are related to a lack of physical activity. Reid et al have reported that in a 
cohort of 89 individuals 8.9 years post bariatric surgery with mean age of 50 years at time 
of follow-up do not meet current recommended step per day guidelines for physical 
activity.
58
 More work is needed to determine if a lack of physical activity, independent of 
aging and other factors, is contributing to the apparent decrease in LST and functional 
strength.  
 
Others have reported that in the long-term weight regain is a significant concern 
after bariatric surgery. In one cohort (n=300 with mean age at surgery=45.6 years) after a 
mean time of 6.9 years after surgery mean weight regain (as a percent of weight lost) was 
23.4%.
66
 In our cohort, mean percent weight loss was approximately 33% of total body 
weight while weight regain after 8.5-years was approximately 14% of weight loss and 
percent of weight regain from FM after 8.5-years was approximately 27% of FM lost, and 
21% of weight lost.  
3.7.2:  Markers of Inflammation After RYGB 
Macrophage infiltration of adipose tissue consists of pro-inflammatory (M1) and 
anti-inflammatory (M2) macrophages. M1 macrophages are recruited by pro-
inflammatory cytokines related to expanded adipose tissue depots in obesity and once 
they infiltrate adipose tissue they secrete more inflammatory cytokines including MCP-1, 
TNF-α, IL-6, IL-1, IL-1β and IL-8.177 We observed a trend towards decreased MCP-1, 
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IL-6 and IL-8, in long-term adipose biopsy samples which may indicate that over the 8.5-
years after surgery, participants had less adipose infiltration from M1 macrophages 
compared to time of surgery, despite remaining classified as obese after weight loss. 
More research is needed to confirm this hypothesis. Interestingly, we were unable to 
detect any change in the monocyte/macrophage markers, CD40 and ITGAM, mRNA 
expression in our subcutaneous adipose tissue samples. CD40 is also expressed on human 
adipocytes, so this is by no means a perfect marker for macrophage infiltration of adipose 
tissue.
178
  
 
Our finding of increased MCP-1 in plasma samples compared to baseline and 1-
year does not agree with findings by others who have reported that plasma MCP-1 is 
higher in obese subjects compared to lean subjects and trends toward decreased levels 
after weight loss from RYGB (P=0.093).
179
 We believe that our findings are directly 
related to the instability of plasma MCP-1 (and other cytokines) in long-term storage.
175
 
Future studies stemming from this pilot work should test cytokines in plasma samples as 
soon after collection as possible, and prior to freezing samples. Whenever possible for 
long-term studies where cytokine analysis by multiplex ELISA is planned or expected, an 
internal control should be created.
180
 
 
For the other inflammatory genes of interest, COX-2 was only detectable at 
measurable levels in two sample pairs, which we might expect given that it may only be 
present during periods of active inflammation. In these two pairs there was no significant 
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difference between pre- and post-RYGB (P=0.36), but post-surgical expression was much 
lower than mean pre-surgical expression and the power to detect a difference was clearly 
limited by our sample size. Differences in eNOS expression, while also not significant 
(P=0.33), suggest that eNOS may have been lower in the post-surgical samples. An 
apparent trend towards decreased COX-2 and eNOS expression further supports the 
hypothesis that tissue level inflammation was decreased in the long-term post-surgical 
state. 
3.7.3:  Vitamin D, Copper, and Zinc Status 
Micronutrient status has not been studied in relation to changes in overall 
inflammatory status and body composition in the long-term following RYGB. The 
significance of this research is that zinc and copper deficiency have been implicated not 
only with anemia and neutropenia,
78
 but also with neuromuscular dysfunction
71
 and 
impaired immunity
73
 making it relevant to monitor these essential trace elements in 
relation to long-term changes in body composition and immune function. Vitamin D has 
also become recognized as an immune modulator and is more closely monitored after 
surgery due to concerns with bone loss after surgery.
86,90
  
 
We saw no evidence of copper deficiency in the long-term after RYGB. Our 
cohort reported good compliance with supplementation regimens, which likely 
contributed to their normal copper status. However it is well established that copper 
deficiency, while rare, can occur following RYGB. Others have reported that analysis of 
copper levels in 52 patients five years following RYGB showed that 3.8% had copper 
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deficiency.
73
 A retrospective chart review of 136 patients who were on average 33 
months post-surgery, found that 9.6% were copper deficient.
77
 A longitudinal study 
following 16 patients for 24 months after RYGB found that plasma copper decreased by 
10.1% at 24 months, and ceruloplasmin activity decreased by 18.6% compared with 
baseline.
77
 Compared with baseline values, a statistically significant decrease in white 
blood cells was reported 6 and 24 months post-surgery and the incidence of the 
development of copper deficiency this population was 18.8%.
77
 It is not reported if these 
studies use trace-element free tubes for plasma collection. Furthermore, a published case 
study documented the development of two cases of severe acquired copper deficiency at 
least 10 years following RYGB. In these cases, typical presentation includes 
abnormalities in gait, anemia, neutropenia associated with severe copper depletion.
78
  
 
The relationship between dietary and serum copper with inflammation is complex 
and not fully understood. Copper may contribute to both pro- and anti-inflammatory 
effects. The major copper containing protein in the blood, ceruloplasmin, is an acute 
phase plasma protein that may contribute to protection from inflammation and injury in 
various inflammatory states, e.g., inflammatory bowel disease.
75
 However, in a large 
population based cohort study, serum copper concentrations were shown to be inversely 
related to unfavorable metabolic markers (e.g. circulating glucose, uric acid, total 
cholesterol, and LDL cholesterol) and positively associated with increased high-
sensitivity CRP, a marker of inflammation.
76
 At 8.5-years post-surgery all individuals in 
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our study had normal copper levels; therefore, we cannot draw conclusions about the 
potential inflammatory effect of copper in this cohort. 
 
We saw no evidence of zinc deficiency in our cohort, and no evidence of any 
relationship with inflammatory status. Overt zinc deficiency has also been shown to 
increase susceptibility to disease and infection.
82
 While more common following 
biliopancreatic diversion, zinc deficiency can occur following RYGB. The prevalence of 
zinc deficiency in a group of 52 subjects following RYGB has been reported to be 15.4% 
and 21.2% at 48 and 60 months post-RYGB, respectively.
73
 In the same study, the 
circulating zinc level was found to be determined by the alimentary limb length resulting 
from the surgery.
73
 One long-term study looking at deficiency at least 5 years after 
RYGB (average 6.9 years) showed that 40.5% were deficient in zinc at their last follow-
up.
79
  
 
In our cohort all individuals had normal zinc status at their long-term follow-up. 
We do not have data for their baseline zinc status, though as with copper, it is likely that 
at baseline, zinc status was normal as zinc deficiency is exceedingly rare in the general 
population. Therefore we do not think that zinc status in our cohort was associated with 
any inflammatory changes. Zinc plays an important role in many of the functions of the 
immune system and is essential for the development of neutrophils and natural killer 
(NK) cells.
80
 Mild zinc deficiency, induced by restricting dietary zinc intake to 3-5 mg 
daily in healthy subjects, has been shown to impair cell-mediated immunity, IL-2 
  87 
production, and decrease NK cell lytic activity.
81
 Additionally, in mild zinc deficiency, 
IFN-γ was decreased, but IL-4, IL-6 and IL-10 expression was not altered.80  
 
We have previously reported that in the first year following RYGB, serum 
25(OH)D  levels increased concomitantly with weight loss in many (but not all) 
individuals.
84
 However, others have observed that vitamin D deficiency develops in as 
many as 60.5%
79
 or 63%
85
 of patients after an average of 6.9
79
 and 4 years,
85
 
respectively. In recent years, many studies have been published linking vitamin D levels 
to inflammation. Vitamin D’s distribution includes adipose deposition.84 Vitamin D 
appears to modulate macrophage inflammation and treatment of low vitamin D status 
may reduce adipose inflammation. In a recent study utilizing peripheral blood 
mononuclear cells and cultured bone marrow derived macrophages from mice, within 
physiologic ranges, higher 25- and 1,25-dyhydroxy vitamin D concentrations were shown 
to decrease TNF-alpha mRNA levels and decrease IL-6 in culture supernatants.
86
 TNF-
alpha is known to be a potential inhibitor of mitochondrial biogenesis and function 
through a number of mechanisms including inhibition of endothelial nitric oxide synthase 
(eNOS).
87
 Vitamin D may shift T cell profiles from Th1 toward Th2.
88,89
 Vitamin D 
status has also been linked with the levels of a number of interleukins (including IL-2, IL-
6, IL-8, IL-12), IFN and MCP-1.90,91 To the best of our knowledge, vitamin D deficiency 
in relation to inflammation post RYGB has not been studied. We saw no evidence of 
vitamin D deficiency in our cohort. Vitamin D status continued to increase throughout the 
study. At the final follow-up visit, all 5 of the returning subjects had vitamin D levels >30 
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ng/ml and there was no indication that vitamin D levels were associated with any changes 
in circulating or tissue level cytokines, although some subcutaneous adipose tissue 
cytokines did show a decreasing trend. More work is needed to determine if improved 
vitamin D status after RYGB is associated with tissue-level inflammatory improvement 
after RYGB. 
 
3.8:  Limitations 
We recognize that there are a number of limitations with our study. This long-
term follow-up study had a small sample size and was not powered to detect differences 
in small changes in inflammatory makers or gene expression or to detect differences in 
methods for comparing body composition (i.e. between 4-component model and 
DXA/BOD POD
®
). This pilot study was partly completed to determine the feasibility of 
long-term in-depth measurement of changes in body composition and inflammation. We 
found that between 8- and 9- years post-RYGB, only 25% of patients who completed the 
original study were willing to return. Future long-term studies in similar populations 
should consider the potential for very low return rates when powering studies.  
 
Our study did not incorporate any male subjects. It is possible that changes in 
body composition for male subjects after RYGB are different from those seen in female 
subjects. There was also an inherent bias in our study sample. We do not know anything 
about the long-term weight loss success in the 15 women who did not return for follow-
up, and it is possible that our return cohort was self-selected to include individuals who 
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had lost and maintained their body weight since the original study ended. Clearly, the 
cohort for this study was successfully able to lose and maintain their weight loss and all 
were compliant with supplementation regimens as evidenced by normal plasma vitamin 
and mineral levels. Finally, in any future assessments of the relationship between lean 
tissue and functional status it will be important to control for dietary protein intake and 
physical activity.  
 
Given the long time between original study visits and the long-term follow-up a 
number of methodologies used were different. In particular, oral dosing was used in place 
of IV dosing for deuterium and bromide. We have attempted to account for these 
differences by using a 1-hour later time point for analysis of both deuterium and bromide 
than the original study. Serum 25(OH)D was assessed by immunoassay at the time points 
throughout the first year and by LC-MS/MS at the final time point. It has been reported 
that the DiaSorin LIAISON immunoassay method has good agreement with LC-MS/MS 
with concordance correlation coefficient (CCC) of 0.95, and r of 0.95.
181
 The mean bias 
of the LIASON compared to LC-MS/MS is reported as 0.2 ng/ml.
181
 Therefore, we have 
confidence that these two methods are close enough to be used for the purposes of our 
comparisons over time.   
 
3.9:  Conclusions 
The continued loss of lean mass during the process of weight regain is a 
concerning trend in this population. This combined with the significant relationship 
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between loss of functional status as measured by handgrip strength and LST while 
controlling for age further indicates that in the long term there may be physiologically 
important loss of muscle mass and function in this population. On the positive side, we 
saw an increase in serum 25-OH-D and a trend towards improved tissue level 
inflammatory status. Clearly there is a tradeoff here; on the one hand we saw these 
women improve their vitamin D and inflammatory status (and at least in one case, 
metabolic status/blood glucose control), while on the other hand we saw that in the long-
term there appeared to be a loss of functional status. More work is needed to control for 
factors including protein intake and activity level in a larger cohort, to determine the 
cause of lean tissue loss, and to demonstrate if it is reversible with exercise and lifestyle 
intervention.  
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CHAPTER 4:   EVALUATION OF NEW ADVANCED BIOIMPEDANCE 
SPECTROSCOPY MODELS FOR MEASURING BODY COMPOSITION IN 
HEALTHY INDIVIDUALS (NHANES 1999-2004) AND THOSE UNDERGOING 
MASSIVE WEIGHT LOSS FOLLOWING ROUX-EN-Y GASTRIC BYPASS 
SURGERY 
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4.1:  Overview 
 
Background:  Bioimpedance spectroscopy (BIS) devices utilize biophysical modeling to 
generate body composition data. The addition of body mass index (BMI) to modified 
Xitron-Hanai-based mixture equations improved BIS estimates (Moissl et al. Physiol 
Meas 2006). A model for distinguishing excess fluid (ExF) from normally hydrated lean 
(NH_LT) and adipose tissue (NH_AT; Chamney et al. AJCN 2007) may further improve 
BIS estimates. We aimed to validate a BIS approach based on the Moissl-Chamney 
models for determining fat mass (FM) in healthy individuals (NHANES) and for 
measuring FM changes in individuals undergoing massive weight loss.   
Subjects/Methods:  From the NHANES 1999-2004 dataset, we obtained BIS data 
(Hydra 4200, Xitron Technologies) for 5740 adults (2744 F, 2996 M; BMI 26.7±5.4 
kg/m
2
). We calculated extracellular (ECW) and intracellular water (ICW) by using the 
BMI-corrected mixture equations, then applied the ECW and ICW values to the 
Chamney equations to generate NH_LT, NH_AT and FM. and compared values for FM 
and NH_LT to dual-energy X-ray absorptiometry (DXA) FM and lean soft tissue (LST) 
for method validation by BMI category. For more in-depth validation, we separately 
generated longitudinal BIS data (Hydra 4200) from women with obesity before (BMI 
46.6±6.8 kg/m
2
, n=25) and 1-year following (BMI 31.6±6.3 kg/m
2
, n=15) Roux-en-Y 
gastric bypass (RYGB) surgery. In both datasets, method agreement for FM by BIS and 
DXA was evaluated by correlations, paired t-tests, root mean square error (RMSE), 
Bland-Altman (B-A) plots, and concordance correlation coefficients (CCC).  
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Results:  DXA and BIS-measured FM (adjusted for BMI) was well-correlated in healthy 
adults (r = 0.96, P<.0001, CCC=0.93, RMSE=3.5 kg, n=5740), pre-RYGB (r = 0.93, 
P<.0001, CCC=0.81, RMSE=6.47 kg, n=25) and at 1-year post-RYGB (r = 0.98, 
P<.0001, CCC=0.86, RMSE=3.45 kg, n=15). Although mean FM by the two methods 
was different in the healthy subjects and at both time points in the RYGB subjects, 
measures of change in FM post-RYGB were not different between methods (35.6±8.9 vs 
35.2±9.2 kg, BIS vs DXA, n=15) and were in reasonably good agreement (r = 0.84, 
P<.0001, CCC=0.84, RMSE=4.99 kg), although the B-A analysis revealed several 
outliers (-9.6 to 10.3 kg). Interestingly, when evaluating the loss of lean tissue over the 
one-year follow-up period, our 15 subjects lost an average of 11.5±10.1 kg FFM by 
DXA, 9.4±2.5 by BIS BMI adjusted FFM and 11.6±10.1 kg of LST by DXA, but only 
1.3±2.5 kg of NH-LT by BIS, suggesting that the LST loss was almost entirely adipose 
tissue water, assuming that the Moissl-Chamney model was valid in these subjects based 
on FM comparisons. 
Conclusions:  Taken together, these findings suggest that the incorporation of Moissl-
Chamney type models into BIS approaches is an advancement that may ultimately prove 
groundbreaking for assessing and monitoring human body composition, with additional 
refinements in resistivity and other constants specific to the patient population of interest.  
Its ability not only to differentiate ICW from ECW, but also the potential to more 
specifically monitor lean tissue in the clinical setting is particularly promising. 
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4.2:  Background 
 Bioimpedance spectroscopy (BIS) involves the application of biophysical 
modeling algorithms to bioimpedance data measured across a spectrum of frequencies 
(e.g. from ~5 to 1200 kHz, using data from 50 or more frequencies) in order to generate 
body composition data. Simply put, at low frequencies (e.g. approaching theoretical 0 
frequency), the current produced by a BIS device is conducted only by extracellular water 
(ECW), due to the capacitance effect of cell membranes and tissue interfaces. At 
relatively high frequencies (e.g. approaching theoretical infinity frequency), BIS devices 
measure intracellular water (ICW) as the capacitive property is lost, allowing the current 
to pass through cell membranes and tissues and thus quantifying both ICW and ECW (i.e. 
total body water, TBW). The bioimpedance data are fit to the Cole model
30
 using 
nonlinear least squares curve fitting; the semicircle formed by plotting resistance (R) and 
reactance (X) values is extrapolated to reach the x-axis in order to determine R at zero 
(R0, also called RE) and infinity (R).  From these, RI can be calculated, representing the 
resistance related to the ICW. Cell membrane capacitance (CM) is also calculated in the 
model. Cole model terms can be applied to the Xitron-Hanai-based
31,32
 mixture equations 
to determine ECW and ICW; these equations are based on the conductivity of 
suspensions
33
 and consequently can be used in conjunction with the presumed 
conductivity and resistivity of the different body compartments (i.e. ECW and ICW).  
 
 These equations incorporate several constants including intra- and extra-cellular 
apparent resistivity, shape factor, and body density. The most commonly utilized 
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apparent resistivity constants are the ones published by De Lorenzo et al;
31
 these 
predominate in the literature and are programmed into the software accompanying the 
Hydra 4200 BIS device. The apparent resistivity constants for the intra- and extracellular 
compartments that are applied to the mixture equations require the assumption that the 
resistivity of all tissue types is constant, however, it has been shown that these constants 
may vary with adiposity, and the errors in ICW and related lean tissue compartments 
increase with increasing adiposity.
34–36
  Although the use of obesity-specific resistivity 
constants did not significantly improve BIS estimates in individuals with extreme 
obesity,
34,35
 better success was achieved by adjusting ECW and ICW estimates for body 
mass index (BMI).
182
 Moissl et al
182
 demonstrated that the addition of BMI to modified 
Xitron-Hanai-based mixture equations substantially improved BIS estimates at the 
extremes of BMI.
182
  
 
BIS devices hold promise for bedside assessment in the clinical setting, as they 
provide a cost-effective, non-invasive technique which can be used for repeated measures 
with minimal risk to the individual.
29
 They offer the potential for a more individualized, 
flexible approach to body composition assessment because of the fact that data are 
collected over an entire spectrum of frequencies and then fit to a mathematical, 
biophysical model (i.e. the Cole model) of human tissue; these qualities set BIS apart 
from the more traditional single- and multiple-frequency bioelectrical impedance analysis 
(SF-BIA, MF-BIA) approaches which rely on statistically derived, population-specific 
prediction equations.  In particular, BIS offers the unique opportunity to individually 
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evaluate ECW and ICW, which would be particularly advantageous in individuals with 
acute or chronic disease who may have abnormal fluid distribution and edema. From 
ECW and ICW estimates, fat mass (FM), fat free mass (FFM), and other lean tissue body 
compartments can be calculated.  Chamney et al have described a novel three-
compartment whole-body model for distinguishing excess fluid (ExF) from normally 
hydrated lean (NH_LT) and normally hydrated adipose tissue (NH_AT) which may 
further improve BIS estimates.
183
 This three-compartment model, based upon dilution, 
DXA and cadaver data, has been shown to have clinical utility for the assessment of 
excess fluid and tailoring clinical management in large scale studies of individuals 
undergoing dialysis.
184,185
   
 
Dual energy X-ray absorptiometry (DXA) is frequently utilized as a reference 
method for comparison with BIS, particularly for FM and FFM measures. DXA typically 
produces photons at 40 and 70 keV, which pass through tissues at rates depending on 
their elemental composition.
14
 DXA output allows for visualization and analysis of the 
separate tissue types. While DXA has its own limitations and sets of assumptions, it is 
well regarded as a method to accurately assess bone mineral content (BMC), FM, FFM, 
and non-bone lean mass, termed lean soft tissue (LST). Height, weight and width 
limitations have historically restricted the use of DXA to those individuals who are 
mobile and who meet the physical size specifications required to use the machine. 
However, newer machines are capable of measuring larger individuals.  
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The application of BIS data to Moissl BMI-corrected Xitron-Hanai-based mixture 
equations to generate the ECW and ICW values needed to calculate the Chamney 3-
compartment model would potentially allow for a more specific evaluation of lean tissue 
by evaluating the NH_LT, accounting for excess fluid that can accumulate in both 
adipose and lean tissue compartments in clinical populations with fluid overload (e.g. 
individuals on dialysis, with extreme obesity, or with acute or chronic illness). The 
measurement of FM at the bedside would also be highly advantageous to the clinician 
interested in monitoring individuals undergoing weight loss interventions.  Because we 
have no directly comparable reference compartment using DXA to validate the NH_LT 
compartment, we can evaluate it indirectly through the comparison of FM measures.  
Thus, we aimed to validate a BIS approach based on the combination of the Moissl-
Chamney models for determining FM in healthy individuals from an NHANES data set 
compared to DXA measures, and for determining FM changes in individuals undergoing 
massive weight loss following Roux-en-Y gastric bypass surgery (RYGB).  
 
4.3:  Subjects 
4.3.1:  NHANES 1999-2004 Dataset 
 Observations were extracted from the NHANES 1999-2004 datasets for both 
DXA and BIS data. BIS data were only available for individuals aged between 8 and 49 
years. Body composition is heavily influenced by age, growth, and stage of development 
and estimating body composition in children may require specific equations incorporating 
child-specific resistivity, shape and body density constants; therefore, we restricted our 
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analysis to data from adults between the ages of 18 and 49 years. After exclusion of 
missing data and outliers the final sample consisted of 5740 observations.  
 
4.3.2:  Longitudinal Dataset 
 Data were gathered from women with extreme obesity before (mean BMI 
46.6±6.8 kg/m
2
, n=25), 6-months (mean BMI 35.7±6.3, n=16), and 1-year following 
(mean BMI 31.6±6.3 kg/m
2
, n=15) RYGB surgery as part of a study conducted between 
2005 and 2009 at the University of Minnesota-Twin Cities, Minnesota. Partial body 
composition data from this study have been previously described.
36,45
 Briefly, women 
with extreme obesity who were planning to undergo laparoscopic RYGB were recruited 
from the Weight Loss Management and Surgery Center at the University of Minnesota 
Health to take part in a longitudinal study of changes in body composition and nutritional 
status after RYGB.  Ethical approval for this study protocol was obtained from the 
Institutional Review Board and the General Clinical Research Center (GCRC) at the 
University of Minnesota. Subjects provided written, informed consent before 
participating.  
 
4.4:  Methods 
4.4.1:  NHANES 1999-2004 Dataset 
 NHANES is a cross-sectional study that assesses the health and diet of the 
civilian, non-institutionalized, United States (US) population using a multistage clustered 
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design. NHANES is administered by the National Center for Health Statistics, Centers for 
Disease Control and Prevention. Certain demographic groups, including older adults, 
Mexican-Americans, non-Hispanic blacks, and low-income persons, are over-sampled in 
this dataset. The NHANES 1999-2000, 2001-2002, and 2003-2004 datasets contain 
whole body DXA scans, which were acquired with a Hologic QDR-4500A fan-beam 
densitometer (Hologic, Inc., Bedford, Massachusetts). This NHANES DXA dataset has a 
large amount of missing data due to the way invalid data were handled in the data 
file.
186,187
 Of the 21,230 eligible DXA participants, non-missing data were obtained from 
16,973, or 80% of the eligible population. Due to weight and height restrictions, the 
likelihood of missing DXA data was related to increasing age, BMI, weight, and 
height.
186,187
 Therefore, the subset of non-missing data may not be treated as a random 
subsample as it may be biased towards the participants with non-missing data.
186,187
 
NHANES DXA data sets consist of 5 sets of imputed measurements to account for 
missing measurements in a large subset of the data set. Observations for individuals 
where the 5 imputed values were not identical (i.e. where imputation was applied) were 
excluded from the dataset for the purposes of our analysis. Imputation was not applied to 
pregnant women or to individuals with amputations, thus these individuals were also 
excluded from the dataset. Total FM as measured by DXA (DXA FM), total lean body 
mass with (DXA FFM) and without bone (DXA LST) was extracted from the DXA data 
for comparison with calculated BIS values for FM and FFM. 
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 BIS data were collected with a HYDRA ECW/ICW Bio-Impedance Spectrum 
Analyzer (Hydra Model 4200, Xitron Technologies, Inc., San Diego, California). The 
NHANES BIS data set is smaller than the DXA data set as BIS was only conducted on 
individuals aged 8 to 49 years. Individuals were excluded from BIS measurements if they 
were pregnant, had any non-finger or non-toe amputations, had artificial joints, pins, 
plates or metal in their bodies, had a pacemaker or automatic defibrillator, had coronary 
stents or metal suture material in the heart, or weighed over 300 lbs.
188
 Therefore, as with 
the DXA data, BIS data is biased towards those who were eligible to complete the BIS 
examination. BIS data including resistance related to ECW (RE) and ICW (RI) estimated 
from Cole-modeling, were extracted from the dataset. Anthropometric measures for 
height and weight were also extracted from the NHANES dataset. 
 
4.4.2:  Longitudinal Dataset 
 For a longitudinal validation, we separately generated BIS data and Cole model 
terms RI and RE (Hydra Model 4200, Xitron Technologies, Inc., San Diego, California) 
from women with obesity before (n=25), 6-months following (n=16) and 1-year 
following (n=15) RYGB surgery. Whole body BIS measurements were obtained at 10 
minutes after participants assumed a supine position, using standard wrist-ankle 
tetrapolar arrangement of electrodes on the hand and the foot on the right side of the 
body. The distance between electrodes was measured and remained constant for repeated 
measurements at follow-up visits. We previously reported BIS precision with the Hydra 
device; inter-day, inter-observer coefficients of variation (CV) for ECW and ICW 
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measures with electrode repositioning were 1.28% and 1.72%, respectively.
189
 
Anthropometric measurements were completed following a standard protocol.
45
 
 
 Half-body DXA scans were performed on the same instrument (GE Lunar 
Prodigy; GEMedical Systems, Madison, WI) for each study visit by an experienced 
technician at the University of Minnesota General Clinical Research Center Body 
Composition Laboratory. All scans were performed in “thick” mode using software 
version 8.8; a modified protocol for conducting half body scans was utilized, as described 
previously.
45
 The precision of the half-body protocol was CV of 5% or less based upon 3 
repeat scans with repositioning at baseline.
45
 
 
4.5:  Calculations 
4.5.1:  Calculation of Xitron-Hanai-Based Mixture Equation Estimated ECW and ICW 
 Using the raw frequency data available from the NHANES and longitudinal data 
sets, we calculated ECWHydra and ICWHydra estimates following the standard Xitron-
Hanai-based mixture equations as follows, and designated as the Hydra method, given 
that these are the same equations and constants utilized by the Hydra device software:31,33  
Equation 4-1:  Xitron-Hanai-based mixture equation for ECW 
ECWHydra =
1
100
(
ρECW∙KB∙Height
2∙√Weight
√D∙R0
)
2
3
     (1) 
where ρECW is the extracellular resistivity (female: 39 Ωcm, male: 42 Ωcm)
31
, D is the 
body density (defined as 1.05 kg/L), KB = 4.3 and is a factor correcting for body shape in 
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whole body wrist-ankle measurement, and R0 is resistance at zero frequency which can 
be considered equivalent to RE.
31,182
  
ICW was calculated using the second generation Xitron-Hanai-based mixture 
equations:
32
 
Equation 4-2:  Xitron-Hanai-based mixture equation for ICW 
ICWHydra = ECWHydra ([
𝜌𝑇𝐵𝑊∙𝑅E+𝑅I
𝜌𝐸𝐶𝑊∙𝑅I
]
2
3
− 1)     (2) 
where ρTBW is total body resistivity and is calculated as:  
Equation 4-3:  Total body resistivity 
𝜌TBW = 𝜌ICW − (𝜌ICW − 𝜌ECW) ∙ (
𝑅I
𝑅E+𝑅I
)
2
3
     (3) 
where ρICW is the intracellular resistivity (female: 264.9 Ωcm, male: 273.9 Ωcm)
31
. 
 
4.5.2:  Calculation of FM and FFM From Xitron-Hanai-Based Mixture Equation 
Estimated ECW and ICW 
 FM was calculated from the ECWHydra and ICWHydra values using the following 
relationship where FFM is estimated using the equation:   
Equation 4-4: FFM calculation from Xitron-Hanai-based mixture equations 
FFMHydra = (𝑑ECW × 𝑉ECW) + (𝑑ICW + 𝑉ICW)    (4) 
where dECW and dICW are the mean densities of the ECW and ICW as defined by Xitron 
(dECW: 1.106 kg/L and dICW:1.521 kg/L, Xitron-Hydra manual)
31
, and VECW and VICW are 
the ECWHydra and ICWHydra volumes previous determined by equations (1) and (2). Then, 
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FMHydra was calculated by subtracting FFMHydra from the participants’ measured 
weight
188
: 
Equation 4-5:  FM calculation from weight and FFM 
FMHydra = Weight − FFMHydra      (5) 
 
4.5.3:  Calculation of Moissl BMI-Corrected ECW and ICW Values 
 ECWMoissl and ICWMoissl were calculated using the BMI-corrected Xitron-Hanai-
based mixture equations equations developed by Moissl et al
182
: 
Equation 4-6:  ECW with Moissl correction 
 ECWMoissl = 𝑘𝐸𝐶𝑊 (
𝐻𝑒𝑖𝑔ℎ𝑡2∙√𝑊𝑒𝑖𝑔ℎ𝑡
𝑅E
)
2
3
     (6) 
Equation 4-7:  ICW with Moissl correction 
ICWMoissl = 𝑘𝐼𝐶𝑊 (
𝐻𝑒𝑖𝑔ℎ𝑡2∙√𝑊𝑒𝑖𝑔ℎ𝑡
𝑅I
)
2
3
      (7) 
where kECW and kICW are functions of BMI based on height, weight and resistance, as 
described by Moissl et al.
182
: 
Equation 4-8:  Moissl BMI-based correction equations 
𝑘𝐸𝐶𝑊 =  
𝑎
BMI
+ 𝑏,  𝑘𝐼𝐶𝑊 =  
𝑐
BMI
+ 𝑑     (8) 
where a, b, c, and d are constants determined by Moissl et al. as follows:
182
  
a = 0.188, b = 0.2883, c = 5.8758 and d = 0.4194. 
The resulting ECWMoissl and ICWMoissl were applied to the equations (4) and (5) to 
generate Moissl-BMI adjusted FM and FFM (FMMoissl and FFMMoissl, respectively). 
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4.5.4:  Generation of Chamney Values for NH_LT, NH_AT and FM From Moissl ECW 
and ICW 
 The ECWMoissl and ICWMoissl values were converted to mass using a value of 
0.993 kg/L at 37C and were applied to the Chamney model183 to generate values for 
ExFMoissl, NH_LTMoissl, NH_ATMoissl and FMM-C using the following equations:
183
 
Equation 4-9:  Chamney ExF 
ExFMoissl = 1.136 × ECWMoissl − 0.430 × ICWMoissl − 0.114 × Weight (9) 
Equation 4-10:  Chamney NH_LT 
NH_LT
Moissl
= 2.725 × ICWMoissl + 0.191 × ExFMoissl − 0.191 × Weight (10) 
Equation 4-11:  Chamney NH_AT 
NH_AT
Moissl
= Weight − ExFMoissl − NH_LTMoissl    (11) 
Equation 4-12:  Chamney FM 
FMM-C = 0.753 × NH_ATMoissl      (12) 
 
 It should be noted that the Chamney equations have not been developed to 
prevent the generation of non-physiological (i.e. ≤0 kg) values of FM, therefore the 
application of the Chamney equations to the Moissl adjusted values for ECW and ICW 
resulted in the generation of a small number of observations with negative, non-
physiological values for estimated NH_ATMoissl and FMM-C. For analysis purposes we left 
these values in the dataset (n=21, mean BMI=19.3±1.5, all male).  
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4.5.5:  Generation of Chamney Values for NH_LT, NH_AT and FM From Hydra ECW 
and ICW (i.e. No BMI Correction) 
 To evaluate the Chamney model without the correction for BMI in the Xitron-
Hanai-based mixture equations, we also applied the Chamney equations (9-12) using the 
ECWHydra and ICWHydra values to generate Chamney values without BMI correction. 
These values are referred to as ExFHydra, NH_LTHydra, NH_ATHydra, and FMH-C. 
 
4.5.6:  Selection of Observations for Inclusion in Analysis 
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Figure 4-1 is a flowchart that shows how observations were selected for inclusion in the 
analysis. The BIS, demographic, and anthropometric NHANES datasets for each of the 
three time periods (1999-2000, 2001-2002, and 2003-2004) were merged by respondent 
sequence identification (ID) number. The three datasets for the DXA data consist of 5 
imputed values for each individual and were transposed before they could be merged 
with the other data. The DXA data were merged with the BIS, demographic, and 
anthropometric datasets and observations with imputed values for DXA were removed 
from the dataset. Weight, height, gender, ethnicity, DXA data, and BIS data were 
extracted from the datasets. Observations with missing values for RE and RI were 
removed. Calculations for Moissl BMI-adjusted ECW and ICW and unadjusted ECW and 
ICW were completed, and only BIS data determined to have an ‘excellent’ or ‘good’ 
quality of fit to the Cole model were included in the analysis. Chamney variables were 
calculated and any observations with missing values for BIS and DXA data or BMI were 
removed from the dataset. The dataset was limited to observations for individuals 
between the ages of 18 and 49.  
 
 Regression analysis between DXAFM and each of the four methods for FM 
estimation from BIS data were assessed for outliers. Two outliers (NHANES subject 
identification numbers 681 and 16964) were identified using regression analysis between 
DXAFM and FMM-C and between DXAFM and FMMoissl and determined to have high 
values for Cook’s distance (relative to other observations in the sample) and to also have 
high horizontal leverage. Observations with high Cook’s distance but no horizontal 
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leverage effect were not removed from the sample. Closer inspection of the two outliers 
revealed that both had BMI greater than 37 kg/m
2
, but were otherwise unremarkable. 
Removal of these two outliers did not significantly alter the results due to the large 
number of observations include in the analysis. After all exclusions, the resulting dataset 
consisted of 5740 individuals who had complete information for all variables used for 
this study. 
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Figure 4-1:  Flowchart of observation selection from NHANES 1999-2004.  
 
 
 
Abbreviations:  BIS, bioimpedance spectroscopy; NHANES, national health and nutrition 
examination survey; ID, subject identification number; DXA, dual energy X-ray 
absorptiometry; ICW, intracellular water; ECW, extracellular water; RE, resistance of 
ECW; RI, resistance of ICW; FM, fat mass; BMI, body mass index; M-C, Moissl-
Chamney. 
  
BIS NHANES 1999-2000
n=5311
BIS NHANES 2001-2002
n=5949
BIS NHANES 2003-2004
n=5329
DXA NHANES 1999-2000
n=6235 (observed or imputed)
DXA NHANES 2001-2002
n=8242 (observed or imputed)
DXA NHANES 2003-2004
n=7656 (observed or imputed)
Demographics 1999-2000
n=9965
Demographics 2001-2002
n=11039
Demographics 2003-2004
n=10122
Anthropometrics 1999-2000
n=9282
Anthropometrics 2001-2002
n=10477
Anthropometrics 2003-2004
n=9643
Merged BIS, Demographics, 
Anthropometrics with DXA data set
n=27229
Excluded observations with less than "good"
 or "excellent" fit for BIS data
n=363
Excluded observations missing both DXAFM and 
FMM-C, n=43
Calculated Chamney model variables
 n = 11854
Excluded missing BMI, n=5
Excluded missing measured values from Hydra device
n=38
n=11811
Merged data set by ID
n=31126
Merged datasets and transposed imputed DXA results
n=22133
Imputed DXA data removed
n=3897
Calculated values for 
ICW and ECW
n=12260
Excluded missing RE and RI 
n=14969
n=11897
n=5742 Excluded ages <18 and >49 years
n=6069
Removed outliers identified using linear regression between 
DXAFM and FMM-C identified as having high Cook's distance, 
and high horrizontal leverage
n=2
Final data set
n=5740
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4.5.7:  Statistical analysis 
 In both datasets, unless otherwise noted, method agreement for FM by BIS and 
DXA was reported as mean ± SD, compared between genders, and evaluated for 
agreement between methods using linear regression analysis, Pearson’s correlation (r), 
coefficient of determination (r
2
), concordance correlation coefficients (CCC), and Bland-
Altman (B-A) analysis. B-A analysis included reported values for the bias between the 
two methods (i.e. the mean difference) as well as the limits of the agreement (1.96 x SD) 
of the bias. These data allowed for the calculation of percent error (PE) by taking the 
limits of agreement for the difference between the two methods and dividing by the mean 
of the reference (DXA) method (referred to as B-A PE). B-A PE <30% was deemed to 
indicate acceptable agreement between methods. We also discuss error as root mean 
square error (RMSE) and percent RMSE (%RMSE) whereby %RMSE=RMSE/reference 
mean x 100. %RMSE <15% was deemed to indicate acceptable error between methods. 
Where appropriate, the r
2
 for the regression line for the B-A analysis was reported. 
Significant r
2
 between the difference and average between methods, assessed by the B-A 
plot, indicated a proportional bias. Given the size of the dataset, small deviations from 0 
were found to be significant, therefore, only significant r
2
 values that were also > 0.10 
were considered to indicate the presence of a proportional bias. Non-parametric paired t-
tests were used for comparison of mean values with P <0.05 used to determine statistical 
significance. All data analysis was completed using SAS software, versions 9.4 of the 
SAS System (SAS Institute Inc., Cary, NC, USA).  
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4.6:  Results 
4.6.1:  NHANES Dataset Descriptive Statistics 
 Descriptive statistics from the NHANES dataset are shown in Table 4-1. From the 
combined NHANES 1999-2004 datasets body composition data measured by both DXA 
and BIS was available for 5740 adults between the ages of 18 and 49 years. Of the 5740 
individuals, 2744 were female and 2996 were male with an overall mean BMI of 
26.7±5.4 kg/m
2
; 34% identified as Mexican American or Hispanic, 40% identified as 
non-Hispanic white, 22% identified as non-Hispanic black, and 4% identified as another 
race or multiracial. Males and females had significantly different mean age, weight, 
height and BMI. BIS measured values for RE and RI differed by gender.  
 
 Body composition data for males and females in the NHANES sample is 
presented in Table 4-2 and includes the measured mean FM, FFM and LST values from 
DXA as well as the estimated FM and FFM from the Hydra device with and without 
adjustment for BMI using the Moissl equations. Chamney model values estimated from 
the BIS raw data, with and without adjustment for BMI using the Moissl equations are 
also reported. All values except for ExF with and without correction for BMI were 
different by gender.  
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Table 4-1:  Descriptive statistics and BIS raw data for the NHANES dataset by 
gender 
 
All 
(n=5740) 
Male 
(n=2996) 
Female 
(n=2744) 
P-value 
Age, years 31.2 ± 10.1 (18-49) 30.9 ± 10.0 31.6 ± 10.2 0.007 
Weight, kg 75.9 ± 16.8 (34-138) 80.5 ± 15.8 71.0 ± 16.6 <0.0001 
Height, cm 168.6 ± 9.7 (133-194) 174.8 ± 7.6 161.9 ± 6.8 <0.0001 
BMI, kg/m
2
 26.7 ± 5.4 (15-52) 26.3 ± 4.6 27.1 ± 6.0 <0.0001 
 
BIS raw values 
RE, Ω  644.6 ± 96 (406-1075) 596.8 ± 73.6 696.8 ± 90.2 <0.0001 
RI, Ω  1281 ± 321 (595-2768) 1088 ± 204 1494 ± 291 <0.0001 
 
Abbreviations:  BMI, body mass index; BIS, bioimpedance spectroscopy; RE, resistance 
of extracellular fluid; RI, resistance of intracellular fluid. 
Sample values are mean ± SD (range); male and female values are mean ± SD. 
P-values are comparison between males and females by student’s t-test.  
PA is calculated as: tan−1(𝑋50 𝑅50⁄ ) × (180 𝜋⁄ ), and reported in degrees. 
IR is calculated as: Z200/Z5, were Z is impedance at 200 kHz and 5 kHz. 
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Table 4-2:  Mean body composition by method of calculation for the NHANES data 
set 
 
 All Male Female P-value 
DXA 
DXA LST, kg 49.8 ± 11.2 57.5 ± 8.7 41.5 ± 8.8 <0.0001 
DXA FFM, kg 52.2 ± 11.6 60.1 ± 9.0 43.6 ± 7.1  <0.0001 
DXA FM, kg 24.4 ± 10.2 21.2 ± 8.6 28.1 ± 10.7 <0.0001 
% fat by DXA 31.6 ± 9.1 25.5 ± 6.2 38.4 ± 6.7 <0.0001 
Hydra 
ECWHydra, L 16.4 ± 3.5 18.5 ± 2.9 14.0 ± 2.4 <0.0001 
ICWHydra, L 22.6 ± 6.4 26.9 ± 5.2 17.9 ± 3.8 <0.0001 
FFMHydra, kg 52.4 ± 13.3 61.3 ± 10.7 42.7 ± 8.1 <0.0001 
FMHydra, kg 23.5 ± 10.7 19.2 ± 8.9 28.3 ± 10.5 <0.0001 
% fat by Hydra 30.7 ± 10.8 23.2 ± 7.8 38.9 ± 7.0 <0.0001 
Moissl-Corrected 
ECWMoissl, L 15.9 ± 3.2 17.8 ± 2.6 13.9 ± 2.3 <0.0001 
ICWMoissl, L 22.4 ± 5.2 26.3 ± 3.7 18.3 ± 2.7 <0.0001 
FFMMoissl, kg  51.7 ± 11.1 59.6 ± 8.4 41.1 ± 6.3 <0.0001 
FMMoissl, kg 24.3 ± 12.0 20.9 ± 10.8 27.9 ± 12.4 <0.0001 
% fat by Moissl 30.9 ± 11.2 24.8 ± 9.2 37.6 ± 9.1 <0.0001 
Hydra-Chamney 
ExFHydra, kg 0.14 ± 1.5 0.16 ± 1.6  0.12 ± 1.4 0.30 
NH_LTHydra, kg 46.6 ± 15.0 57.4 ± 11.6 34.8 ± 7.7 <0.0001 
NH_ATHydra, kg 29.2 ± 14.4 22.9 ± 11.8 36.1 ± 13.8 <0.0001 
FMH-C, kg 22.0 ± 10.8 17.3 ± 8.9 27.2 ± 10.4 <0.0001 
% fat by Hydra-
Chamney 
28.7 ± 11.3 20.7 ± 8.2 37.3 ± 7.3 <0.0001 
Moissl-Chamney 
ExFMoissl, kg -0.3 ± 0.99 -0.3 ± 1.1 -0.26 ± 0.9 0.003 
NH_LTMoissl, kg 46.2 ± 12.2 55.6 ± 8.4 35.9 ± 5.6 <0.0001 
NH_ATMoissl, kg 30.1 ± 16.2 25.3 ± 14.4 35.4 ± 16.4 <0.0001 
FMM-C, kg 22.7 ± 12.2 19.0 ± 10.8 26.7 ± 12.4 <0.0001 
% fat by Moissl-
Chamney 
28.8 ± 11.7 22.3 ± 9.7 35.9 ± 9.5 <0.0001 
 
Abbreviations: DXA, dual energy X-ray absorptiometry; FM, fat mass; FFM, fat free 
mass; ECW, extracellular water; ICW, intracellular water; ExF, extracellular fluid; 
NH_LT, non-hydrated lean tissue; NH_AT, non-hydrated adipose tissue.  
Values are mean ± SD.  
P-values are comparison between males and females by student’s t-test.  
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4.6.2:  Method Agreement for the Assessment of Fat Mass 
 We calculated FM using each of the four methods described previously (FMHydra, 
FMMoissl, FMH-C, and FMM-C), see Table 4-2. Each method was compared to DXAFM to 
assess for method agreement. The results of these comparisons are reported in Table 4-3. 
For the overall data set (n=5740), all four methods systematically underestimated FM (by 
0.2-2.5 kg) when compared with DXA (P<0.0001). However, all four methods were 
highly correlated with DXAFM with the FMMoissl and FMM-C methods most highly 
correlated (r = 0.96, P<0.0001).  The RMSE for FMHydra, FMH-C, FMMoissl, and FMM-C 
were 4.2 (17%), 4.6 (19%), 3.4 (14%), and 3.5 (14%), respectively; indicating that the 
Moissl correction for BMI decreased the error of the estimates. The application of the 
Chamney model appeared to slightly increase the error of the estimates. CCC indicated 
better correlation between DXA and BMI-adjusted methods (FMMoissl = 0.95 and FMM-C 
= 0.93) than between DXA and BMI-unadjusted methods (FMHydra = 0.92, FMH-C = 
0.88). B-A PE was lower for BMI-adjusted methods (FMMoissl = 29% kg, FMM-C = 30%) 
than for BMI-unadjusted methods (FMHydra = 34%, FMH-C = 37%). 
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Table 4-3:  Methods comparison with DXA for FM generated using Hydra, Moissl, Hydra-Chamney and Moissl-Chamney 
methods, by BMI category 
 
Comparison 
Mean difference, 
kg (P-value)
a r 
b
 
RMSE, 
kg 
CCC  
B-A limits  
of agreement 
FMMethod 
Mean, kg 
DXAFM  
Mean, kg 
B-A PE
c 
r
2
 for regression line 
through B-A plot  
(P-value)
d 
DXAFM−FMHydra 0.94 ± 4.2* 0.92 4.2 0.916  -7.3 to 9.2 23.5 ± 10.7 24.5 ± 10.3 34% 0.01 (<0.0001) 
<18.5 kg/m
2 
-2.2 ± 2.7* 0.72 2.7 0.54 -7.6 to 3.1 13.0 ±3.9 10.8 ± 2.6 49% 0.30 (<0.0001) 
18.5-24.9 kg/m
2
 
0.06 ± 3.6 
(0.44) 
0.82 3.5 0.79 -7.0 to 7.1 16.9 ± 6.2 16.9 ± 4.7 42% 0.19 (<0.0001) 
25-29.9 kg/m
2
 1.5 ± 4.2* 0.81 4.1 0.74 -6.7 to 9.8 23.6 ± 7.1 25.2 ± 5.1 33% 0.26 (<0.0001) 
30-39.9 kg/m
2 
1.9 ± 4.7* 0.86 4.7 0.81 -7.3 to 11.2 34.5 ± 9.1 36.4 ± 7.0 25% 0.21 (<0.0001) 
≥40 kg/m2 2.1 ± 5.0* 0.80 5.4 0.74 -7.7 to 12.0 51.6 ± 8.4 53.8 ± 3.3 18% 0.20 (<0.0001) 
DXAFM−FMMoissl 0.2 ± 3.6* 0.96 3.4 0.947 -6.8 to 7.3 24.3 ± 12.1 24.5 ± 10.3 29% 0.26 (<0.0001) 
<18.5 kg/m
2
 2.2 ± 2.6* 0.74 2.6 0.55  -2.8 to 7.3 8.6 ± 3.8 10.8 ± 2.6 47% 0.27 (<0.0001) 
18.5-24.9 kg/m
2
 1.5 ± 3.1* 0.85 3.1 0.79  -4.5 to 7.6 15.4 ± 5.9 16.9 ± 4.7 36% 0.16 (<0.0001) 
25-29.9 kg/m
2
 
0.05 ± 3.4 
(0.53) 
0.84 3.4 0.82 -6.6 to 6.7 25.1 ± 6.2 25.2 ± 5.1 27% 0.12 (<0.0001) 
30-39.9 kg/m
2
 -1.8 ± 3.7* 0.89 3.7 0.86 -9.2 to 5.5 38.3 ± 8.3 36.4 ± 7.0 20% 0.13 (<0.0001) 
≥40 kg/m2 -3.3 ± 3.9* 0.85 3.9 0.74 -10.9 to 4.2 57.1 ± 7.3 53.8 ± 3.3 14% 0.07 (0.0072) 
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Comparison 
Mean difference, 
kg (P-value)
a r 
b
 
RMSE, 
kg 
CCC  
B-A limits  
of agreement 
FMMethod 
Mean, kg 
DXAFM  
Mean, kg 
B-A PE
c 
r
2
 for regression line 
through B-A plot  
(P-value)
d 
DXAFM−FMH-C 2.5 ± 4.6* 0.91 4.6 0.879  -6.5 to 11.5 22.0 ± 10.8 24.5 ± 10.3 37% 0.02 (<0.0001) 
<18.5 kg/m
2
 -1.3 ± 3.0* 0.72 2.9 0.60 -7.1 to 4.5 12.1 ± 4.2 10.8 ± 2.6 54% 0.36 (<0.0001) 
18.5-24.9 kg/m
2
 1.4 ± 3.9* 0.80 3.9 0.74 -6.3 to 9.1 15.5 ± 6.6 16.9 ± 4.7 45% 0.25 (<0.0001) 
25-29.9 kg/m
2
 3.2 ± 4.6* 0.80 4.5 0.66 -5.8 to 12.2 22.0 ± 7.5 25.2 ± 5.1 36% 0.31 (<0.0001) 
30-39.9 kg/m
2
 3.7 ± 5.2* 0.85 5.7 0.73 -6.4 to 13.9 32.7 ± 9.5 36.4 ± 7.0 28% 0.25 (<0.0001) 
≥40 kg/m2 3.9 ± 5.4* 0.79 5.4 0.66 -6.8 to 14.6 49.9 ±8.8 53.8 ± 3.3 20% 0.24 (<0.0001) 
DXAFM−FMM-C 1.8 ± 3.8* 0.96 3.5 0.93  -5.6 to 9.2 22.7 ± 12.2 24.5 ± 10.3 30% 0.27 (<0.0001) 
<18.5 kg/m
2
 3.6 ± 2.8* 0.74 2.8 0.43 -1.8 to 9.0 7.2 ± 4.0 10.8 ± 2.6 51% 0.33 (<0.0001) 
18.5-24.9 kg/m
2
 3.1 ± 3.3* 0.85 3.2 0.71 -3.4 to 9.5 13.8 ± 6.2 16.9 ± 4.7 38% 0.22 (<0.0001) 
25-29.9 kg/m
2
 1.7 ± 3.6* 0.84 3.7 0.78 -5.3 to 8.7 23.5 ± 6.5 25.2 ± 5.1 28% 0.17 (<0.0001) 
30-39.9 kg/m
2
 
-0.3 ± 3.9 
(0.012) 
0.89 3.8 0.87 -7.9 to 7.3 36.7 ± 8.5 36.4 ± 7.0 21% 0.16 (<0.0001) 
≥40 kg/m2 -2.0 ± 4.0* 0.84 4.0 0.80 -9.8 to 5.9 55.7 ± 7.5 53.8 ± 3.3 15% 0.09 (0.0019) 
For BMI categories: <18.5 kg/m
2
, n=170; 18.5-24.9 kg/m
2
, n=2302; 25-30 kg/m
2
, n=1876; 30-40 kg/m
2
, n=1289; >40 kg/m
2
, n=103. 
a:  Mean difference calculated as dual energy X-ray absorbtometry (DXA) – comparison method. P-value reported by paired t-test.     
* indicates, P-value <0.0001. b:  r =Pearson correlation coefficient. All values are significant, P-value <0.0001. c:  Bland-Altman (B-
A) percent error (PE) calculated as limits of agreement for the difference between the two methods (1.96(SD)) divided by the mean for 
the reference DXA method x 100%. d:  r
2
 is reported, P-value indicates significant deviation of regression slope from zero. Unless 
otherwise noted, all values are mean ± SD. Abbreviations: FM, fat mass; RMSE, root mean square error; CCC, concordance 
correlation coefficient. 
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 A proportional bias was evident in the B-A assessment for each of the four 
methods. Although significant, r
2
 for the regression line through the B-A plot (difference 
v. average) only accounted for 26% and 27% of the variance in the model for the BMI-
corrected methods (FMMoissl and FMM-C, respectively), and accounted for even less (1-
2%) of the variance in the BMI-uncorrected methods (see Figure 4-2). Incorporation of 
the Moissl BMI correction to the Xitron-Hanai-based mixture equations improved the 
method agreement with the reference DXA method, but also imparted a proportional bias 
where, as the average of the FM ([DXAFM + FM]/2) increased, the difference between 
the methods decreased. This proportional bias indicated that the methods did not agree 
over all weight classes. As can be seen in Figure 4-2, for the B-A analysis of each of the 
four FM method comparisons with DXA, the x-intercept for regression line (i.e. 
indicating the average of the FM where there was no bias between methods) was 45.6 kg 
for FMHyda, 25.7 kg for FMMoissl, 68.0 kg for FMH-C, and 33.7 kg for FMM-C. With a lower 
average of the FM estimates (FM average < regression line x-intercept) there was a larger 
positive difference between the methods and for higher average FM estimates (FM 
average > regression line x-intercept) there was a larger negative difference between the 
methods. For the FM estimates, the slope of the regression line through the B-A plot 
became slightly more negative after application of the Chamney model to the Moissl 
BMI-adjusted ECW and ICW values. 
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Figure 4-2:  Comparison between FM estimates and DXA FM by linear regression 
and Bland-Altman analysis. 
 
 
 
Abbreviations: DXA, dual energy X-ray absorptiometry; FM, fat mass; RMSE, root mean 
square error; FMHydra, FM calculated from Xitron-Hanai-based mixture equations (A and 
B); FMMoissl, FM corrected for BMI (C and D); FMH-C, Chamney FM calculated with 
ECW and ICW from Hydra (E and F); FMM-C, Chameny FM calculated with Moissl-BMI 
adjusted ECW and ICW (G and H).  
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4.6.3:  Contribution of BMI to the Error Between Methods 
 Using a general linear regression model, we assessed the contribution of age, 
gender, ethnicity, and BMI on the difference (i.e. the residual) between DXAFM and FM 
by each of the four BIS methods. We determined that gender, ethnicity and BMI were 
significant predictors of the difference between DXA and three of the methods tested 
(FMHydra, FMH-C and FMM-C). Both BMI and ethnicity, but not gender, were significant 
predictors of the difference between DXA and FMMoissl. Based on this finding and our 
interest in the assessment of body composition in individuals with obesity, we completed 
regression analysis for the difference between DXA FM and FM by each of the four 
methods (i.e. the residual between methods) with BMI. As can be seen in Figure 4-3 and 
Table 4-4 comparing the residual for each method to BMI confirmed that BMI was 
significantly associated with the residual for each method comparison with DXA 
(P<0.0001). However, for Moissl-BMI adjusted methods (FMMoissl and FMM-C) this 
association was negative (slope= -0.27 for both; i.e. larger BMI results in smaller errors), 
while for non-BMI adjusted methods (FMHydra and FMH-C) this association was positive 
(slope=0.18 and 0.22 respectively; i.e. larger BMI results in larger errors).  
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Figure 4-3:  Linear regression analysis for the difference between DXA FM and each of the FM methods across BMI 
 
 
Abbreviations:  DXA, dual energy X-ray absorptiometry; FM, fat mass; BMI, body mass index; FMHydra, FM calculated from Xitron-
Hanai-based mixture equations; FMMoissl, FM corrected for BMI; FMH-C, Chamney FM calculated with ECW and ICW from Hydra; 
FMM-C, Chamney FM calculated with Moissl-BMI adjusted ECW and ICW. 
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Table 4-4:  Linear regression analysis for the difference between DXA FM and each 
of the FM methods across BMI 
 
 Model r
2
 RMSE, kg Intercept BMI P-value 
DXA 
FM v. 
FMHydra 0.05 4.08 -3.89 0.18  <0.0001 
FMMoissl 0.16 3.33 7.54 -0.27 <0.0001 
FMH-C 0.06 4.46 -3.42 0.22 <0.0001 
FMM-C 0.15 3.51 9.00 -0.27 <0.0001 
 
Abbreviations:  DXA, dual energy X-ray absorptiometry; FM, fat mass; RMSE, root 
mean square error; BMI, body mass index; FMHydra, FM calculated from Xitron-Hanai-
based mixture equations; FMMoissl, FM corrected for BMI; FMH-C, Chamney FM 
calculated with ECW and ICW from Hydra; FMM-C, Chamney FM calculated with 
Moissl-BMI adjusted ECW and ICW. 
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4.6.4:  Assessment of FM Method Agreement by BMI Category 
 From the results of our regression analyses and what has been reported in the 
literature
34,35,182
 we hypothesized that BMI category may impact the success of the 
methods. Table 4-3 shows the assessment of the comparison between DXAFM and each 
of the four methods by BMI category. BMI categories were defined as underweight 
(<18.5 kg/m
2
), normal weight (between 18.5 and 24.9 kg/m
2
), overweight (between 25 
and 29.9 kg/m
2
), obese (between 30 and 39.9 kg/m
2), and severe obesity (≥40 kg/m2). 
 
4.6.5:  Comparison Between DXAFM and FMHydra by BMI Category 
 Below 18.5 kg/m
2
, the Hydra unadjusted equations systematically overestimated 
FM relative to DXAFM by ~2.2 kg.  Between 18.5 and 24.9 kg/m
2
, the Hydra equations 
did not differ from DXAFM. Above 25 kg/m
2
, the Hydra equations underestimated FM 
relative to DXAFM by ~1.5 to 2.1 kg. For BMI values <18.5 kg/m
2
, r was less than 0.75, 
indicating moderate association between methods. For all BMI categories ≥18.5 kg/m2, r 
was >0.8, indicating a stronger association between methods. RMSE ranged from a low 
value of 2.7 kg for BMI <18.5 kg/m
2
, and increased with increasing BMI to 5.4 kg for 
BMI values ≥40 kg/m2, although %RMSE decreased over the same range, from 25% to 
10%, respectively. The highest CCC occurred for BMI category 30-39.9 kg/m
2
 and the 
lowest occurred for BMI category <18.5 kg/m
2
, 0.81 and 0.54, respectively. For the BMI 
range where DXAFM and FMHydra were not different (18-24.9 kg/m
2
), CCC was 0.79, 
indicating moderately strong correlation between methods. B-A PE analysis between 
methods showed that the highest B-A PE occurred for the <18.5 category, with B-A PE 
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of 49%; and the lowest occurred for the ≥ 40 kg/m2 category, with B-A PE of 18%. For 
the BMI range where the methods were not different (18-24.9 kg/m
2
), with B-A PE of 
42%. B-A analysis revealed a proportional bias for all BMI category comparisons.  
 
4.6.6:  Comparison Between DXAFM and FMMoissl by BMI Category 
 Below 24.9 kg/m
2
, the BMI-corrected, Moissl equations systematically 
underestimated FM relative to DXAFM, by ~1.5 to 2.2 kg. Between 25 and 29.9 kg/m
2
 
the BMI-adjusted FM estimates did not differ from DXAFM. Above 30 kg/m
2
, Moissl 
adjusted FM estimates overestimated FM relative to DXAFM by ~1.8 to 3.3 kg. For BMI 
values <18.5 kg/m
2
, r was less than 0.75, indicating moderate association between 
methods. For all BMI categories ≥18.5 kg/m2, r was>0.85, indicating a strong association 
between methods. RMSE ranged from a low value of 2.6 kg for BMI <18.5 kg/m
2
, and 
increased with increasing BMI to 3.9 kg for BMI values ≥40 kg/m2, although %RMSE 
decreased from 24% to 7%, respectively over the same range. The highest CCC occurred 
for BMI category 30-39.9 kg/m
2
 and the lowest occurred for BMI category <18.5 kg/m
2
, 
0.86 and 0.55, respectively. For the BMI range where DXAFM and FMMoissl were not 
different (25-29.9 kg/m
2
), CCC was 0.82, indicating strong correlation between methods. 
B-A PE analysis between methods showed that the highest PE occurred for the <18.5 
kg/m
2
 category, with B-A PE of 47%; and the lowest occurred for the ≥ 40 kg/m2 
category, with B-A PE of 14%. For the BMI range where the methods were not different 
(25-29.9 kg/m
2
) B-A PE was 27%. B-A analysis revealed a proportional bias for all BMI 
category comparisons, except for BMI ≥40 kg/m2. Compared to the BMI-unadjusted 
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comparison of FMHydra with DXAFM, the BMI-adjusted comparison between FMMoissl 
and DXAFM appeared to improve the method for FM estimation. 
 
4.6.7:  Comparison Between DXAFM and FMH-C by BMI Category 
 FM estimates using the application of Hydra unadjusted ECW and ICW values to 
the Chamney equations were different from DXAFM for all BMI categories. Below 18.5 
kg/m
2
, FMH-C systematically overestimated FM relative to DXAFM by ~1.3 kg. Above 
18.5 kg/m
2,
 FMH-C underestimated FM relative to DXAFM by ~1.4 to 3.9 kg. For BMI 
values <18.5, r was less than 0.75, indicating a moderate association between methods. 
For all BMI categories ≥18.5 and <39.9, r was>0.80, indicating a stronger association 
between methods. For BMI values ≥40, r was 0.79, indicating a relatively strong 
association. RMSE ranged from a low value of 2.9 kg for BMI <18.5 kg/m
2
, and 
increased with increasing BMI to 5.4 kg for BMI values ≥40 kg/m2, although %RMSE 
decreased from 27% to 10%, respectively over the same range. The highest CCC 
occurred for BMI category 18.5-24.9 kg/m
2
 and the lowest occurred for BMI category 
<18.5 kg/m
2
, 0.74 and 0.60, respectively. Compared to other methods, the Hydra-
Chamney model was not well correlated with DXAFM. B-A PE analysis between 
methods showed that the highest B-A PE occurred for the <18.5 category, with B-A PE 
of 54%; and the lowest occurred for the ≥ 40 kg/m2 category, with B-A PE of 20%. B-A 
analysis revealed a proportional bias for all BMI category comparisons. 
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4.6.8:  Comparison Between DXAFM and FMM-C by BMI Category 
 Below 29.9 kg/m
2
, the BMI corrected, Moissl ECW and ICW values applied to 
the Chamney equations underestimated FM relative to DXAFM. Between 30 and 39.9 
kg/m
2
 the FMM-C estimates did not differ from DXAFM. Above 40 kg/m
2
, FMM-C 
estimates overestimated FM relative to DXAFM. For BMI values <18.5 kg/m
2
, r was less 
than 0.75, indicating moderate association between methods. For all BMI categories 
≥18.5 kg/m2, r was>0.84, indicating a strong association between methods. RMSE ranged 
from a low value of 2.8 kg for BMI <18.5 kg/m
2
, and increased with increasing BMI to 
4.0 kg for BMI values ≥40 kg/m2, although %RMSE decreased from 26% to 7%, 
respectively over the same range. The highest CCC occurred for BMI category 30-39.9 
kg/m
2
 and the lowest occurred for BMI category <18.5 kg/m
2
, 0.87 and 0.43, 
respectively. For the BMI range where DXAFM and FMM-C were not different (30-39.9 
kg/m
2
), CCC was 0.87, indicating strong correlation between methods. B-A PE analysis 
between methods showed that the highest B-A PE occurred for the <18.5 category, with 
B-A PE of 51%; and the lowest occurred for the ≥ 40 kg/m2 category, with B-A PE of 
15%. For the BMI range where the methods were not different (30-39.9 kg/m
2
), with B-A 
PE of 21%. B-A analysis revealed a proportional bias for all BMI category comparisons, 
except for BMI ≥40 kg/m2. Compared to the BMI-unadjusted, Chamney model 
comparison of FMH-C with DXAFM, the BMI-adjusted, Chamney model comparison 
between FMM-C and DXAFM appeared to improve the method for FM estimation, 
particularly in individuals with obesity (BMI ≥ 30 kg/m2). 
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4.6.9:  Assessment of Moissl-Chamney Model FM by BMI Category and Gender 
 Based on the results of the BMI category assessment, we determined that for 
individuals with obesity (BMI between 30-39.9 kg/m
2
) the Moissl-Chamney model 
appeared to be the most effective for estimation of FM from BIS data. To further 
investigate the application of the Moissl-Chamney model for assessment of FM and to 
account for gender in the difference between the models, we compared FMMoissl to DXA 
FM by gender for each BMI category (data not shown). While the proportional bias 
introduced by the Moissl-BMI correction persisted throughout the genders and 
categories, the mean difference between the methods decreased as the BMI category 
increased. The best method agreement appeared to be for men and women with obesity; 
B-A PE for men with BMI between 30-39.9 kg/m
2
 was 26% (n = 580, mean difference = 
-0.37 ± 4.3, P=0.04, r = 0.85, mean DXAFM =32.9 kg/m
2
) and for women with BMI 
between 30-39 kg/m
2
 was 17% (n = 709, mean difference = -0.19 ± 3.5, P=0.15, r = 0.9, 
mean DXAFM =39.3 kg/m
2
). Of note, there was no difference between DXAFM and 
FMM-C estimates for women with BMI between 30-39 kg/m
2
. 
 
4.6.10:  Assessment of FFM Method Agreement  
 In parallel with our assessment of FM by BMI category, we completed an 
assessment of BIS estimates of FFM (by Hydra and Moissl) compared with DXA FFM, 
and NH_LT (by Hydra-Chamney and Moissl-Chamney) compared to DXA LST for the 
overall data set and by BMI category. Table 4-5 shows the assessment of the comparison 
between DXA FFM and the two BIS methods used to generate FFM and between DXA 
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LST and the two BIS methods used to generate NH_LT, by BMI category. Unlike FM 
estimates, the comparisons between NH_LT and DXA LST are limited and thus, should 
be interpreted with caution because they do not represent exactly the same tissue 
compartments due to the differences in methodology.  
 
 For the overall data, the FFMHydra slightly overestimated FFM compared to DXA 
FFM (by ~0.2 kg). The two methods were well correlated, (r = 0.95, CCC = 0.94) and the 
error between the methods was relatively low (RMSE = 4.0 kg, 8%). B-A analysis 
revealed moderate limits of agreement (-8.4 to 8.0 kg) and B-A PE was 16%, however 
there was a proportional bias. FFMMoissl underestimated FFM compared to DXA FFM. 
The two methods were also well correlated, (r = 0.95, CCC = 0.95) and the error between 
the methods was low (RMSE = 3.5 kg, 7%). B-A limits of agreement were relatively 
small (-6.7 to 7.8 kg) and the B-A PE was 14%. Although statistically significant 
(r
2
=0.02, P-value <0.0001), based on our cutpoint of r
2
<0.10, there was essentially no 
proportional bias, indicating overall good agreement between the methods.  
 
 Because the Moissl-Chamney approach is a multi-component model with a more 
specific representation of the lean tissue compartment than the more global FFM, it was 
not deemed to be advantageous from a validation point of view to calculate a FFM from 
the FMM-C (i.e. weight – FMM-C = FFMM-C) for comparison with DXA.  However, in the 
interest of completeness, we did calculate FFMM-C and found that it was well-correlated 
with DXA FFM for the overall dataset (r = 0.94, p<0.001).  The next closest DXA lean 
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tissue compartment to NH_LT would be the DXA LST, although they reflect different 
components; for example LST is a more global compartment and includes everything in 
the FFM except bone. As anticipated, NH_LTHydra underestimated lean tissue compared 
with DXA LST (see Table 4-5). For the overall data, the two methods were well 
correlated (r = 0.89, CCC=0.83), but there was relatively high error between the methods 
(RMSE=6.8 kg, 14%), which was expected given that the magnitude of the two 
compartments was quite different. B-A limits of agreement were wide (-11.2 to 17.5 kg) 
and B-A PE was 28% with a proportional bias present. Correction for BMI by applying 
the M-C model to generate NH_LTMoissl also underestimated mean lean tissue mass 
compared with DXA LST. Although the two methods were well correlated (r = 0.82, 
CCC=0.78). Error between the methods was relatively high (RMSE=6.9 kg, 14%). B-A 
limits of agreement were wide (=10.4 to 17.7 kg) and B-A PE was 28% with a slight 
proportional error. Therefore, for evaluation of lean tissue in the whole data set the BMI-
corrected Moissl equations appeared to have the best agreement with DXA LST. No 
further analyses on the comparison between DXA LST and NH_LTMoissl were conducted. 
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Table 4-5:  Methods comparison for DXA LST and FFM with FFM by Hydra and Moissl, and NH_LT by Hydra-Chamney 
and Moissl-Chamney methods, by BMI category 
 
Comparison 
Mean difference, 
kg (P-value)
a r
b
 
RMSE, 
kg 
CCC  
B-A limits of 
agreement 
FFM or 
NH_LTMethod 
Mean, kg 
DXA  
Mean, kg 
B-A 
PE
c 
r
2
 for regression 
line through B-A 
plot (P-value)
d
 
DXA FFM− 
FFMHydra 
-0.20 ± 4.2 
(0.0004) 
0.95 4.0 0.94 -8.4 to 8.0 52.4 ± 13.3 52.2 ± 11.6 16% 0.17 (<0.0001) 
<18.5 kg/m
2
 2.7 ± 2.7* 0.94 2.7 0.88 -2.6 to 8.0 37.0 ± 7.8 39.7 ± 7.1 13% 0.06 (0.0014) 
18.5-24.9 kg/m
2
 0.6 ± 3.6* 0.95 3.5 0.94 -6.5 to 7.7 46.9 ± 10.9 47.5 ± 9.6 15% 0.14 (<0.0001) 
25-29.9 kg/m
2
 -0.73 ± 4.2* 0.94 4.1 0.93 -9.0 to 7.5 55.1 ± 12.2 54.4 ± 10.7 15% 0.13 (<0.0001) 
30-39.9 kg/m
2 
-1.1 ± 4.7* 0.94 4.6 0.93 -10.4 to 8.2 59.8 ± 13.8 58.7 ± 12.1 16% 0.14 (<0.0001) 
≥40 kg/m2 
-1.6 ± 4.9 
(0.001) 
0.87 4.9 0.83 -11.3 to 8.1 61.0 ± 10.0 59.3 ± 7.9 16% 0.19 (<0.0001) 
DXA FFM− 
FFMMoissl 
0.51 ± 3.7* 0.95 3.5 0.95 -6.7 to 7.8 51.7 ± 11.1 52.2 ± 11.6 14% 0.02 (<0.0001) 
<18.5 kg/m
2
 -1.76 ± 2.6* 0.95 2.6 0.92 -6.8 to 3.3 41.4 ± 7.8 39.7 ± 7.1 13% 0.07 (0.0003) 
18.5-24.9 kg/m
2
 -0.88 ± 3.14* 0.95 3.1 0.94 -7.0 to 5.3 48.4 ± 10.0 47.5 ± 9.6 13% 0.02 (<0.0001) 
25-29.9 kg/m
2
 0.77 ± 3.4* 0.95 3.4 0.95 -6.0 to 7.5 53.6 ± 10.7 54.4 ± 10.7 12% 0.00 (0.85) 
30-39.9 kg/m
2
 2.7 ± 3.8* 0.95 3.7 0.93 -4.8 to 10.1 56.0 ± 11.6 58.7 ± 12.1 13% 0.01 (<0.0001) 
≥40 kg/m2 3.8±3.8* 0.89 3.7 0.79 -3.6 to 11.2 55.5 ± 7.9 59.3 ± 7.9 13% 0.00 (0.93) 
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Comparison 
Mean difference, 
kg (P-value)
a r
b
 
RMSE, 
kg 
CCC  
B-A limits of 
agreement 
FFM or 
NH_LTMethod 
Mean, kg 
DXA  
Mean, kg 
B-A 
PE
c 
r
2
 for regression 
line through B-A 
plot (P-value)
d
 
DXA LST− 
NH_LTHydra 
3.2 ± 7.1* 0.89 6.8 0.83 -11.2 to 17.5 46.6 ± 15.0 49.8 ± 11.2 28% 0.29 (<0.0001) 
<18.5 kg/m
2
 5.5 ±4.6* 0.87 4.5 0.68 -3.7 to 14.7 32.1 ± 9.0 37.6 ± 7.8 24% 0.24 (<0.0001) 
18.5-24.9 kg/m
2
 2.9 ± 6.2* 0.90 5.7 0.82 -9.6 to 15.4 42.3 ± 13.0 45.2 ± 9.2 27% 0.39 (<0.0001) 
25-29.9 kg/m
2
 2.3 ± 7.2* 0.89 6.8 0.82 -12.3 to 16.7 49.6 ± 14.5 51.9 ± 10.3 27% 0.36 (<0.0001) 
30-39.9 kg/m
2
 4.3 ± 8.3* 0.88 7.8 0.79 -12.3 to 21.0 51.8 ± 16.5 56.1 ± 11.7 29% 0.36 (<0.0001) 
≥40 kg/m2 8.2 ± 8.5* 0.78 8.3 0.52 -8.7 to 25.2 48.6 ± 12.8 56.8 ± 7.7 29% 0.40 (<0.0001) 
DXA LST− 
NH_LTMoissl 
3.7 ± 7.0* 0.82 6.9 0.78 -10.4 to 17.7 46.2 ± 12.2 49.8 ± 11.2 28% 0.02 (<0.0001) 
<18.5 kg/m
2
 -2.5 ± 4.3* 0.90 4.0 0.82 -11.0 to 6.1 40.1 ± 9.2 37.6 ± 7.8 22% 0.31 (<0.0001) 
18.5-24.9 kg/m
2
 
-0.3 ± 5.2 
(0.02) 
0.90 5.0 0.88 -10.7 to 10.2 45.4 ± 11.7 45.2 ± 9.2 23% 0.24 (<0.0001) 
25-29.9 kg/m
2
 4.0 ± 5.4* 0.90 5.4 0.83 -6.7 to 14.9 47.9 ± 12.3 51.9 ± 10.3 21% 0.14 (<0.0001) 
30-39.9 kg/m
2
 9.1 ± 6.1* 0.89 6.1 0.67 -2.3 to 22.1 46.2 ± 13.1 56.1 ± 11.7 21% 0.06 (<0.0001) 
≥40 kg/m2 16.9 ± 5.9* 0.78 5.8 0.26 5.28 to 28.5 39.9 ± 9.3 56.8 ± 7.7 20% 0.09 (0.003) 
For BMI categories: <18.5 kg/m
2
, n=170; 18.5-24.9 kg/m
2
, n=2302; 25-30 kg/m
2
, n=1876; 30-40 kg/m
2
, n=1289; >40 kg/m
2
, n=103. 
a:  Mean difference calculated as dual energy X-ray absorptiometry (DXA) – comparison method. P-value reported by paired t-test. * 
indicates, P-value <0.0001. b:  r = Pearson correlation coefficient. All values are significant, P-value <0.0001. c:  Bland-Altman (B-A) 
percent error (PE) calculated as limits of agreement for the difference between the two methods (1.96(SD)) divided by the mean for 
the reference DXA method x 100%. d:  r
2
 is reported, P-value indicates significant deviation of regression slope from zero. 
Unless otherwise noted, all values are mean ± SD.  
Abbreviations: FFM, fat free mass; LST, lean soft tissue; NH_LT, non-hydrated lean tissue; CCC, concordance correlation coefficient.
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4.6.11:  Comparison Between DXA FFM and FFMHydra by BMI Category 
 Below 24.9 kg/m
2
, FFMHydra underestimates DXA FFM by ~0.6 to 2.7 kg. Above 
25 kg/m
2
, the Hydra unadjusted equations overestimated FFMHydra relative to DXA FFM 
by ~0.732 1.6 kg. For BMI values <39.9 kg/m
2
, r was at least 0.94, indicating strong 
association between methods. Above BMI 40 kg/m
2
, r was slightly decreased to 0.87, 
which still indicates a strong association between methods. RMSE ranged from a low 
value of 2.7 kg for BMI <18.5 kg/m
2
, and increased with increasing BMI to 4.9 kg for 
BMI values ≥40 kg/m2, although %RMSE remained relatively constant between 7% to 
8%, over the same range. The highest CCC occurred for BMI category of 18.5-24.9 
kg/m
2
 and the lowest occurred for BMI category ≥40 kg/m2, 0.94 and 0.83, respectively. 
B-A PE analysis between methods showed that the highest B-A PE occurred for both the 
30-39.9 kg/m
2
 and ≥40 kg/m2 categories, with B-A PE of 16%; the lowest occurred for 
the ≤ 18.5 kg category, with B-A PE of 13%. B-A analysis revealed a proportional bias 
for all BMI category comparisons.  
 
4.6.12:  Comparison Between DXA FFM and FFMMoissl by BMI Category 
 For the categories below 24.9 kg/m
2
, the BMI-corrected Moissl equations 
overestimated FFMMoissl relative to DXA FFM by ~0.882 1.76 kg. Above 40 kg/m
2
, the 
BMI-corrected Moissl equations underestimated FFMMoissl relative to DXA FFM by 
~0.772 3.8 kg. For all BMI categories <39.9 kg/m
2
, r was 0.95 and CCC ranged from 
0.92-0.95, indicating strong association between methods. Above BMI 40 kg/m
2
, r was 
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slightly decreased to 0.89, which still indicated a strong association between methods 
however, CCC=0.79 indicating a moderately strong association. RMSE ranged from a 
low value of 2.6 kg for BMI <18.5 kg/m
2
, and increased with increasing BMI to 3.7 kg 
for BMI values ≥30 kg/m2, although %RMSE remained relatively constant around 6%, 
over the same range.  The highest CCC occurred for BMI category 25-29.9 kg/m
2
 and the 
lowest occurred for BMI category ≥40 kg/m2, 0.95 and 0.79, respectively. B-A PE 
analysis between methods showed that for all BMI categories, B-A PE was 12-13%. B-A 
analysis revealed no proportional bias for all BMI category comparisons based on our r
2
 
cutpoint of 0.10, and particularly strong evidence for no bias was observed for BMI 
categories 25-29.9 and ≥40 kg/m2 where the slope was zero and was not statistically 
significant. Overall, the Moissl FFM equations appear to have moderately good 
agreement with DXA FFM. 
 
4.6.13:  Longitudinal Dataset and Descriptive Statistics 
 After demonstrating that the application of the Moissl-Chamney model was 
particularly effective for the assessment of FM in overweight women we then applied the 
model to a group of women with obesity undergoing massive weight loss in the first year 
after RYGB. Demographic data for the longitudinal dataset including the 6-month and 1-
year post surgery time points are shown in Table 4-6. All women in the cohort identified 
as non-Hispanic white. Body weight and BMI in this cohort were lower at 6-months 
compared to baseline, and lower at 1-year compared with baseline and 6-months post- 
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Table 4-6:  Descriptive statistics and BIS raw data, calculated values for BMI 
adjusted ECW and ICW, BMI adjusted 3-compartment values, and LST and FM 
from DXA of women undergoing weight loss after RYGB. 
 
 Time of follow-up post-RYGB 
 
Baseline 
(n=25) 
6-months 
(n=16) 
1-year 
(n=15) 
Age at time of surgery, 
years 
48 ± 10 47 ± 10 47 ± 10 
Weight, kg 127.4 ± 22.4 98.99 ± 19.9
a
 87.7 ± 19.8
b
 
Height, cm 165 ± 6 166 ± 5 166 ± 5 
BMI, kg/m
2 
46.6 ± 6.8 35.7 ± 6.3
a
 31.6 ± 6.3
b
 
 
BIS 
 
RE, Ω 545 ± 61 586 ± 56 582 ± 56 
RI, Ω 1273 ± 138 1602 ± 224
a 
1618 ± 161
a 
 
Moissl 
 
ECWMoissl, L 19.9 ± 3.1 17.8 ± 2.7
a 
17.2 ± 2.6
b 
ICWMoissl, L 21.4 ± 2.6 18.3 ± 2.3
a 
18.0 ± 1.9
b 
 
Chamney-Moissl 
 
ExFMoissl, kg -1.2 ± 1.3 1.0 ± 1.0
a 
1.8 ± 1.1
b 
NH_LTMoissl, kg 33.3 ± 5.5
a 
30.7 ± 5.6
b 
32.3 ± 4.9
ab 
NH_ATMoissl, kg 95.3 ± 22.9 67.3 ± 21.7
a 
53.6 ± 21.8
b 
FMM-C 71.8 ± 17.2 50.6 ± 16.3
a 
40.3 ± 16.4
b 
 
DXA 
 
DXA FFM 65.3 ± 12.1   55.7 ± 8.4
a 
56.0 ± 7.3
a 
DXA LST 62.7 ± 12.2 52.7 ± 8.3
a 
53.2 ± 7.1
a 
DXA FM 64.1 ± 13.8 44.3 ± 13.6
a 
33.2 ± 13.3
b 
 
Abbreviations:  BMI, body mass index; BIS, bioimpedance spectroscopy; RE, resistance 
of extracellular water; RI, resistance of intracellular water; ECW, extra cellular water; 
ICW, intracellular water; ExF, excess fluid; NH_LT, non-hydrated lean tissue; NH_AT, 
non-hydrated adipose tissue; FM, fat mass; DXA, dual energy X-ray absorptiometry; 
LST, lean soft tissue; RYGB, Roux-en-Y gastric bypass. 
 
a,b 
Means that do not share a letter within a row are significantly different (P<0.05) by 
paired t-test; comparison between baseline and 6-months, n=16; between baseline and 1-
year, n=15; between 6-months and 1-year, n=14; means that share a letter within a row 
are not significantly different by paired t-test.  
All values are mean ± SD.  
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RYGB (P<0.001). BIS values for RE were not different between visits, however, RI 
values were higher than baseline at 6-months and 1-year (P<0.001).  
 
4.6.14:  Comparison Between DXA FM and FMM-C in Obese Women Undergoing 
Massive Weight Loss 
 Analysis of FMM-C compared to DXA FM at the three time points of interest 
(baseline, 6-months, and 1-year) is displayed in Table 4-7 and shows that the Moissl-
Chamney model systematically overestimated FM at each time point. This agreed with 
the NHANES dataset, where for women with BMI between 30 and 39.9 kg/m
2
 there was 
no difference between the two methods, (n=709, DXA FM=39.3 kg v. FMM-C=39.5, 
P=0.15), and for women with BMI ≥ 40 kg/m2 the Moissl-Chamney model overestimated 
FM compared to DXA (n=89, DXA FM=54.6 v. FMM-C =56.5, P<0.0001). The methods 
were highly correlated with good CCC values at all time-points. B-A PE was below 30% 
for each time point (20%, 26%, and 26%) with %RMSE below 15% for each time point 
(10%, 13%, and 10%). however, the B-A limits of agreement were wide and there was a 
significant proportional bias for each time point. 
 
 As is shown in Table 4-7, when changes in FM by DXAFM and FMM-C between 
visits were compared using the longitudinal data set, there was no significant difference 
between the two methods for the weight change intervals from baseline to six months 
(P=0.3), from baseline to 1-year (P=0.8), and from 6-months to 1-year (P=0.1).  
Correlation between the two methods was moderate for the change from baseline to 6-
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Table 4-7:  Total FM as measured by DXA and as calculated from BIS estimates using the Moissl-Chamney equations for the 
longitudinal data set. 
 
Timepoint n 
Mean 
difference, 
kg 
r 
RMSE, 
kg 
CCC r
2
 
B-A Limits of 
agreement   
FMM-C, kg DXAFM, kg 
B-A  
PE 
r
2
 for the 
regression line 
through the B-A 
plot (P-value) 
Pre-RYGB 25 -7.6 ± 6.7* 0.93* 6.47 0.81 0.86 -20.8 to 5.5 71.8 ± 17.2 64.1 ± 13.8 20% 0.27 (0.008) 
6-months 
post-RYGB 
16 -6.3 ± 5.9* 0.94* 5.80 0.85 0.88 -17.8 to 5.2 50.6 ± 16.3 44.3 ± 13.6 26% 0.22 (0.07) 
1-year post-
RYGB 
15 -7.2 ± 4.3* 0.98* 3.45 0.86 0.96 -15.7 to 1.3 40.3 ± 16.4 33.2 ± 13.3 26% 0.53 ( 0.002) 
∆ Baseline 
to 6-months 
16 1.3 ± 5.3 0.68* 4.26 0.64  0.46 -9.1 to 11.8 -26.5 ± 5.6 -25.2 ± 7.2
 
- 0.11 ( 0.22) 
∆ Baseline 
to 1-year 
15 0.36 ± 5.1 0.84* 4.99 0.84  0.71 -9.6 to 10.3 -35.6 ± 8.9 -35.2 ± 9.2 - 0.002 (0.87) 
∆ 6-months 
to 1-year 
14 -1.3 ± 2.8 0.88* 2.83 0.86  0.78 -6.9 to 4.2 -9.2 ± 5.7 -10.6 ± 5.9 - 0.002 (0.87) 
 
Abbreviations:  BIS, bioimpedance spectroscopy; RYGB, Roux-en-Y gastric bypass; DXA, dual energy X-ray absorptiometry; M-C, 
Moissl-Chamney model; RMSE, root mean square error; B-A, Bland-Altman analysis;  FMM-C, fat mass from Chamney equation with 
Moissl correction for BMI; CCC, concordance correlation coefficient; FM, fat mass; PE, percent error. P-E not calculated for FM 
change intervals because the magnitude of error in all cases was greater than the mean difference between methods. 
Values are reported as mean ± SD unless otherwise noted.  
* indicates significantly different, P-value <0.001. 
 
 
  136 
 
months (r = 0.68, P=0.004; CCC = 0.64, 95% CI = 0.23 – 0.86), and well correlated for 
the change from baseline to 1-year (r = 0.84, P < 0.0001; CCC = 0.84, 95% CI = 0.56 – 
0.95) and from 6-months to 1-year (r = 0.88, P < 0.0001; CCC = 0.86, 95% CI = 0.59 – 
0.96). 
 
4.6.15:  B-A Analysis of Change Intervals for DXA FM and FMM-C in Obese Women 
Undergoing Massive Weight Loss 
 B-A analysis of the three change intervals are shown in Figure 4-4. For the 
change from baseline to six months, bias between the two methods was 1.33 kg with 
wide limits of agreement of ± 5.33 kg (11.79 kg to -9.12 kg). For the change from 
baseline to 1-year, bias between the two methods was 0.36 kg with wide limits of 
agreement of ± 5.08 kg (10.31 kg to -9.6 kg). For the change from 6-months to 1-year, 
bias between the two methods was -1.32 kg with smaller limits of agreement of ± 2.84 kg 
(4.24 kg to -6.88 kg). For each of the three change intervals, there was no proportional 
bias in the B-A plot. 
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Figure 4-4:  Comparison of DXA FM and Moissl-Chamney FM for weight loss 
change periods in the first year after RYGB. 
 
Abbreviations:  DXA, dual energy X-ray absorptiometry; FM, fat mass; FMMC, fat mass 
calculated from the Chamney model with BMI-correction from the Moissl equations; M-
C, Moissl-Chamney.  
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4.6.16:  Comparison Between DXA FFM And FFMM-C in Obese Women Undergoing 
Massive Weight Loss 
 The strong method agreement between FM estimates from DXA and the Moissl-
Chamney model suggested that it may be worthwhile to also assess the agreement 
between DXA FFM and FFMM-C in this longitudinal data set. DXA FFM and FFMM-C 
were significantly correlated at each of the time points [i.e. baseline (r = 0.71, P<0.0001), 
6-months (r = 0.85, P<0.0001) and 1-year post-RYGB (r = 0.89, P<0.0001)].  For the 
change interval from baseline to one-year, the measures of change in DXA FFM and 
FFMM-C were not different (-11.5 ± 9.8 vs -9.7 ± 2.5 kg, respectively; P=0.48), but were 
not correlated (r = 0.3, NS).  For the change interval from 6-months to one-year post-
RYGB, the measures of change in DXA FFM and FFMM-C were different (-0.06 ± 2.8 vs 
-1.7 ± 2.2 kg, respectively; P=0.03), but were correlated (r = 0.55, P=0.04). In this group, 
there was an approximately 50% difference of magnitude between NH_LTMoissl and DXA 
LST (see Table 4-6); thus we did not make further method comparisons using these lean 
tissue variables. Interestingly, when evaluating the loss of lean tissue over the one-year 
follow-up period, our 15 subjects lost an average of 11.5±10.1 kg DXA FFM, 11.6±10.1 
kg DXA LST, and 9.4±2.5 kg FFMMoissl, , but only 1.3±2.5 kg NH-LTMoissl. 
 
4.7:  Discussion 
 We have shown, through use of the NHANES dataset, that BIS can be used to 
provide reasonably accurate FM and FFM estimates in healthy individuals. We provided 
further comparison data of BIS methods with DXA through the use of our longitudinal 
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dataset in women with extreme obesity undergoing RYGB. This study was one of the 
first to validate a relatively recent BIS approach that incorporates the Moissl
182
 BMI-
correction to the Xitron-Hanai-based mixture equations and the Chamney 3-component 
model
183
 in a diverse healthy population sample. The strength of the Moissl-Chamney 
approach is its ability to characterize body composition in terms beyond the 2-
compartment (FM and FFM) model. It is particularly compelling from a clinical point of 
view because it offers the potential to improve BIS estimates of lean tissue by targeting a 
more specific lean tissue compartment (i.e. NH_LT) than FFM. The importance of lean 
tissue as it relates to nutritional status is paramount and has gained significant interest in 
the clinical community as assessment of muscle loss is one of the defining characteristics 
of malnutrition.
190,191
 The use of FFM as a marker of nutritional status is inherently 
limited, because it is not very specific and includes bone, connective tissue, and 
extracellular water, among other components. Changes in measured FFM could simply 
be a reflection of changes in body water (e.g. edema). On the other hand, the NH_LT 
theoretically represents a compartment closer to what has been termed the body cell 
mass, reflecting the metabolically active tissue that is thought to be the target of 
nutritional interventions.
192
 Furthermore, an accurate method for quantifying FM 
changes, particularly in individuals undergoing weight loss interventions would also be of 
great benefit to clinicians.  
 
 In this validation study, our first priority was to compare DXA FM and FMM-C, in 
part because the direct comparison of NH_LT with LST or FFM by DXA is complicated 
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by the fact given that there can be a substantial magnitude of difference between them, 
particularly at higher BMIs. FMM-C is directly calculated from NH_AT, which is derived 
from NH_LT and ExF, incorporating BMI-corrected ECW and ICW. It is not ideal to 
calculate FFMM-C by simply subtracting FMM-C from body weight in order to compare 
with DXA FFM because it increases the potential for error to back-convert to a 2-
component model. Thus, we narrowed the focus of our validation effort primarily to the 
FM measures with a more limited approach to the FFM and NH_LT comparisons. If the 
agreement between FMM-C and DXA FM were sufficiently strong, then it should follow 
that the lean estimates could be considered equally valid. 
 
 From our analyses of the NHANES dataset (n=5740) inclusive of mixed ethnicity, 
gender and ages 18-49 years, the Moissl BMI correction of the Xitron-Hanai-based 
mixture equations (FMMoissl) appeared to provide better estimates of FM than uncorrected 
values (FMHydra) in healthy people. However, a proportional bias was introduced by the 
BMI-correction that was not previously evident. The Moissl-Chamney approach (FMM-C) 
estimated FM better than FMH-C and equally as well as FMMoissl compared to DXA FM, 
although the proportional bias was still evident. It appeared that no single BIS approach 
for FM estimation worked optimally across all BMI ranges in comparison to DXA FM 
measures. It is important to recognize that BIS techniques were developed from dilution 
techniques to measure water compartments and thus, using DXA as a reference against 
which these techniques are compared is somewhat flawed and may be associated with 
some systematic over- or under-estimation (i.e. scaling error).  
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 Upon closer inspection by BMI-category, it appeared that FMMoissl compared best 
(no mean bias, lowest B-A PE and %RMSE, reasonably good correlations, and minimal 
proportional bias) to DXA FM for BMI ≥25 kg/m2. However, FMMoissl systematically 
overestimated FM at BMI ≥30 kg/m2 and underestimated FM at BMI <25 kg/m2 
compared to DXA. Similarly, it appeared that FMM-C performed best at BMI ≥30 kg/m
2
. 
However, FMM-C overestimated FM at BMI ≥30 kg/m
2
 and underestimated at BMI <30 
kg/m
2
. By both methods, proportional bias was quite minimal at BMI ≥40 kg/m2. Taken 
together, these findings confirm that correcting for BMI may improve FM agreement 
with DXA for both the Moissl and Moissl-Chamney models at higher BMIs. This is 
important because the Moissl-Chamney approach, if valid for FM, can potentially 
provide specific information about the lean tissue compartment as well as hydration 
status. Further evidence to support this reasoning comes from the comparison of 
FFMMoissl and DXA FFM, which had high correlation and CCC, low RMSE and low B-A 
PE with minimal or no proportional bias overall and for all BMI categories in healthy 
individuals. It is not surprising that the proportional bias disappears when correcting for 
BMI in the FFM estimates because the equations used to calculate FFM rely heavily on 
ICW which is adversely affected the most by increasing adiposity.
34
  
 
 Our longitudinal study in women undergoing RYGB provided another way to 
evaluate the Moissl-Chamney approach, in a model of rapid weight loss with substantial 
body composition changes. These data are uniquely suited for this evaluation given that 
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mean BMI was ≥30 kg/m2 throughout the study. At all time-points (baseline, 6-months 
and 1-year post-RYGB) FMM-C was in good agreement with DXA FM by correlation, 
%RMSE, and CCC, but systematically overestimated FM compared to DXA FM with B-
A PE slightly higher than those reported for the NHANES population, indicating wide 
individual variability. The comparison of changes were more variable across time, with 
the strongest support (lowest RMSE, strong correlation and CCC, no proportional bias) 
for the Moissl-Chamney approach for the change interval between 6-months and 1-year. 
It should be noted that, as described previously,
45
 the quality of the baseline DXA data 
were suboptimal in some extremely obese individuals which was thought to be due to 
partial beam attenuation at the trunk causing underestimation of bone estimates. By 6-
months, this was no longer an issue due to the substantial weight loss experienced by our 
subjects. Furthermore, the fact that we conducted half-body scans and used an acrylic 
board to separate the breast tissue from the arm could have contributed error to the DXA 
measurement despite correction.
45
  
 
 Although the Moissl BMI correction has been validated in healthy individuals and 
those on dialysis for body water compartments,
182
 there are limited published data 
comparing the Moissl-Chamney approach for FM and lean tissue compartments against 
reference methods. Two abstracts describing validation efforts for FM and FFM by this 
approach in healthy individuals and those with cancer, liver, and renal disease are cited
193
 
but are unavailable in any indexed databases or search engines. Therefore, our ability to 
compare our results in terms of measurement error against published literature on this 
  143 
method was limited. In light of this, we have primarily referred to the published literature 
on body water measurements by the Moissl-BMI correction for comparison purposes. 
 
 The interpretation of comparative statistics in methods validation is complicated 
by the lack of consensus on the definition of acceptable error. Moreover, the level of 
agreement between methods needed to establish validity for population level studies is 
different from that needed to apply a method at the individual level for bedside 
assessment. Although not widely adopted in the body composition field, we utilized B-A 
PE values with a cut point for method agreement acceptability defined as B-A PE less 
than 30%. This conception of error has been advocated in the clinical evaluation 
literature
194–196
 and more recently for application to bioimpedance validation studies.
197
 
More commonly, error is reported as RMSE in absolute terms, and sometimes as % 
RMSE; however, there is no clear consensus in the field on what constitutes good 
agreement. We have suggested that %RMSE values <15% represent an acceptable level 
of error, although we recognize that a low %RMSE does not necessarily ensure good 
agreement, in that it could be obtained by a method with high precision but high 
systematic error compared to the reference. From our perspective, we considered 
evidence of strongest validity to include a combination of correlation >0.9, CCC>0.75, 
%RMSE <15%, and B-A PE <30%; with no significant mean difference between 
methods, recognizing that if all other parameters were met, a significant mean difference 
could signify fixed systematic error (i.e. under- or over-estimation) due to scaling 
differences. Furthermore, when the errors between methods reflected by the BA analysis 
  144 
indicated a significant slope, then a systematic proportional error was likely present. 
Fixed systematic error is potentially less problematic than proportional systematic error, 
as it could theoretically be corrected with a scalar. The presence of proportional error 
detracts from a method’s validity. Summing this evidence to determine validity is 
challenging, and whether or not our cut points for error (particularly B-A PE) are 
sufficiently low to guarantee accuracy at the individual level is unclear. We have 
attempted to present the most complete picture as possible in our presentation of results.  
 
 Much of the BIS literature focuses on the assessment of water volumes using the 
unadjusted Xitron-Hanai-based mixture equations, rather than FFM or FM, because the 
BIS method was originally developed for the purpose of measuring ICW and ECW 
(although these volumes can be used to calculated FFM). There are no published reports 
comparing FM by the Moissl-Chamney method in any population. Similarly, the very 
limited BIS Moissl BMI-correction literature that has focused on body composition 
compartments other than fluid volumes has reported on FFM, rather than FM. Our 
findings in a healthy diverse US population (18-49 years, n=5740) using the Moissl BMI-
correction approach for FFM compared to DXA are similar to those reported by Tengvall 
et al
198
 in an elderly Swedish cohort (75 year old, n=1332). We calculated B-A PE for 
their FFMMoissl data which was 15% for men and 19% for women; similarly we reported 
14% for FFMMoissl in our mixed gender overall dataset. These authors reported no mean 
difference between FFMMoissl compared to DXA FFM, and the measures were highly 
correlated (r = 0.93, SEE = 4.4 kg). 
198
 Because BIS FFM relies on ICW and ECW 
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estimates and because ICW comprises a major fraction of the FFM, it is useful to look at 
the BMI-adjusted ICW error estimates (i.e. ICWMoissl) in the literature. Based on our 
interpretation of BA plots from Moissl et al,
182
 it appeared that  ICWMoissl and ECWMoissl 
estimates are associated with ~18.5% and ~16.5% B-A PE, respectively, with minimal 
mean bias, compared to dilution estimates in both healthy individuals (n=120) and those 
on dialysis (n=32). In our study, we found low error in terms of %RMSE for FFMMoissl 
(around 6%) compared to DXA FFM; and in earlier work, we reported 6-9 %SEE with no 
mean bias and high correlations with multiple dilution data in ICWHydra estimates using 
the De Lorenzo
31
 apparent resistivity constants in individuals with HIV infection.
189
 
Another widely cited report
199
 on the unadjusted BIS approach for ICW and ECW 
estimates (using older apparent resistivity constants, i.e. not the De Lorenzo constants) 
was used to calculate B-A PE compared to multiple dilution for healthy individuals 
indicating 34% and 33% for ICWHydra, and 20% and 28% for ECWHydra for men and 
women, respectively. This unadjusted BIS approach also significantly underestimated 
ICW and overestimated ECW compared to multiple dilution.
199
 In a study of individuals 
with renal disease, we reported FFMHydra estimates (using the De Lorenzo
31
 apparent 
resistivity constants) that were not different from, and highly correlated with DXA FFM 
in both healthy individuals (n=23) and those on hemodialysis (n=16) and those not yet on 
dialysis (n=12).
200
 The B-A PE for FFMHydra estimates were 14%, 20%, and 17%, 
respectively. In individuals with overweight and obesity (n=90; BMI 23 – 62 kg/m2), 
Cox-Reijven et al
34
 compared ECWHydra and TBWHydra using the De Lorenzo
31
 apparent 
resistivity constants to multiple dilution measures, and used the dilution data to generate 
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new obesity-specific constants. TBWHydra estimates were not different and highly 
correlated with dilution, with B-A PE 10 – 11% for the two sets of constants. The 
ECWHydra estimates were significantly greater than, but also highly correlated with 
dilution, and B-A PE were 18% for the two sets of constants. There was a significant 
proportional bias with increasing BMI that was not corrected by using the obesity-
specific resistivity constants, and several of the constants in the equations were also 
correlated with BMI, underscoring the need to identify other factors that might be 
corrected in the equations to improve BIS estimates.
34
 
 
 Although not an ideal comparison, we found that in healthy individuals 
NH_LTMoissl had reasonably good agreement with DXA LST and the Moissl-BMI 
correction improved these results compared to the agreement between NH_LTHydra and 
DXA LST. As expected, the best agreement was found in normal weight individuals who 
are unlikely to have issues with excess fluid. In support of this, in our overall NHANES 
dataset, ExF was quite low (see Table 4-2). This suggests that with normal weight and 
hydration status DXA LST and NH_LT are measuring very similar lean tissue 
compartments. At higher BMIs this relationship may not hold because DXA cannot 
distinguish between overhydrated lean tissue and fluid compartments. 
 
 Interestingly, when looking at our longitudinal DXA data (see Table 4-6), it 
seems that our subjects lost a substantial amount of LST. However, by the BIS Moissl-
Chamney approach, the loss of NH_LTMoissl is fairly minimal. At this point, it would be 
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difficult to say BIS is providing the correct information, but it is certainly possible that 
the inability of DXA to distinguish excess fluid in adipose and lean tissue in extreme 
obesity could be skewing DXA LST loss estimates upward. From a slightly different 
perspective, this could be interpreted to mean that the observed DXA LST loss was 
almost entirely adipose tissue water, assuming that the Moissl-Chamney model was valid 
in these subjects based on our FM change comparisons. This underscores that DXA may 
be deficient under these conditions and a method such as the BIS Moissl-Chamney 
approach that can distinguish excess fluid from lean tissue mass could offer significant 
advantages, particularly for the assessment of clinical populations with edema and 
individuals with obesity who have abnormal fluid distribution. Indeed, particularly in the 
most obese state at baseline, our DXA measurements had some error from partial beam 
attenuation in our heaviest subjects as discussed earlier. On the other hand, the Moissl-
Chamney approach can produce negative numbers in the body composition estimates, 
thus in this case, potentially skewing the NH_LT downward. These issues need to be 
resolved.  
 
 Of note, the Chamney 3-component model was originally developed for the 
purpose of distinguishing excess fluid from adipose and lean tissue compartments in 
order to better target the clinical management of individuals on dialysis.
183
 Its 
incorporation in conjunction with the Moissl BMI-correction to the Xitron-Hanai-based 
mixture equations into software accompanying the BIS device used by Fresenius Medical 
Care Europe (BCM Body Composition Monitor) has allowed for application of ExF 
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assessment during dialysis.
184,185,193
 Compelling evidence of the efficacy of this approach 
for lean tissue assessment came from a recent report that demonstrated that individuals on 
hemodialysis who had NH_LT values below the 10
th
 percentile from healthy reference 
data had significantly higher mortality, suggesting that it could be indicative of 
malnutrition and poor clinical status.
185
 This approach may ultimately prove to be useful 
as a way to assess nutritional status and monitor clinical response to nutritional 
interventions in other populations. 
 
4.8:  Conclusions 
 Taken together, the results from our methods comparison between the BIS 
Moissl-Chamney equations and DXA generally support the utility of this BIS approach 
for FM, particularly for overweight and obese populations. It also appeared to be a 
reasonable method for measuring changes in FM with weight loss based on mean level 
comparisons. However, the presence of proportional bias and wide limits of agreement in 
the individual time point measures of our longitudinal data set was concerning. It is 
encouraging that the proportional bias resolved in our measures of FM change, although 
the apparent systematic overestimation and wide limits of agreement further underscore 
the need for method refinement before this approach can be relied upon for accurate 
monitoring of body composition changes at the individual bedside.  
 
 We utilized liberal cutpoints to define method acceptability (e.g. B-A PE <30%, 
%RMSE <15%), assuming the precision of our reference method to be ~5%.  Given that 
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these cutpoints allowed for fairly wide (and probably unacceptable for individual 
assessment purposes) limits of agreement, it seems likely that a target of B-A PE 10 – 
20% and %RMSE of 5 – 10% (or lower) would provide more optimal results, and would 
allow for the detection of small changes in body composition.   
 
 Our findings also emphasize the promise of this technique for the assessment of 
the more specific lean tissue compartment (NH_LT). Its successful application for 
assessing excess fluid (ExF) for the tailoring of dialysis regimens provides compelling 
reason to consider its evaluation in other clinical populations. However, further 
refinement in the constants used to calculate ExF and the other compartments is needed 
to protect against the generation of non-physiologic values and to improve the accuracy 
of the model components. Industry partners that have access to large databases containing 
both reference (DXA, multiple dilution, 4-component model) and BIS data can work 
together to further refine Moissl-Chamney types of models to allow for better accuracy 
and precision in BIS estimates. These kinds of collaborations are essential to move the 
field forward and resolve questions about the applicability of BIS techniques at the 
bedside. 
 
 Monitoring of lean tissue changes (independent of fluid changes) remains a high 
priority for nutrition care and monitoring outcomes and success of interventions in the 
clinical setting of acute and chronic illness. It would be particularly advantageous to have 
a method to assess lean tissue loss in individuals with obesity, who may not exhibit 
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visible signs of muscle loss by physical exam, but may be significantly malnourished. 
Additional research is needed to (1) refine the constants in the BIS Moissl-Chamney 
model equations using dilution and DXA data from large, diverse population datasets; (2) 
resolve the issue of non-physiologic values for the BIS Moissl-Chamney model 
estimates; and (3) confirm if the refined and improved BIS Moissl-Chamney approach or 
some derivation can be effectively used to monitor body composition changes in 
individuals with obesity, and in individuals with acute and chronic disease.  
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CHAPTER 5:   CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Bariatric surgery is highly successful for inducing weight loss and improving 
metabolic health outcomes. However, the long-term ramifications of bariatric surgery on 
body composition, and the potential implications of the complex interactions between 
nutritional status and inflammation on long term health outcomes is not well studied. In 
part, this is due to the relative recent history of bariatric surgery and the logistical 
challenges inherent in completing long term follow up studies. Substantial losses of 
weight and FM in the first year after bariatric surgery are clearly observed. Because of 
the role that adipose tissue plays in inflammatory processes, these changes could have 
implications for long term health outcomes. 
 
In our pilot study of 5 women, weight regain occurred and was accompanied by a 
substantial increase in percent body fat in the long-term post-RYGB. Although we saw 
no changes in inflammatory and nutritional status at 8.5-years post-RYGB, the finding of 
weight regain primarily as FM is concerning. In our pilot study, good adherence to 
recommended supplementation may have offset the risk for nutritional issues. The 
continued loss of lean tissue with weight regain over time, and the correlation of these 
losses with loss of muscle strength is also alarming, given its implications for diminished 
functional status, particularly in light of the aging obese population and the increasing 
rates of bariatric surgery in the US.  
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Based on the findings of our pilot study, it seems of vital importance to be able to 
monitor body composition changes in individuals who undergo bariatric surgery as they 
age. Available reference methods for the assessment of body composition are costly, 
cumbersome, and time intensive. Field techniques that are inexpensive, portable, and 
accurate are needed.  Our BIS study evaluated a new application of an existing field 
technique based on multicomponent physiologic models, and represents a major step 
forward for measuring changes in body composition after bariatric surgery. With this 
method we were able to track fat mass and lean tissue changes fairly well in 20 women 
over the first year post-RYGB. Our findings, in conjunction with a growing literature on 
the demonstrated effectiveness of this BIS approach in individuals with dialysis for the 
assessment and monitoring of fluid changes and for the assessment of mortality risk, are 
compelling.  BIS using these models appears to be at the forefront of the bioimpedance 
field; however, it remains to be seen if additional refinements can lead to its 
establishment as a useful tool to assess body composition at the individual bedside. 
 
In the coming years, bariatric surgery is sure to remain a popular treatment for 
obesity and it is clear that we need better methods to assess changes in body composition 
in a more comprehensive way, in order to better understand the ramifications of these 
changes in light of long-term nutritionally relevant health outcomes, including 
inflammation. This dissertation could serve to inform future studies that should aim to 
tease apart the factors contributing to long-term FM gain, but more importantly loss of 
LST and muscle strength, to establish evidence based guidelines.  
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